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Abstract 
 
Literature reports have previously shown interesting antimicrobial activities of compounds 
containing the α,β unsaturated carbonyl function and various piperidone and tropanone 
derivatives have attracted interest. A series of ring substituted N-piperidone dieneones and 
a novel parent tropan-3-one were synthesized and characterized. Novel compounds along 
with a previously synthesized library of 1,2-benzothiazines were examined for their 
antifungal properties. The tropan-3-one and benzothiazines proved to be ineffective 
inhibitors of Saccharomyces cerevisiae growth (<20%). Dieneones of N-piperidone and N-
methyl piperidone showed a wide spectrum of activities whereby the free bases are 
marginally more potent than their respective hydrochloride salts. Based on their potencies 
against S. cerevisiae a subset of dieneones were screened against Candida albicans and 
Aspergillus niger. Yeast cells were incubated with the compounds for 24 or 48 hours 
whereas A. niger cells were incubated with the compounds for 16, 24, 48 or 72 hours 
respectively. Generally the presence of the N-methyl group decreases potency against yeast, 
whilst the opposite is true in A. niger.  The compounds are not as effective at inhibiting cell 
growth against A. niger when compared to the yeast. Compound 41n was the most potent 
inhibitor giving IC90 values of 1.35 x 10
-3 M (S. cerevisiae) and 1.55 x 10-3 M (C. albicans), 
whereas compound 39n was the most potent inhibitor of A.niger growth with an MIC value 
of 3.6 x 10-10 M. Selected piperidone dieneones were screened for cytotoxic properties 
against the A549 cancer cell line using the MTS and LDH assays. Compound 41n was found 
to be the most cytotoxic. Potency of benzene ring substitution was para>meta>ortho. 
Substituents of larger volume and lower electron withdrawing properties produce more 
potent compounds. The 3’-iodo substituted piperidones (39n and 41n) emerged as the most 
promising agents from the group of compounds in respect to their antifungal and cytotoxic 
potencies, although the compounds were not as effective as the reference drug miconazole. 
 
Keywords: α,β unsaturated carbonyl, piperidone, tropan-3-one, benzothiazine, antifungal, 
cytotoxicity   
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Chapter 1: Introduction   
 
1.1 Introduction and Rational  
The proposed research will study the synthesis and biological activities of novel compounds 
with six membered heterocyclic rings and 7 membered rings containing nitrogen.     
Various compounds containing either azo or diaza heterocyclic six or seven membered ring 
systems will be synthesized and characterized.  
The aim is to synthesize a library of various benzene ring substituted tropan-3-one and 
piperidone dieneones. Along with a synthesized library of 1,2-benzothiazines they will be 
examined for their antifungal and anticancer properties. The antifungal and anticancer 
properties of some tropanones (Dimmock et al, 2002), piperidones (Pati et al, 2009) and 1,2-
benzothiazines (Park, Chang, Lee & Kwon, 2002 and Ahmad, Zia-ur-Rehman, Siddiqui, Ullah 
& Parvez, 2011) reported in previous studies encouraged the present research.   
1.2 The Cell Cycle 
The cell cycle consists of several phases, through which the immature cell has to undergo in 
order to divide successfully. For a eukaryotic cell to divide, it requires the replication of its 
genome (DNA) in the synthesis, or S phase, of the cell cycle and the splitting of that genome 
in half during the mitotic or M phase. The Gap-1, or G-1, phase is a period in the cell cycle 
during interphase, before the S phase. For many cells, this phase involves a major period of 
cell growth including the production or division of new organelles and the duplication of 
cellular components excluding the chromosomes (Bock, Cardew, & Goode, 2001).   
The cells may also enter the resting state otherwise known as the G0 state where they 
become inactive and do not replicate or divide. Usually cells enter this phase due to a lack of 
nutrients or growth factors. In order to divide the cell must re-enter the cycle in the S phase.    
During the S phase each of the 46 chromosomes undergo duplication in the cell. The main 
purpose of the S phase is DNA replication where two identical semi-conserved 
chromosomes are produced. Pre-replication complexes are loaded onto the DNA at 
replication origins during G1-phase to prevent more than one replication from occurring. 
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These complexes are subsequently degraded in the S-phase as DNA replication begins (Bock 
et al, 2001).       
The Gap-2, or G2-phase, occurs after the S-phase but before the M-phase. During this phase 
rapid cell growth and protein synthesis occur as the cell prepares itself for mitosis. The G2-
phase ends with the onset of the prophase which is the first phase of mitosis, during which 
the cell’s chromatin condenses into chromosomes. The cell is said to be in interphase if it is 
in any phase of the cell apart from mitosis (Morgan, 2007). 
 
 
 
 
 
 
Figure 1- The various phases involved in the cell cycle of a eukaryotic cell (www.biology.arizona.edu 
(University of Arizona), 2004) 
In order to ensure that the cell may divide successfully it is important that the cell cycle is 
controlled and regulated tightly (Bock et al, 2001). Should the normal control and regulation 
of the cell cycle be lost, it can lead to the development of cancer in higher eukaryotes. 
Control involves a variety of cytoplasmic proteins including cyclins and cyclin dependant 
kinases (Cdks) which along with cyclins cause the cell to advance from phases G1 to S, or G2 
to M respectively. The Maturation Promoting Factor (MPF) consists of cyclins and Cdks that 
trigger cell cycle progression by promoting progression to the M phase (Morgan, 2007). The 
protein p53 plays a fundamental role in DNA repair as it is able to block the cell cycle if DNA 
is damaged. If the damage is severe this protein can initiate apoptosis (programmed cell 
death) (Morgan, 2007). Another key protein is p27, which prevents entry into the S phase by 
inhibiting cyclins A and E (Kaldis, 2006).  
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1.3 Cancer 
This is a disease in which abnormal cells divide in an uncontrolled manner and invade 
surrounding tissues (Cavallo, De Giovanni, Nanni, Forni & Lollini, 2011). Cancer cells have 
the ability to spread to different tissues in the body, developing secondary tumours through 
the blood and lymph systems. This process is known as metastasis (Macdonald, Ford & 
Casson, 2004).  Although many treatments are available for suppressing or eliminating 
cancers and tumours, the prognosis is still limited in many cancer types. Research to 
develop novel anti-neoplastic agents is therefore still required.    
The role of chemotherapeutic drugs is to slow and hopefully prevent the growth and spread 
of the cancer. However these drugs are often feared because of their toxicity and many 
adverse side effects which they may cause the patient (Macdonald et al, 2004). Therefore 
research into producing effective drugs which not only eliminate the cancer but can do so 
without significantly harming the host is still required.    
1.4 A549 cells  
Cancer research has advanced over the years due to the accessibility of many cell lines 
derived from oncological tissues obtained from various cancer patients (Ferreira, Filomenga 
& Chaves, 2013). The adherent culture strain of the human adenocarcinoma alveolar basal 
epithelial A549 (ATCC CCL-185) was used in this study. The cell line was introduced in 1972 
through explant culture of lung carcinomatous tissue from a Caucasian male 58 years of age. 
Since then the cell line has been actively used in various anti-cancer studies (Ehrhardt and 
Kim, 2007). 
1.5 Fungi  
Fungi are members of large group of eukaryotic organisms including microorganisms such as 
yeasts and filamentous fungi or moulds of various types (Kavanagh, 2011). Fungal cells are 
surrounded by a cell wall consisting of chitin, a complex polysaccharide. Some fungi are 
difficult to notice because of their small structures and their anonymity in soil or on 
decaying matter. Once the fungi begin to reproduce, either as moulds or mushrooms, they 
may become visible. Fungi play an important role in nutrient recycling and exchange, as well 
as decomposition of organic matter (Kavanagh, 2011).    
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Although fungi are useful in everyday life, certain species of fungi can produce bioactive 
compounds called mycotoxins. Mycotoxins include certain alkaloids and polyketides which 
are toxic to animals. Mycotoxins are toxic compounds many of which are produced by 
Aspergillus, Penicillium and Fusarium species. Under the correct conditions these fungi 
proliferate and produce harmful mycotoxins (Parker, 2003). Some species have structures 
containing psychotropic compounds which are consumed recreationally (Kavanagh, 2011). 
Additionally fungi may have adverse effects on environments such as buildings. Many 
species are pathogenic to humans and other animals. Fungal diseases also lead to crop 
losses which can have a detrimental impact on food supplies and human health (Parker, 
2003).   
Many fungi exist as unicellular and multicellular, in which the fungal cells are unicellular. 
They are usually oval or round and they reproduce by either budding or by fission 
(Kavanagh, 2011). Yeasts are classified in the phyla (divisions) Ascomycota or Basidiomycota. 
Yeasts, particularly those of the Saccharomyces genus are of major industrial importance as 
being used in alcoholic fermentations, bread-making, and in treating various ailments due to 
brewer’s yeast containing a high content of thiamine and other B-complex group vitamins 
(Kavanagh, 2011). Filamentous fungi such as Aspergillus niger are multicellular organisms 
consisiting of long branched filaments called hyphae which aggregate to form a mass 
mycelium (Bärlocher, 2008). They have functions in maintenance of ecosystems by breaking 
down dead organic material, production of commercial enzymes, organic acids and various 
drugs such as penicillin (El-Enshasya, 2007).  
Fungi that cause disease in humans or other organisms are termed pathogenic fungi. 
Though fungi are eukaryotic organisms many pathogenic fungi are microorganisms (Parker, 
2003). Saccharomyces cerevisiae is usually not considered a pathogen as diseases caused by 
this type of yeast are rare however there have been reported incidents (Mermel et al, 
2009). Candida species are the most common human pathogens often causing nasal, 
subcutaneous and gastrointestinal infections especially in immune compromised patients 
including AIDS sufferers and transplant patients (Bärlocher, 2008). Other pathogenic 
Candida species include; C. tropicalis, C. parapsilosis and C. dubliniensis which are 
responsible for various infections (Sardi, Scorzoni, Bernardi, Fusco-Almeida & Mendes-
Giannini, 2013). Although most yeast infections are commonly associated with C. albicans 
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exposure to S. cerevisiae particularly for immunosuppressed individuals can be fatal. 
(Mermel et al, 2009).   
Aspergillus niger is a filamentous fungus which can cause serious lung diseases 
(aspergillosis) and it is the most common cause of otomycosis (fungal ear infection). We are 
constantly exposed to airborne Aspergillus spores as they are ubiquitous. This exposure is 
generally harmless and poses no threat to human health; however exposure to large doses 
of fungal spores can be lethal (Favor, 2004). Aspergillus cause fungal diseases in three 
specific ways. The disease can be caused via localized or systemic infections, through 
induction of allergenic responses or through the production of mycotoxins. A common 
pathogenic species is Aspergillus flavus which along with being a toxin is also a carcinogen 
and can contaminate foods such as nuts. Other species include Aspergillus fumigatus and 
Aspergillus clavatus which can cause allergy related diseases (Favor, 2004).  
Most Cryptococcal species are harmless and do not cause disease in humans. The major 
human and animal pathogen is Cryptococcus neoformans which can cause disease of the 
lungs and secondary infections in HIV and AIDS sufferers (Parker, 2003).  
Other pathogenic fungi include: Histoplasma capsulatum which can cause histoplasmosis in 
both humans and animals;  Pneumocystis carinii, which can cause pneumonia in people with 
weak immune systems and Stachybotrys chartarum which can cause respiratory damage 
and major headaches (Parker, 2003).  
Both S. cerevisiae and C. albicans have been sequenced to the genome level and have been 
extensively studied in terms of their cell biology, whereas A.niger is the most studied of the 
filamentous species. These properties mean many useful strains are easily available and 
therefore they are good models for aiding novel antifungal drug development strategies 
(Kavanagh, 2011). 
1.6 Infection  
An infection is caused by the invasion of a host organism’s bodily tissues by microorganisms 
such as bacteria, parasites or fungi. Microorganisms that are naturally found in the body are 
not considered infectious and they do not usually cause any harm to the host. However 
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disease-causing microbes such as those previously mentioned can invade bodily tissue, 
multiply and release toxins which are harmful to the host. The host normally combats 
infections using their immune system via an innate response such as inflammation followed 
by an adaptive response. However in many cases the immune response cannot tackle the 
infection alone so drugs that fight infectious diseases, such as antibiotics or antimicrobials, 
are used. Many infections can be subclinical and not cause any symptoms, or it may be 
clinically apparent and cause symptoms. Infections can also be either concentrated in a 
specific area of the body (localised) for example nails, nose, groin, intestine etc. or they may 
spread through the lymphatic or blood vessels (disseminated) (Escobar, 1988).     
In some cases viral and bacterial infections cause similar symptoms which makes it difficult 
to determine the cause of the infection. Viral infections are not treated using antibiotics so 
it is important to distinguish whether it is a viral, bacterial or fungal infection, in order to 
give the correct drug treatment (Shetty, Tang & Andrews, 2009).    
1.7 Antimicrobials and Antimicrobial Resistance  
Anti-infective drugs are usually administered prophylactically prior to an infection occurring 
to prevent people from getting the infection in the first place. They are also administered to 
patients suffering from an infection to suppress the infection caused by a harmful 
microorganism attacking and inhabiting tissue in the host’s body. There are three types of 
anti-infective drugs: antiviral, antifungal and antibacterial. Most infectious diseases are 
caused by bacteria as they are easy to catch and spread. Antibiotics, which are natural or 
semi-synthetic in origin, are administered to treat bacterial and some fungal infections. They 
are given either by mouth, injection or applied topically depending on the severity and form 
of the infection. Intravenous antibiotics may be used to aid the treatment of severe brain 
infections. Antibiotics function by suppressing bacterial multiplication or by eliminating the 
bacteria in the host. They may be used in combination to increase efficiency and decrease 
the risk of resistance (Finberg & Guharoy, 2007). 
Antimicrobial drugs are used to selectively inhibit the growth of or kill harmful 
microorganisms such as protozoans, bacteria or fungi. Since the discovery of antimicrobials 
such as penicillin and tetracycline the interest in synthesizing novel antimicrobials has 
increased. Antibiotics are generally derived from natural resources or are semi synthetic 
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(e.g. most penicillins). Whereas antimicrobials include synthetically produced compounds 
such as the sulfa drugs (Drlica & Perlin, 2011).          
Antibiotics have become an integral part of modern medicine. They either initiate cell death 
or inhibit growth by targeting essential cell physiology and biochemistry. Today most 
infections are treated using antibiotics. Antibiotics are also essential in surgery, without 
which many procedures, such as open heart surgery, cannot be performed (Yount, 2004).  
Many antibiotics are available targeting a wide spectrum of bacteria and fungi. The most 
common classes of antibiotics used in medicine include penicillins, cephalosporins, 
quinolones, aminoglycosides, macrolides and tetracyclines (Yount, 2004). Synthetic 
antimicrobials include sulphonamides that are used in treating bacterial infections and the 
azoles and allylamines which are used in treating fungal infections (Drlica & Perlin, 2011).       
Antifungal resistance occurs due to a stable, inheritable modification in a fungal cell against 
an antifungal agent. Such mutations result in less than normal sensitivity to that antifungal 
and the effects of the antifungal are decreased. Mutations in genes may cause: changes in 
the affinity or turnover of the target enzymes; by increasing deactivation of the drug or by 
exporting the drug from the cell (Projan & Youngman, 2002). 
The increasing emergence of drug-resistant strains of fungi is a threat to societal and human 
health as immunocompromised patients such as those suffering from HIV/AIDS or those 
undergoing chemotherapy or transplantation are more susceptible to fungal infections. 
(Norby, Nord & Finch, 2005). 
There is a growing concern about the lack of development of new antimicrobial drugs. The 
European Society of Chemical Microbiology and Infectious Diseases (ESCMID) has noted that 
development of novel antimicrobial compounds has significantly decreased in the last 
decade (Norby et al, 2005). The number of cases of multidrug resistant fungal infections is 
increasing (Gulshan & Moye-Rowley, 2007) suggesting an urgent need for new classes of 
antifungal agent (Oren, Yalcin, Sener & Ucarturk, 2004). There is thus an increasing risk of 
organisms resistant to most or all existing antimicrobials giving rise to common infections 
which are untreatable or even lethal (Norby et al, 2005). Thus the development of novel 
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compounds which act as antifungal agents, but differ chemically and target different 
enzymes and or receptors from existing compounds, is vital.    
Various drugs are available that may be used to treat fungal infections. These can be 
classified on the basis of their mechanism of action. Antifungal agents are available that: 
impair membrane barrier functions including polyenes such as Amphotericin B (Amp B); 
inhibit macromolecule synthesis by acting as antimetabolites (flucytosine); interact with 
microtubules (griseofulvin); inhibit ergosterol synthesis (allylamines and (tri)azole 
derivatives) or inhibit cell wall (chitin) synthesis (enchinocandins) (Projan & Youngman, 
2002).  
Azoles are a class of antifungals which act by blocking ergosterol synthesis. Decyl imidazole, 
the first azole found to inhibit ergosterol production, was the lead compound from which 
various azoles have been developed. Azole type drugs therefore contain an imidazole or, 
more recently, a triazole structure.  Ergosterol is an essential steroid found in fungi and is 
required for plasma membrane stability (Lewis, 2011). The pathway of conversion of 
lanesterol to ergosterol requires specific enzymes called demethylases which are examples 
of cytochrome P450 enzymes. The enzymes 14 alpha demethylase, 4 alpha demethylase and 
delta 22, 23 desaturase are blocked by azoles and triazoles. Synthesis of ergosterol is 
inhibited due to a dative bond formed by a lone pair of electrons on one of the nitrogen 
atoms of the imidazole with the iron atom in the P450 enzymes (Lewis, 2011). Miconazole is 
a commonly used example from the class of azole drugs used to treat various fungal 
infections (Sawyer, Brogden, Pinder, Speight & Avery, 1975). In the present study 
miconazole nitrate was used as a reference drug. The antifungal properties of all 
compounds tested were compared against miconazole as an internal control.   
In recent years interest in the synthesis of bioactive heterocycles has increased significantly 
as many compounds with biological activity contain one or more heterocyclic atoms in their 
structures. Amongst the large family of heterocyclic compounds, those containing sulphur, 
nitrogen and oxygen attract the most attention from medicinal chemists due to the large 
range of biological activities observed with these compounds. Nitrogen heterocycles are 
most commonly used as many classes can be easily synthesized (Projan & Youngman, 2002). 
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Previous experiments involving the use of tropan-3-one and piperidin-4-one derivatives 
showed that these compounds had cytotoxic properties against J774 mouse macrophages 
(Hussain, 2012). One of the aims of this investigation was to explore these compounds in 
more depth and to introduce different substituent groups in various positions in eneone 
structures. The potency of these compounds against certain fungal species and a cancer cell 
line were examined. Also a previously synthesized library of benzothiazine derivatives (Patel, 
2012) was screened for their antifungal properties. As previous work involving similar 
compounds has produced promising results this research will aim to extend those studies in 
order to determine ways of synthesizing and testing potentially more potent compounds 
(Patel, 2012 and Hussain, 2012).    
Synthesized tropan-3-one along with a library of piperidone dieneones and 1,2-
benzothiazines were tested against various fungal species to determine if any of the 
compounds had antifungal properties. The compounds were compared against miconazole 
nitrate. Based on their potencies against fungi, a subset of compounds were tested against 
the epidermal cancer cell line A549 to determine any cytotoxic properties. All compounds 
were compared to a positive kill control (Triton X-100).    
1.8 QSAR  
Medicinal chemistry deals with the design and synthesis of new therapeutic chemicals and 
their development into useful medicines (Thomas, 2011). Medicines are formulated 
substances used in the treatment of disease, whilst drugs are the active molecules found in 
the medicines used to treat or prevent disease (Thomas, 2003). Medicinal chemistry 
involves the isolation of natural compounds or the synthesis of new molecules and 
investigating how altering the structure of molecules affects their biological activities. The 
drugs are tested using purified enzymes or receptors, cells, tissues or whole organisms. Such 
structural changes can lead to an increase, a decrease or no change in the activity of the 
drug. Such changes may also alter the absorption, bioavailability, distribution, metabolism 
and excretion of the drug which also alters its overall potency (Patrick, 2001).  
Similarly in this investigation modifying the structures of the parent compounds can 
potentially promote cell death or block cell division. Thus they may prove to be to be useful 
in developing novel antifungal or anticancer agents.   
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The results generated by this study can be applied to the development of one or more 
QSARs to examine whether the hydrophobicity and or the structure of the compounds 
tested are related to their known bioactivities. If clearly visible relationships are observed, 
then novel compounds could be developed and synthesized with optimal LogP or, LogD 
values, sizes volumes or electronic distributions which hopefully will give rise to molecules 
with higher potencies. To do this the antifungal and anticancer potencies will need to be 
compared to various physiochemical properties in order to generate QSARS which will allow 
further molecules with improved potencies to be developed (Thomas, 2003).   
1.9 Cell Growth and Dose-response Curves  
In biology growth curves are frequently used for quantities such as population size, cell 
viability or biomass.  A graph can be constructed displaying the values of the measured 
property (i.e. number of viable cells) against the concentration of the novel compound.  
The analysis of growth curves is pivotal in cancer research. For patients that are undergoing 
treatment using anti-cancer drugs, growth curves can be used to determine how efficient 
the drug is in reducing the cancer (Nadeau, 2012). It is also a vital tool in antifungal studies 
as it can determine the effects antifungals have on the growth of particular fungal species.      
Growth curves were used in this study to analyse the growth of both fungal and cancer cells 
and for determining their respective exponential phases. The exponential phase is the point 
at which the cells are proliferating at their maximum rate (Bergman, 2001).  
 
 
 
 
 
 
 
 
 
 
  
Figure 2- Various phases observed during cell growth (www.biology.arizona.edu (University of Arizona), 
2004). 
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Dose-response curves are used to describe the relationship between the response to drug 
treatment and the drug concentration (or dose). These are useful in determining safe and 
hazardous concentrations of the tested drug. The graphical software package GraphPad, 
Prism 5 is used to construct dose-response curves using a four-parameter logistic equation 
to construct a suitable sigmoidal curve. A four-parameter logistic nonlinear regression 
model is commonly used for dose-response curves in both antifungal and anticancer studies 
(Panetta, 1997).  
 
The equation is as follows;  
 Y= 100 / (1 + 10^((LogIC50-X) * Hill slope))  Equation (1) 
Where X is log of drug concentration, Y is the normalized response, 100% down to 0% 
decreasing as X increases and the Hill slope is the slope factor.  
The IC50 is defined as the concentration required to induce 50% inhibition of cell growth or 
equally 50% decrease in cell viability. It measures the efficiency of a compound or agent to 
inhibit biological or biochemical functions (Rege & Medintz, 2009). IC50 measurements 
specify the concentration of the drug/agent required to successfully inhibit a biochemical or 
biological process. GraphPad Prism 5 software calculates the IC50 values whereas IC10 and 
IC90 values (concentration required to inhibit 10% and 90% cell growth or cell viability) were 
manually obtained from the dose response curves.  
 
1.10 Antifungal Susceptibility Testing using Yeast and Filamentous Fungi 
Various methods are available for antifungal susceptibility testing of both yeast and 
filamentous fungi (Fothergill, 2012). The Clinical Laboratory and Standards Institute (CLSI) 
and European Committee on Antimicrobial Susceptibility Testing (EUCAST) have approved 
methods for antifungal susceptibility testing of both yeast and moulds (filamentous fungi). 
According to the CLSI and EUCAST the liquid broth dilution method is most appropriate for 
yeasts whereas the disk diffusion assay is more suited to filamentous fungi (Fothergill, 2012, 
CLSI, 2013 & Kahlmeter et al, 2006). 
The liquid broth dilution method allows the determination of whether a test compound is 
fungicidal at a specified concentration. Fungal cells are grown and maintained in broth 
media which contains all the nutrients required for the cells to grow when incubated at an 
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appropriate temperature. The drug under examination is incubated with the cells at various 
concentrations and the inhibition of cell growth by the drug analysed by measuring the 
optical densities obtained (Fothergill, 2012, CLSI, 2013 & Kahlmeter et al, 2006).      
Disk diffusion assays use solid media agar plates which are widely used because of their 
simplicity and cost effectiveness (Sardi et al, 2013). Absorbent paper disks containing 
various amounts of the drugs to be examined are placed onto agar plates which have been 
inoculated with a specific amount of conidia. The diameter of the zone of inhibition is 
measured at the end of the incubation period and compared with reference drugs. 
(Fothergill, 2012, CLSI, 2013). 
The effects of the compounds on the inhibition of growth of the yeast species was analysed 
by determining; IC10, IC50 and IC90 values. MIC values are generally obtained from 
susceptibility assays using agar plates or glass tubes (Fothergill, 2012). An earlier study 
revealed that when three types of yeast species were treated with miconazole the MIC 
values vary significantly with inoculum size whereas IC50 values remain constant  (Galgiani & 
Stevens, 1976). Thus interlaboratory comparisons should be easier if IC50 values were 
measured and quoted.  
Assays of microbial susceptibility to drugs via the agar diffusion method were analysed using 
linear fitting of either the diameter or squared diameter of the inhibition zones against the 
natural logarithm (ln) of drug concentration at the source;  
ln (MIC) = ln (c) – D2 /4dt  Equation (2)  
Where D= zone of inhibition diameter, d= diffusion coefficient presumed to be independent 
of concentration and t= time of drug diffusion) (Kronvall, 1982). This reflects a solution of 
the differential equation describing free diffusion in one dimension which takes into account 
the dependence of the drug concentration on distance from the source and on time. 
(Bonev, Hooper & Parisot, 2008). In order to find the most suitable linear fitting, various 
graphs were plotted of D, D2, Ď (corrected by subtracting from the diameter of the paper 
disks) and Ď2 against ln (drug concentration). R2 values were deduced from each graph and 
then compared (Microsoft Excel). R2 values indicate how well data points fit a linear 
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regression as it represents the variation of the data explained by the fitted line. The closer 
the R2 value is to 1 the better the linear regression fit (Colin & Windmeijer, 1997).        
1.11 Cytotoxicity Studies  
Cell viability was used to determine if cells are living or dead using a total cell sample 
(Mather & Roberts, 2006). Cell viability assessments have been applied in many areas of 
research including cancer research. Such methods have been used to determine the viability 
of cancerous cells, and the rejection of implanted organs. This technique is also useful when 
testing the effectiveness of insecticides, or to assess the effect of toxins on the environment 
(Johnson & Spence, 2010). 
 
Cell viability measurements evaluate healthy cells within a sample, which is accomplished by 
calculating the number of healthy cells by counting them or by measuring an indicator for 
healthy cells in cell populations (e.g. by adding a specific dye when using a microtitre plate 
assay). An increase in viability exemplifies cell growth, whereas a decrease is usually due to 
the toxic effects of the compounds being added or in other cases contaminated culture 
conditions (Stoddart, 2011).    
 
In comparison to cell viability studies, cell proliferation measures the growth of cell number 
within a sample. This assessment allows the determination of the actual number or 
proportion of proliferating cells in cell cultures or tissues, though quiescent non-growing 
healthy cells are not identified by this analysis (Mather & Roberts, 2006).      
 
Most viability assays focus on the integrity of the cell membrane or some specific metabolic 
activity of healthy cells. A cell population is incubated with a tetrazolium salt (e.g., MTT, XTT, 
and WST-1) which is cleaved to a coloured formazan product by metabolically active cells. 
This procedure is commonly used for measurement of metabolic activity (Cory, Owen, 
Barltrop, & Cory, 1991). Also analysing the ATP status of the cells can indicate the cellular 
energy capacity and consequently viability of such cells (Mosmann, 1983). An alternative 
assay analyses cytoplasmic membrane integrity. Dead cells show a stained cytoplasm while 
healthy cells are normal and can be directly counted (Mather & Roberts, 2006).    
 
Several cytotoxicity assays have been approved by the National Cancer Institute (NCI) of 
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which the most commonly used are the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H  tetrazolium, inner salt (MTS) and lactate 
dehydrogenase (LDH) assay (Baharith, Al-Khouli & Raab, 2006).  
 
1.11.1 The MTS Assay  
 
When a cell is damaged it loses the capability to maintain and provide energy for metabolic 
cell function and growth. Metabolic activity assays work on this principle and usually 
measure mitochondrial activity. A colorimetric substrate such as MTT, XTT or WST-1 is used 
and incubated within the cell samples (Davey & Lord, 2003).   
 
The MTS assay is used to determine if compounds have an effect on reducing mitochondrial 
activity thus indicating the possession of cytotoxic properties. The MTS assay is often 
defined as a ‘one-step’ MTT assay as the reagent can be added directly to the cell culture 
without the need of intermediate steps (Burger & Fiebig, 2004). The test is centred on the 
ability of viable cells to convert the MTS reagent into a soluble blue/purple formazan dye. 
Thus viable cells appear blue/purple whereas dead cells are unaffected and remain pale 
yellow (Burger & Fiebig, 2004). The exact cellular mechanism of MTS reduction into 
formazan involves reactions with intracellular NADH-oxidoreductases (Berridge, Herst & 
Tan, 2005). It is believed to occur mainly through the action of mitochondrial succinate 
dehydrogenase (Lobner, 2000).   
 
Figure 3- Conversion of MTS into aqueously soluble formazan salt (Promega, 2012) 
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1.11.2 The LDH Assay 
The effect on cell membrane integrity by potentially toxic compounds was measured using 
the lactate dehydrogenase (LDH) assay. LDH is an oxidoreductase which exists in most 
organisms and it catalyses the inter-conversion of pyruvate and lactate with an associated 
inter-conversion of NADH and NAD+, LDH is used as a catalyst. Pyruvate is used by the cell as 
a ‘dump’ for excess reducing power i.e. NADH in the absence of oxygen. This is facilitated by 
the action of the enzyme LDH (Fotakis & Timbrell, 2006). When a tissue suffers membrane 
damage, cells release LDH into the bloodstream. Since LDH is a stable enzyme it is widely 
used for the detection of damaged cells (Fotakis & Timbrell, 2006). The assay measures the 
release of LDH from cells with damaged membranes by measuring changes in fluorescence 
of reosurfin which is proportional to the quantity of released LDH (Promega, 2012). An 
increase in LDH release is shown by an increase in fluorescence which indicates increasing 
cytotoxicity.   
 
 
 
 
 
 
Figure 4- Release of LDH from damaged cells is measured by providing lactate, NAD
+
 and resazurin as 
substrates in the presence of diaphorase. Production of the fluorescent reosurfin product is proportional to 
the quantity of LDH.  (Promega, 2012) 
 
1.11.3 Trypan Blue Assay  
The Trypan Blue test is a dye exclusion method which can be used to determine the number 
of viable and/or non-viable cells within a cell suspension (Kalter, 2010). Trypan Blue is a 
diazo dye which actively stains the cytoplasm of dead cells. They can consequently be 
visualized using a microscope. Viable cells with intact cell membranes exclude dyes such as 
trypan blue; therefore their cytoplasm is not stained by this method. Cells are very selective 
as to what compounds pass through their membrane. A viable cell will exclude the trypan 
blue dye whereas non-viable cells will absorb the dye with resultant staining of its 
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cytoplasm. Under the microscope a living cell will possess a clear cytoplasm, whilst a dead 
cell will have a blue cytoplasm (Baust & Baust, 2007).                                                                                                                                   
 
1.12 Benzothiazine 
Benzothiazine is a heterocyclic compound composed of a benzene ring conjoined to a 6-
membered heterocyclic thiazine (Figure 5). Over the years benzothiazines have been studied 
in great detail (Niewiadomy, Matysiak & Karpinska, 2011 and Park et al, 2002). The 
preparation of this class of compound along with studies of their pharmacological and 
biological properties have been investigated in detail (Park, et al, 2002) and there is growing 
interest in this class of compound. (Niewiadomy et al, 2011).  
  
 
 
Figure 5- Structure of the 2, 1-benzothiazine nucleus (1) 
Several synthetic approaches to produce benzothiaizne and its derivatives have been 
discovered (Zinnes, Comes & Shavel, 1967). More recently their biological actions such as 
anticancer or antifungal properties have been studied (Niewiadomy et al, 2011). 
Ever since Braun and co-workers synthesized the first benzothiazine in 1923, a growing 
interest into their properties has occurred. Many thousands of compounds for the 
prospective treatment of diseases have since been synthesized. In the 1950s Abe and co-
workers discovered the anti-inflammatory and analgesic action of the benzothiazines by 
synthesizing various derivatives and noting these compounds exhibited medical, 
microbiocidal and agrochemical properties (Abe, Yamamoto & Matsui, 1956). Since Abe and 
co-workers initial discovery, interest into the pharmacological and biological activities of 
benzothiazines has gradually increased (Park et al, 2002).  
Depending on the substituents present; benzothiazine derivatives have exhibited a wide 
range of biological activities ranging from antipsychotic to anti-inflammatory activities    
(Camoutsis & Catsoulacos, 1992). The medical application of benziothiazine is however 
(1) 
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limited as a result of their detrimental side effects such as severe headache and 
gastrointestinal ulceration (Tumbleson & Schook, 1996). Over the last twenty years 
extensive research has been conducted to determine ways to limit or prevent these adverse 
side effects and produce benzothiazines with improved pharmacological properties 
(Niewiadomy et al, 2011). 
1.13 Biological Activities of Benzothiazine 
1.13.1 Antimicrobial Activities of Benzothizines 
3-Phenyl-N-(2,2-dimethoxyethyl)-3,4-dihydro-2H-1,4-benzothiazine was tested against 
Aspergillus niger and it demonstrated an antifungal activity 16-fold greater than miconazole 
(Armenise, Trapani, Stasi & Morlacchi, 1998). The same compound also demonstrated 
antibacterial activity against strains of Micrococcus luteus producing a minimum inhibitory 
concentration (MIC) of 31 µg/ml (Armenise et al, 1998). 
Derivatives of 2H-Benzo[1,4]thiazin-3-one (2) were administered to bacterial species 
including Micrococcus flavus, Proteus vulgaris, Salmonella enteritidis, Staphylococcus 
aureus, Escherichia coli and Bacillus cereus. The results obtained showed that these 
derivatives expressed activity against all strains tested (Guarda et al, 2001).  
 
 
 
 
 Figure 6- Structure of 2H-Benzo[1,4]thiazin-3-one (2) 
2H-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides derivatives were synthesized using a 
microwave. These compounds displayed anti-microbial activity against fungi and both Gram 
negative and Gram positive bacteria (Ahmad et al, 2011).  
1,2-Benzothiazine analogs having tetracycline structures were studied by  Zinnes et al (1967) 
which demonstrated antifungal activity against Aspergillus arogens and antibacterial 
activities against Bacillus megaterium, Escherichia coli and Bacillus subtilis.  
(2) 
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The compound groups 7-Chloro-5-trifluoromethyl-4H-1,4-benzothiazines, 7-fluoro-4H-1,4-
benzothiazines and 7-trifluoromethyl-4H-1,4-benzothiazines when compared to the 
reference drugs chloramphenicol and fulvin, showed moderate antimicrobial activity against 
organisms such as Bacillus subtilis, Bacillus megaterium, Escherichia coli, Aspergillus arogens 
and Aspergillus awamori (Rathore, Singh & Kumar, 2006).  
4H-1,4-benzothiazine derivatives were tested against Gram positive bacteria and C. albicans 
by Armenise et al (2006). The compounds 1-(5-chloro-7-fluoro-4H-1,4-benzothiazin-2-yl-
ethanone and  1-(5-chloro-7-fluoro-3-methyl-4H-1,4-benzothiazin-2-yl)-ethanone 
demonstrated antibacterial activity against strains of Bacillus cereus and Bacillus subtili. Also 
MIC values of 63 µg/ml and 16 µg/ml were obtained against Enterococcus faecalis and 
Staphylococcus aureus respectively. The same compounds also showed antifungal activity 
(MIC 125 µg/ml) against four strains of C. albicans (Armenise et al, 2006). 
 
Figure 7: Structures of (1-(5-chloro-7-fluoro-4H-1,4-benzothiazin-2-yl)-ethanone) (3) and (1-(5-chloro-7-
fluoro-3-methyl-4H-1,4-benzothiazin-2-yl)-ethanone)(4). 
In 2011 Sharma and co-workers reacted substituted 1,4-benzothiazines with either 
morpholine or N-(2 hydroxyethyl) piperazine to produce Morpholinyl or Piperazinyl 
benzothiazines. These compounds exhibited activity against both Bacillus cereus and 
Escherichia coli (Sharma, Kumar, & Vats, 2011). 
1.13.2 Benzothiazines as Anticancer Agents  
 
Peroxicam is a non-steroidal anti-inflammatory drug of the oxicam class which is used as an 
analgesic (Manjarrez, Perez, Solis & Luna, 1996). It has been shown that the risk of 
colorectal cancer can be reduced by 40-60% and telomerase activity can be inhibited using 
non-steroidal anti-inflammatory drugs (NSAIDs) (Brown et al, 2000). Recently 1,2 
benzothiazine derivatives have been shown to be highly effective non-steroid anti-
inflammatory agents (Manjarrez et al, 1996). Apart from Piroxicam, Sudoxicam and Isoxicam 
(3) (4) 
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are also examples of drugs used as anti-inflammatory agents (Brown et al, 2000). 1,2-
Benzothiazine-1,1-dioxides represent a new class of anti-inflammatory agent which includes 
the drug peroxicam (Manjarrez et al, 1996).  
 
 
 
Figure 8- Structure of piroxicam (5) 
 
1,4-Benzothiazine derivatives were synthesized by Abbas and co-workers (2010) and tested 
against the colon cancer cell line HCT-116, liver carcinoma cell line HPEG2-1 and human 
breast cell line MCF-7. Results indicated that the compounds 3-Acetyl-7,8-dimethoxy-2-
methyl-10H-pyrido-[3,2-b][1,4] benzothiazine, 2-(4-Chlorophenylhydrazono)-6,7-dimethoxy-
2H-1,4-benzothiazin-3(4H)-one and 6,7-Dimethoxy-2-(4-nitrophenylhydrazono)-2H-1,4-
benzothiazin-3(4H)-one showed activity against all tested cell lines, with the greatest activity 
being shown against HCT-116 cell line. Some of the 1,4-benzothiazine derivatives also 
showed antibacterial and antifungal activities with significant activities displayed against 
E.coli and S. Aureus (Abbas & Farghaly, 2010). 
 
 
 
 
 
Figure 9- Structures of 3-Acetyl-7,8-dimethoxy-2-methyl-10H-pyrido [3,2-b][1,4]benzothiazine (6), 2-(4-
Chlorophenylhydrazono)-6,7-dimethoxy-2H-1,4-benzothiazin-3(4H)-one (7) and 6,7-Dimethoxy-2-(4-nitro 
phenylhydrazono)-2H-1,4-benzothiazin-3(4H)-one (8). 
 
Derivatives of 2-aryl-4H-3,1-benzothiazine were synthesized and tested for their anti-
proliferative activity by Niewiadomy and co-workers. The compounds were evaluated for 
their anti-proliferative activity against the human cell lines HCV29T cells (bladder cancer); 
(5) 
(6) (7) (8) 
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A549 (human non-small cell lung carcinoma); T47D (human breast cancer) and SW707 
(human rectal adenocarcinoma) cells. The respective ID50 values (the concentration of the 
compound inhibiting the proliferation rate of the tumour cells by 50% as compared to the 
untreated control cells) obtained were compared to cisplatin, a drug used in the treatment 
of bladder cancer. The 2-aryl-4H-3,1-benzothiazine derivatives displayed activity equal to 
that of cisplatin with some derivatives showing greater activity (Niewiadomy et al, 2011). 
 
1.13.3 Other Activities 
As well as showing antimicrobial, anticancer and anti-inflammatory activities, benzothiazine 
derivatives have shown potential as central nervous system (CNS) depressants and anti-
depressants, calpain inhibitors, vasodilators, anticonvulsants, antioxidants and urease 
inhibitors in mammals. Additionally they are used therapeutically as muscle relaxants 
(Lombardino, Wiseman & McLamore, 1971).        
1.14 Synthetic Routes for Benzothiazines 
The first methods for the synthesis of benzothiazine compounds were reported by Abe and 
co-workers (Abe, Yamamoto & Matsui, 1956). The methods to synthesize various 
benzothiazine derivatives were extensively studied by Zinnes and co-workers (Zinnes et al, 
1967). 
 
 
 
 
 
 
Scheme 1- Synthesis of 1,2-benzothiazine using steps (A-D) by Abe & co-workers (Abe, et al, 1956). 
The compound N-Acetonylsaccharin (9) together with 2 equivalents of sodium ethoxide 
gave 80% yield of the 3-acetyl compound (10) (step A). If one equivalent of sodium ethoxide 
A C 
B 
D 
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was used compound (12) was produced (step B). This was readily converted to compound 
(10) when reacted with 2 equivalents of sodium ethoxide (step D).   
The sodium salt of (10) was reacted with methyl iodide in either aqueous or non-aqueous 
solution to obtain the N-methyl compound (11) (step C). There is evidence suggesting that a 
mechanism involving ethanolysis of the carboxamide linkage of (9) followed by a Dieckmann 
ring closure forms 3-acetly-2H-1,2-benzothiazin-4(3H)one 1,1-dioxide (10) (Abe et al, 1956). 
Recently the number of literature references to the 1,2-benzothiazine-1,1-dioxide ring 
system has increased significantly. Many of these concern the discovery of 3-carboxamides 
of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine-1,1-dioxides which act as anti-inflammatory 
agents. A typical example is the drug Piroxicam (5). Although there are a variety of synthetic 
routes available to obtain 1,2-benzothiazine-1,1-dioxides, the most frequently used in 
recent years follows the procedure of the Gabriel Colman rearrangement of saccharin 
derivatives (Scheme 2) (Weeks, Vinick, Breitenbach & Jung, 1983).   
 
 
Scheme 2- Synthesis of 1,2-benzothiazine-1,1-dioxides from saccharin derivatives 
Another method for synthesizing 1,2-benzothiazine derivatives is by using chalcones. An 
aldol condensation between a benzaldehyde (16) and an acetophenone (17) in the presence 
of sodium hydroxide as a catalyst produces chalcones (18) (Patel, 2012).  
 
 
Scheme 3- Synthesis of chalcones 
Substituted chalcones (19) react with chlorosulfonic acid to form sulfonyl chlorides (20), 
which are then reacted with bromine to form the dibromo compounds (21). The dibromo 
(13) (14) (15) 
(16) (17) (18) 
  NaOH in aq EtOH 
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compounds are subsequently treated with various amines to produce a variety of 1,2-
benzothiazines (22).   
 
 
 
 
 
 
 
 
Scheme 4- A general procedure for the synthesis of 1,2-benzothiazines using chalcones. The ‘R’ groups are 
various substituted groups of preference; where R
1
, R
2
 and R
3
 are either H, CH3, F, Cl or Br; R
4 
is either H, CH3, 
CH2CH3, Ph or PhCH2 and R
5
 is Br or NHCH3.   
The synthesis of various 3-carbamoyl benzothiazine derivatives (24) was described by 
Lombardino and co-workers (Lombardino, Wiseman & McLamore, 1971). The compounds 
were produced by the base catalysed reaction of the thiazinone nucleus (23) with a variety 
of aromatic isocyanates. In 1973 Zinnes et al used similar reactions to synthesize various 
other 3-carbamoyl benzothiazine derivatives. A reaction between N-substituted 4-hydroxy-
2H-1,2-benzothiazin-3-carboxylic acid methyl ester (25) with a suitable amine in refluxing 
xylene produced a number of carbamoyl derivatives (Zinnes, Lindo, Sircar, Schwartz & 
Shavel, 1973).  
 
 
 
 
Scheme 5- 3-Carboxamides of 2-alkyl -4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide. 
(19) (20) 
(21) (22) 
(23) (24) (25) 
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1.15 Tropan-3-one and 1-methyl Piperidin-4-one 
Tropane alkaloids are extracted from various plants including Datura stramonium, Datura 
innoxia, Hyoscyamus niger and Atropa belladonna (Gadzikowska and Grynkiewicz, 2002). 
Tropane compounds contain a nitrogenous bicyclic ring system (N-substituted-4-azabicyclo 
[3.2.1] octanes). Many naturally derived tropanes are N-methyl substituted and examples of 
compounds containing this skeleton include: scopolamine, cocaine and hyoscyamine 
(Humphery & O’Hagan, 2001).   
Piperidone comprises of a heterocyclic six-membered ring containing a nitrogen atom as 
well as a carbonyl group (Schilf, Jameson & Kuroki, 2011). Piperidone, is most commonly 
found as 1-methyl piperidin-4-one and its N- substituted derivatives are used in; 
pharmaceutical synthesis including drugs to aid the digestive system and to act as UV 
stabilizers (Schilf et al, 2011). 
 
Figure 10- The chemical structure of piperidin-4-one (26) 
The structures of tropane alkaloids and cocaine were firstly established in 1901 by Richard 
Martin Willstätter (Willstätter, 1901). The synthethic route for tropane alkaloids such as 
tropan-3-one was studied and modified by Robinson in 1917 to a three component one-pot 
double Mannich reaction (Robinson, 1917). As well as tropan-3-one, cocaine is another 
tropane alkaloid, which also comprises of the tropane core structure. Tropanones are 
commonly used as intermediates in the production of drugs such as atropine sulphate 
(Humphrey & O'Hagan, 2001). Tropan-3-one has a piperidone sub structure but it also 
contains an ethylene bridge as part of a 7-membered ring (Figure 11). 
 
(26) 
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Figure 11- The chemical structure of tropan-3-one (27) 
Various derivatives of tropan-3-one and piperidin-4-one have demonstrated inhibition of 
cell growth against J774 mouse macrophages (Hussain, 2012). It was intended to extend this 
study by synthesizing various novel substituted parent tropan-3-one compounds and then 
along with commercially available piperidin-4-one and N-methyl-piperidin-4-one produce a 
range of benzylidene derivatives using the aldol condensation with ring substituted 
benzaldehydes. The interaction is known to occur at positions alpha (α and a’) to the 
carbonyl group on both piperidones and tropan-3-ones. The functional groups C3-C4-O or 
C5-C4-O on piperidones and C2-C3-O or C4-C3-O on tropan-3-ones exist as enolisable 
functionalities thus they can undergo keto-enol tautomerisim fairly easily (Schilf, Jameson & 
Kuroki, 2011). This allows coupling of ring substituted benzaldehydes to occur easily at these 
points with the formation of benzylidene structures. The piperidone and tropan-3-one 
libraries would be screened against various fungal species as well as a mammalian cancer 
cell line to examine their possible antifungal or anticancer properties.   
 
 
 
  
Figure 12- The chemical structure of the intended substituted dibenzylidenes of tropan-3-one and 
piperidones. Where X= (H, H) for the piperidone and methyl-piperidone derivatives and X= (–CH2-CH2-) for 
the tropan-3-one derivatives. For both tropan-3-ones and piperidones Y=H, whereas it is CH3 for the methyl-
piperidones.  Various substituted aromatic aldehydes were reacted at points α and α’. R is various functional 
groups (e.g. fluorine, chlorine, bromine, methoxy or iodine) and they will be identical for each benzene ring.   
(27) 
α α' 
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Both sets of compounds contain a conjugated α,β unsaturated ketone. These are an 
important class of carbonyl compounds capable of undergoing the Michael reaction and 
reacting with nucleophiles such as S-. The Michael addition involves nucelophilic addition to 
the β carbon of the α,β-unsaturated carbonyl compound (Otera, 2001). Such α,β-
unsaturated compounds can undergo Michael reactions with cellular nucleophiles such as 
thiolate anions in proteins and cofactors such as glutathione (Pati et al, 2009).    
Previous studies have revealed that compounds consisting of an α,β -unsaturated ketone 
undergo the Michael reaction with cellular thiolate anions (Pati et al, 2009). Unlike amino 
and hydroxyl groups thiols are not found in nucleic acids. For the mitochondrial permeability 
transition pore complex to open it requires alkylation or cross-linking of a critical thiol within 
the protein permeability transition pore complex (Pati et al, 2009). Since some of the 
compounds used in this investigation contain an α,β-unsaturated ketone they should react 
easily with thiols via the Michael addition, therefore the mitochondrial permeability 
transition pore complex cannot open efficiently. This activates the caspase system which 
leads to the destruction of the mitochondria consequently leading to the initiation of cell 
death by apoptosis. As a consequence of the interaction of the α,β-unsaturated carbonyl 
with cellular thiols, compounds containing α,β-unsaturated carbonyls are known to be 
cytotoxic (Das et al, 2007). The interaction is known to occur at the olefinic carbon atoms 
(shown by CA and CB in figure 13) (Das et al, 2008, Mutus et al, 1989). The nucleophilic 
attack would be expected to occur at these points due to the electron-withdrawing 
influences of the carbonyl group (Manavathu, Dimmock, Vashishtha & Chandrasekar, 1999). 
 
 
 
  
 
Figure 13- The structure of dibenzylidene methyl piperidin-4-ones (where X= CH3) and dibenzylidene-1-
piperidin-4-ones (where X= H). The various substituents on the benzene rings are represented by R. Olefinic 
carbon atoms are shown by C
A
 and C
B    
N 
O 
X 
R R 
C A C B 
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Glutathione is a cellular antioxidant which prevents damage to important cellular 
components (Kaplowitz, 1981). Glutathione and the side chain of the amino acid cysteine 
consist of thiolate anions which act as nucleophiles and attack the olefinic carbons on the 
α,β-unsaturated structure (Das et al, 2008, Mutus et al, 1989). 
Other reports suggest that compounds having an α,β-unsaturated structure block the 
plasma membrane P-type proton-translocating ATPase (H+-ATPase) belonging to the P-type 
ATPase superfamily (Manavathu et al, 1999) of various fungal species (Manavathu et al, 
1999) or block the mitochondrial phosphate transporter (Griffiths, Partis, Sharp & Beechey, 
1981), both of which are essential for cell growth (Graham & Stevens, 1999).  
Alternatively compounds containing the dieneone structure can have an adverse effect on 
fungal cell growth by interfering with certain mitochondrial functions such as ROS 
generation or oxygen consumption by the electron transport chain (Helal et al, 2013). An 
increase in the level of reactive oxygen species (ROS) can lead to an overload of antioxidant 
defences culminating in cell death (Apel & Hirt, 2004). Oxidative phosphorylation is essential 
for cell growth and inhibition of this process may lead to an increase in the concentrations 
of ROS. This would affect the rate of oxygen consumption in the cell and also have a marked 
effect on the mitochondrial membrane potential (MMP) (Helal et al, 2013).          
1.16 Biological Activities of Tropan-3-one and Piperidin-4-one    
In the past various N-substituted tropanone and piperidone derivatives, as well as similar 
compounds, all of which contain an α,β-unsaturated carbonyl have exhibited properties of 
biological and pharmacological interest. They have shown analgesic, anti-depressant, 
antibacterial, cytotoxic, antihypertensive or fungicidal activities (Das et al, 2007).   
1.16.1 Tropan-3-ones and Piperdin-4-ones as Anticancer Agents 
There have been various studies examining the cytotoxic effects of compounds containing 
the α,β-unsaturated carbonyl on a variety of cell types including cancer cell lines.  
Das and co-workers synthesized and analysed the cytotoxic properties of novel 1-[4-(2-
alkylaminoethoxy) phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and  associated 
compounds (Das et al, 2007). The compounds were compared with the established 
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anticancer drugs melphalan and 5-fluorouracil in different bioassays. It was observed that 
most of the novel compounds exhibited greater potencies than the reference drugs. They 
found that the compounds had considerably lower IC50 values when compared to 
established anti-cancer drugs, with some compounds showing IC50 values nine-fold lower 
than that of melphalan (a standard anticancer drug often used as an internal standard). The 
results also indicated that many of the compounds had greater cytotoxic effects on 
malignant tissue than on normal cells (Das et al, 2007). This suggests the series of 
compounds synthesized are more effective and better cytotoxic agents compared to the 
recognised anti-cancer drug melphalan.      
Pati et al (2009) focused their studies on a series of 4-piperidone and tropanone dieneones 
which are very similar to the compounds proposed for in this investigation. Studies revealed 
that these groups of compounds also possessed greater cytotoxicity against cancer cell lines 
when compared to melphalan, a chemotherapeutic drug used in the treatment of multiple 
myeloma and ovarian cancer (Auyang, 2005). In general the 4-piperidone series of 
compounds exhibited greater cytotoxic effects when compared to the tropanone series. It 
was also shown that both sets of compounds, particularly the 4-piperidone series were 
responsible for increased swelling of rat liver mitochondria. Pati and co-workers found that 
some of the piperidone dieneones gave greater toxicity towards various malignant cell lines 
rather than non-cancerous cells (Pati et al, 2009). 
Dimmock et al, (2002) synthesized and tested a group of 1,3-diarylidene-2-tetralones on 
human and murine cancer cell lines.  The studies revealed that this group of compounds 
possessed greater cytotoxicity to the cancer cell lines when compared to melphalan. Some 
compounds exhibited significant toxicity towards leukemic and colon cancer cell lines. 
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Figure 14- The chemical structure of 1-((E)-benzylidene)-3-benzylidene-3,4-dihydronaphthalen-2(1H)-one (28) 
which is from a family of 1,3-diarylidene-2-tetralones  
The studies mentioned previously along with numerous other investigations, have all used 
compounds having structural similarities to the compounds synthesized and tested in this 
research. These studies have reported that similar compounds to those used in this 
research, particularly those containing an α,β unsaturated carbonyl show encouraging 
cytotoxic activities against various cancer cell lines. Therefore it was proposed to synthesize 
further compounds within the tropanone/piperidone class with varying substituents both on 
the nitrogen atom and the benzylidene rings.      
1.16.2 Antimicrobial Properties of Tropan-3-one and Piperidin-4-one Compounds  
Derivatives of 2,6-diaryl-3-methyl-4- piperidone were screened for their antifungal activities 
by Natesh et al, (2003). Of the seven different compounds tested only 2-(4-methylphenyl)-3-
methyl-6-(4-hydroxyphenyl)-piperidin-4-oxime (29) and 2-(4-methoxyphenyl)-3-methyl-6-(4-
chlorophenyl)-piperidin-4-oxime (30) exhibited significant antifungal activity against 
Aspergillus niger as they produced the same level of inhibition as the internal standard 
(ketoconazole). Antifungal activity against Candida albicans was observed only with 2-(4-
dimethyl-aminophenyl)-3-methyl-6-(4-chlorophenyl)-piperidin-4-oxime which produced the 
same level of inhibition as ketoconazole (Natesh et al, 2003).   
 
 
 
(28) 
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Figure 15- The chemical structures of 2-(4-methylphenyl)-3-methyl-6-(4-hydroxyphenyl)-piperidin-4-oxime 
(29) and 2-(4-methylphenyl)-3-methyl-6-(4-chlorophenyl)-piperidin-4-oxime (30) 
 
Senthil and co-workers synthesized and examined the compound 3-methyl, 2-phenyl (3,4-
dihydroxy), 6 phenyl, piperidin-4-one for antimicrobial activitiy. Results obtained showed 
that the compound had no antibacterial activity. However it did exhibit antifungal activity 
against the yeasts Candida albicans and Candida tropicalis, and the filamentous fungus 
Aspergillus niger (Senthil, Kumar & Raju, 2011). 
 
Mittal and colleagues (2011) synthesized various substituted N-benzhydrylpiperidin-4-amino 
derivatives by reductive amination of benzhydrylamine and N-substituted 4-piperidones. 
These compounds were found to have considerable antibacterial and antifungal activities 
when compared to ciprofloxacin (standard antibacterial drug) or fluconazole (standard 
antifungal drug) respectively. All compounds synthesized exhibited better antibacterial 
activity rather than antifungal activity. Additionally the compounds were more active 
against Gram positive bacteria rather than Gram negative bacteria (Mittal, Sarode, Shingare, 
Vidyasagar & Shrivastava, 2011).    
 
 
Figure 16- The chemical structure of N-benzhydrylpiperidin-4-amine (31) 
(29) (30) 
(31) 
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Tropan-3-ones can be considered as 2,6 ethylene bridged piperidones  (27). Tropan-3-one 
derivatives have also shown promising antifungal and antibacterial activities (Pati et al, 
2009). Thus these compounds need further study to possibly develop more potent 
antifungal agents. 
1.17 Synthetic Approaches for Tropan-3-one and Piperidin-4-one    
Historically tropane derivatives have been synthesized utilizing a variety of routes including: 
Michael addition of an amine across an unsaturated cycloheptadieneone or oxalyl addition 
to pyrroles or nitrile oxide cycloaddition (Tufariello, 1979). However the Robinson reaction 
(Robinson, 1917) as modified in 1954 by Stoll and co-workers (Stoll, Jucker & Lindenmann, 
1954) is the most suitable and commonly used route for the synthesis of the tropane 
skeleton. The Robinson one pot synthesis or a variation of it is still routinely used for the 
synthesis of tropane and its derivatives (Thuo, 2008).   
 
Figure 17- Synthesis of tropanone using Robinson’s one-pot synthesis where X= H, CO2H or CO2Et (Thuo, 
2008) 
The Mannich reaction is a very useful organic reaction for the synthesis of carbon-carbon 
bonds (Azizi, Torkiyan & Saidi, 2006). A number of Mannich reactions have been developed 
using different catalysts to produce various Mannich products of high enantioselectivities 
(Humphary & O’Hagan, 2007). The methodology depends on the two component system 
(also known as indirect). The indirect variants are characterized using electrophiles such as 
preformed imines, and stable nucleophiles such as enolates, enamines or enol esters. The 
most favoured method is a direct, one-pot three component strategy as it allows a wide 
range of structural variations (Azizi et al, 2006).  
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In the synthesis of tropanone Robinson’s uses of succindialdehyde, methyl amine, and 
acetone (or the 1,3-dicarboxylic acid derivative of acetone) are used in a one-pot, three 
component reaction (Robinson, 1917). The Robinson synthesis is, in effect, a double 
Mannich reaction (Azizi et al, 2006).  
Piperidones are usually synthesized by combining an alkyl-1,3-acetonedicarboxylate with 
benzaldehyde and an amine. This reaction is known as the Petrenko-Kritschenko piperidone 
synthesis (Li, 2005). However a wide variety of N-substituted piperidones are readily 
available. 
1.17.1 Synthesis of Various Dibenzylidenes using the Aldol Condensation 
The aldol condensation involves a nucleophilic addition between an enolate and the 
carbonyl group of an aldehyde or ketone to produce β-hydroxyketone (aldol) (Noyce & 
Pryor, 1955). The reaction usually involves the use of a strong base such as NaOH in the 
presence of a solvent system usually comprised of an alcohol and water. Alternatively the 
reaction can occur using a strong acid such as HCl in acetic acid. (Leonova, Makarov, 
Klemenkova & Odinets, 2010). Other methods include the use of Lewis acids such as lithium 
perchlorate (LiClO4/TMSNEt2) or magnesium bromide (MgBr2·Et2O/MeOH/Et3N) or 
alternatively Lewis bases such as Bu3P or Ph3P (Leonova et al, 2010).      
Enolate ions act as nucleophiles with the carbonyl group acting as the electrophile. 
Dehydration of the aldols by the E1 mechanism subsequently gives rise to conjugated 
enones by the loss of a water molecule and the formation of an α,β-unsaturated ketone. 
Again this step is usually base catalysed however an acid may be used instead (Climent, 
Corma, Fornés, Guil-Lopez & Iborra, 2002).  
In the base catalysed reaction the hydroxide ion generates the reactive enolate by removing 
the weakly acidic α-hydrogen. The carbonyl carbon on the aldehyde is attacked by the 
nucelophilic enolate carbon atom which produces a tetrahedral intermediate alkoxide. 
(Climent et al, 2002). This is followed by either protonation to yield the β-hydroxy ketone, 
which may undergo dehydration to form the enone, or an acid-base reaction where the 
alkoxide deprotonates a water molecule creating the aldol product as well as a hydroxide 
ion (refer to step 1, figure 15). The dehydration of the aldol product initially involves the 
33 | P a g e  
 
formation of an enolate as a result of the base removing the acidic α-hydrogen (Luo & 
Falconer, 1999). The C=C double bond is formed from the electrons associated with the 
negative charge of the enolate thus resulting in the loss of a water molecule and formation 
of a conjugated α,β enone (refer to Step 2, Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18- Base catalysed aldol condensation of acetaldehyde (Eagleson, 1993).  
In the present study N-substituted piperidones were reacted with various aromatic 
aldehydes using the aldol condensation. Several synthetic approaches have been deployed 
for this reaction, which vary in the nature of the solvent and catalytic base used. In most 
cases the methods used are variations on the condensation of ketones with aldehydes in a 
basic aqueous alcoholic medium (McElvain & Rorig, 1948).  
1.18 Aims and Objectives were to: 
 synthesize and characterise various parent tropan-3-one compounds;  
Step 1  Step 2  
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 synthesize and characterise novel benzene ring substituted 3,5-benzylidene 
derivatives of tropan-3-one and  piperidin-4-one;  
 characterise compounds using 1H and 13C nuclear magnetic resonance (NMR) 
spectroscopy, mass spectrometry, Fourier transform infrared (FT-IR), melting/boiling 
point determination and, where required, ultraviolet visible (UV) spectroscopy and 
retention times from high pressure liquid chromatography (HPLC); 
 examine the antifungal activity of the synthesized compounds along with some 
synthesized 1,2-benzothiazine derivatives by analysing the inhibition of growth of 
yeasts (S. cerevisiae and C. albicans), and filamentous fungi (e.g. A. niger) by 
measuring relevant IC10, IC50, and IC90 or MIC values 
 test the cytotoxic activity of selected compounds by measuring the corresponding 
IC10, IC50, and IC90 values against a tumour cell line (A549).      
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Chapter 2 
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Characterization of Novel 
Nitrogen Containing 6 and 
7-membered Heterocyclic 
Compounds  
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Chapter 2.1: Materials and Methods 
 
2.1.1 Materials: 
The coupling of readily available N-methyl-4-piperidone (32) or 4-piperidone hydrochloride 
monohydrate (33) with various ring substituted benzaldehydes (Figure 20) at the C-3 and C-
5 positions was performed using the aldol condensation to synthesize 3,5-dibenzylidene-
piperidin-4-ones along with the N-methyl derivatives. The reaction was utilized using either 
KOH or 10% NaOH in either aqueous ethanol or aqueous methanol.   
 
  
 
 
 
N-methyl-4-piperidone (32)                  4-piperidone hydrochloride monohydrate (33)  
 
Figure 19- Parent piperidin-4-one molecules  
 
Various ring substituted benzaldehydes were coupled with the parent piperidin-4-one 
compounds to produce a variety of aromatic ring substituted benzylidenes.   
 
  
 
 
 
 
 
 
Figure 20- Structure of R-benzaldehyde (34,) where R= various substituents 
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Table 1- Various R-substituted benzaldehydes used to produce benzylidenes 
 
Compound number R 
34a H 
34b 2-Cl 
34c 3-Cl 
34d 4-Cl 
34e 2-Br 
34f 3-Br 
34g 4-Br 
34h 2-F 
34i 3-F 
34j 4-F 
34k 2-OCH3 
34l 4-OCH3 
34m 2-I 
34n 3-I 
   
In addition to benzylidene derivatives of piperidones, attempts were made to synthesize 
various N-substituted tropane analogues. Initially the synthesis of various parent tropanone 
compounds was attempted prior to coupling with various substituted benzaldehydes. The 
synthesis of:  4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoic acid (35), 2-((1R,5S)-3-
oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoic acid (36), 3-((1R,5S)-3-oxo-8-azabicycle[3.2.1] 
octan-8-yl) benzoic acid (37) and  ethyl-4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) 
benzoate (38) was attempted using the modified Robinson synthesis (Stoll et al, 1954).  
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Figure 21- Proposed parent tropan-3-one molecules 
All chemicals used were purchased from Sigma Aldrich and used in the form they were 
delivered without any further purification. The physical properties and chemical structure of 
all the compounds produced were characterized using various analytical techniques. 
Melting points were determined using an electrothermal capillary melting point apparatus 
(Gallenkamp).  Thin layer chromatography (TLC) was performed using pre-coated silica gel 
plates (Macherey-Nagel: DC-fertigfolien polygram sil G/UV254). The compounds were 
dissolved in an appropriate solvent and a relevant solvent system was used to develop the 
plates. Visualisation was performed using a mineralight UV lamp. Fourier transform-infrared 
spectra were obtained using either a FT/IR-Varian Scimitar or Perkin-Elmer Frontier 
spectrometer with a golden plate attachment and peaks are reported as cm-1. Liquid 
chromatography-mass spectrometry (LC-MS) was performed using a VG Micromass V15 
spectrometer operating at 70 eV (Varian: 210 LC pumps × 2, 1200L Quadrapole MS/MS, 410 
autosampler) using a gradient solvent system of A: water/0.1% formic acid and B: 
acetonitrile/ 0.1% formic acid. LC-MS was used to determine the mass of the compounds as 
well as molecular fragments. Nuclear magnetic resonance (NMR- 1H, 13C and DEPT) was 
performed on all compounds using a JEOL ECA600 spectrometer at a frequency of 600 MHz. 
Chemical shifts were measured in ppm (δ) relative to the solvent used to dissolve the 
compounds (DMSO-d6, methanol-d4 or CDCl3). The following abbreviations are used to 
describe the signal multiplicities: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) 
and br (broad). The following abbreviations are used to identify the different proton 
(35) (36) (37) (38) 
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environments present in the compounds: aliph (aliphatic protons), arom (aromatic protons) 
and benzyldiene (benzyldiene protons). Signal peaks obtained for the solvents utilised to run 
the 1H and 13C NMR are not quoted.  
 
2.1.2 Methodology for the synthesis of dibenzylidenes  
 
2.1.2.1 General procedure for the preparation of aromatic ring substituted 3,5-
dibenzylidene-1-methyl piperidin-4-ones and their hydrochloride salts by coupling of 
substituted benzaldehydes with N-methyl-4-piperidone  
 
 
 
  
 
 
Figure 22- General protocol for the coupling of substituted benzaldehydes with N-methyl-4-piperidone 
 
N-methyl-4-piperidone (1.13ml, 0.01 moles) and 28ml of 40% ethanol were added to a 
100ml round bottomed flask, followed by addition of the relevant benzaldehyde (34a-34n, 
0.02 moles (refer to Table 1, Page 37) and powdered potassium hydroxide (1.2g, 0.02 
moles). The reaction was stirred at room temperature for 60 minutes during which a yellow 
solid precipitated. TLC (Silica gel, Macherey-Nagel) was used to monitor the reaction. When 
the reactants had been consumed the crude solid was filtered, washed with iced methanol 
(3ml) and dried under nitrogen in a vacuum pistol (50°C, 24 hours). Crude material was 
recrystallized from either methanol or 95% ethanol (25-30ml, 50°C) over 24 hours. The 
resultant yellow crystals were filtered, washed with iced methanol (3ml) and dried in a 
vacuum pistol (50°C). Hydrochloride salts were prepared from crude material by either 
recrystallization from 30-35ml of 5% hydrochloric acid (50°C) or by dissolving the crude 
material in 95% ethanol (25-35ml, 50°C) followed by drop-wise addition of 1M hydrochloric 
acid (7-9ml). The solutions were left on ice for 24 hours to produce the hydrochloride salts. 
The fine yellow needles produced were filtered, washed with iced methanol (3ml) and dried 
in a vacuum pistol (50°C). The recrystallized solids, hydrochloride salts, crude materials and 
the starting materials were compared using silica TLC.  
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2.1.2.2 General procedure for the preparation of aromatic ring substituted 3,5-
dibenzylidene-1-piperidin-4-ones and their  hydrochloride salts by coupling of substituted 
benzaldehydes with 4-piperidone hydrochloride monohydrate  
 
 
 
 
  
Figure 23- General protocol for the coupling of substituted benzaldehydes with 4-piperidone hydrochloride 
monohydrate 
 
4-Piperidone hydrochloride monohydrate (1.54g, 0.01 moles) was dissolved in distilled 
water (4ml) in a 100ml round bottomed flask followed by the addition of ethanol (95%, 
20ml) and the relevant benzaldehyde (34a-34n, 0.02 moles (refer to Table 1, Page 37). The 
reaction was stirred and sodium hydroxide solution (10%, 20ml, 0.5 moles) was added in 
small aliquots. After stirring the mixture for 60 minutes a yellow solid had precipitated. The 
reaction was followed to completion using silica gel TLC (Macherey-Nagel) following which 
the precipitate was filtered, washed with iced methanol (3ml) and the crude materials dried 
under nitrogen in a vacuum pistol (50°C, 24 hours). Crude material was recrystallized from 
95% ethanol (14-20ml, 50°C) over 24 hours. The resultant yellow crystals were filtered, 
washed with iced methanol (3ml) and dried in a vacuum pistol (50°C). Further samples from 
the crude products were recrystallized from dichloromethane (7-20ml), followed by the 
addition of  95% ethanol (40°C, 3-8ml) and drop-wise addition of concentrated hydrochloric 
acid (1-1.2ml). The solutions were immersed in ice for 24 hours after which fine 
cream/yellow needles of the hydrochloride salts were produced. The recrystallized salts 
were filtered, washed with iced methanol (3ml) and dried in a vacuum pistol (50°C). Silica 
TLC was used to compare the recrystallized solids, hydrochloride salts, crude material and 
starting reactants.   
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Table 2- Various substituent groups present on the benzene rings of the benzylidene 
products and their associated compound numbers 
R 3,5-
dibenzylidene-1-
methylpiperidin-
4-ones 
3,5-
dibenzylidene-1-
methylpiperidin-
4-one HCl salts  
3,5-
dibenzylidene-
1-piperidin-4-
ones 
3,5-
dibenzylidene-
1-piperidin-4-
one HCl salts 
H 39a 40a 41a 42a 
2-Cl 39b 40b 41b 42b 
3-Cl 39c 40c 41c 42c 
4-Cl 39d 40d 41d 42d 
2-Br 39e 40e 41e 42e 
3-Br 39f 40f 41f 42f 
4-Br 39g 40g 41g 42g 
2-F 39h 40h 41h 42h 
3-F 39i 40i 41i 42i 
4-F 39j 40j 41j 42j 
2-OCH3 39k 40k 41k 42k 
4-OCH3 39l 40l 41l 42l 
2-I 39m 40m 41m 42m 
3-I 39n 40n 41n 42n 
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2.1.3 Methodology for the synthesis of Tropan-3-ones  
 
2.1.3.1 Procedure for the Synthesis of Benzocaine  
 
 
 
 
 
 
 
 
Figure 24- Reaction scheme for the synthesis of benzocaine (43d) 
 
To a 1000ml round bottomed flask containing absolute ethanol (200ml) 4-Aminobenzoic 
acid (27.4g, 0.2 moles) was added followed by sulphuric acid (1ml) as a catalyst. The 
reaction was stirred at 100°C for 4 hours under reflux. Silica gel TLC (Macherey-Nagel) was 
used to follow the reaction to completion. Upon cooling a white solid precipitated, which 
was filtered and washed with iced methanol (5ml). The crude product was dissolved in 
absolute ethanol (39ml, 50°C) followed by the addition of distilled water (11ml). The 
solution was immersed in ice from which fine white crystals formed. The crystals were 
filtered, washed with iced methanol (5ml) and dried using a vacuum pistol (60°C).  
Recrystallized and crude materials were compared using silica gel TLC.   
 
 
 
 
 
 
 
 
 
 
 
(43a) (43d) 
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2.1.3.2 Attempted Two-step Synthesis of (2, 3 and 4)-((1R,5S)-3-oxo-8-azabicyclo[3.2.1] 
octan-8-yl) benzoic acid and ethyl-4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoate 
 
 
Figure 25- Generalised reaction scheme for the synthesis of (2, 3 or 4)-((1R,5S)-3-oxo-8 azabicyclo [3.2.1] 
octan-8-yl) benzoic acids and ethyl-4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoate, where 43a: 4-
NH2/R=H, 43b: 2-NH2/R=H, 43c: 3-NH2/R=H, 43d: 4-NH2/R=Et and 47a: 4-CO2/R=H, 47b: 2-CO2/R=H, 47c: 3-
CO2/R=H, 47d: 4-CO2/R=Et.  
 
2.1.3.3 Procedure for The Two-step Synthesis of 4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-
8-yl) benzoic acid (47a)  
Succindialdehyde (45) was prepared in a 500ml round bottomed flask by mixing 2,5-
dimethoxytetrahydrofuran (16.2 ml, 0.120 moles) with deionised water (250ml) along with a 
few drops of concentrated hydrochloric acid. The mixture was heated for 30 minutes at 55°C 
(step 1) (Stoll et al, 1954). 
In a 1 litre conical flask sodium acetate (50g, 0.61 moles) was dissolved in deionised water 
(300ml) followed by 4-aminobenzoic acid (16.8g, 0.123 moles, (43a)), the succindialdehyde 
mixture from step 1 and acetone 1,3-dicarboxylic acid (3-oxopentanedioic acid) (18g, 0.123 
moles). The reaction was stirred overnight at room temperature (22°C) during which a pale 
yellow solution with a cream/white precipitate formed. The consumption of all reactants 
was followed by silica TLC (Macherey-Nagel). The solid was filtered, washed with iced 
methanol (5ml) and dried in a vacuum pistol (70°C). Crude material (0.5g) was recrystallized 
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from 50ml methanol (68°C) and, following hot filtration, the solution was immersed in ice 
and left overnight. The recrystallized material was filtered, washed with iced methanol (5ml) 
and dried in a vacuum pistol (70°C). Remaining crude material (7.45g) was recrystallized 
from 150ml methanol (68°C).  
Post filtration of the solid from the reaction mixture, further solid material formed. The 
solvent was removed by rotary evaporation (30°C) leaving a solid residue. The solid residue 
was dissolved in methanol (68°C, 200ml) and the resulting solution was concentrated to half 
the volume using rotary evaporation (40°C). The solution was then immersed in ice 
overnight and the resultant crystals were filtered, washed with iced methanol (5ml)  and 
dried (70°C) to constancy. Both recrystallized materials were analysed by silica TLC 
developed with DCM.   
 
2.1.3.4 Procedure for The Attempted Two-step Synthesis of 2-((1R,5S)-3-oxo-8 azabicyclo 
[3.2.1]octan-8-yl) benzoic acid (47b) 
The synthesis of 2-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoic acid was carried out 
in a similar fashion as described in 2.1.3.3, replacing 4-aminobenzoic acid (43a) with 2-
aminobenzoic acid (5.6g, 0.04 moles, (43b)). A smaller scale was used in this experiment 
(step 1: 2,5-dimethoxytetrahydrofuran (5.5ml, 0.04 moles), water (17ml), step 2: sodium 
acetate- 12.51g, 0.15 moles, water (75ml) acetone 1,3-dicarboxylic acid- 6.0g, 0.04 moles). 
This reaction was performed under a nitrogen atmosphere to remove any oxygen which 
could have possibly oxidised the succindialdehyde to succinic acid which might reduce the 
yield. The water used in the experiment was purged with nitrogen gas to remove any 
oxygen which could potentially oxidise the aldehyde. The resulting solution was 
yellow/orange and it was left to stir overnight at room temperature (21°C).  A lumpy solid 
was produced which was dissolved in dichloromethane (150ml). The resulting mixture 
consisted of two layers. The mixture was washed with brine (50ml) following which the 
brine was removed and the organic layer was dried using anhydrous magnesium sulphate 
(2g). The magnesium sulphate was removed by filtration and the solvent removed by rotary 
evaporation (40°C). Diethyl ether (20ml) was added to the solid residue and the residue was 
scraped from the side of the flask and separated from the diethyl ether under vacuum. 
Analysis by silica TLC (Macherey-Nagel) showed that the solid was predominantly 2-
aminobenzoic acid and no product had been formed. It is possible that most the product 
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was lost when washing with brine. As the product formed is possibly zwitterionic, it could 
have been extracted with the brine.  
2.1.3.5 Procedure for The Attempted Two-step Synthesis of 3-((1R,5S)-3-oxo-8 azabicyclo 
[3.2.1]octan-8-yl) benzoic acid (47c) 
The synthesis of 3-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoic acid was conducted 
in a similar fashion as described in 2.1.3.4, replacing 2-aminobenzoic acid (43b) with 3-
aminobenzoic acid (43c). The resulting solution was orange/brown and it was stirred 
overnight at room temperature (21°C). A brown solid was produced which was slightly 
soluble in methanol, the mixture was left initially on ice and then at room temperature 
overnight, after which no change was observed.    
The experiment was repeated under minimum light conditions to reduce photosensitivity 
because it is possible that the reaction is sensitive to light, hence the dark colour of the solid 
obtained from the initial experiment. The crude material obtained was dissolved in 75ml 
methanol (68°C) and 10ml diethyl ether (20°C) was added. Recrystallization did not occur 
when the solution was left overnight on ice therefore it was immersed in ice for a further 48 
hours, however no solid was formed so it was discarded. Analysis by silica TLC (Macherey-
Nagel) showed that the crude material consisted of just starting reactants and no new 
products had formed.        
 
2.1.3.6 Procedure for The Attempted Two-step Synthesis of ethyl-4-((1R,5S)-3-oxo-8-aza 
bicycle [3.2.1] octan-8-yl) benzoate (47d)    
The synthesis of ethyl-4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoate (47d) was 
conducted in a similar manner as described in 2.1.3.3, replacing 4-aminobenzoic acid (43a) 
with benzocaine (43d). The quantities of the reactants were as follows; 2,5-
dimethoxytetrahydrofuran (8.5ml, 0.06 moles), water (20ml), benzocaine (10.7g, 0.06 
moles), sodium acetate (17g, 0.2 moles), water (60ml), acetone 1,3-dicarboxylic acid (9.4g, 
0.06 moles). A cream/white precipitate was formed during the course of the reaction. The 
consumption of the reactants was followed by silica TLC (Macherey-Nagel). Crude material 
obtained from the reaction was filtered, washed with iced methanol (5ml) and dried using a 
vacuum pistol (60°C). The crude product was recrystallized from methanol (75ml, 68°C) and 
incubated overnight in an ice bath. The resultant fine white crystals were filtered, washed 
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with ice cold methanol (5ml) and dried under vacuum (60°C). Purity of the recrystallized 
material was checked by comparing it to the crude material and starting reactants using 
silica gel TLC. 
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Chapter 2.2: Results- Compound Characterisation  
 
Based on the results obtained by reacting benzaldehyde with piperidone derivatives, various 
substituted aldehydes were reacted to yield a series of substituted (E) α and α’ benzylidene 
piperidone derivatives. Each derivative was characterized using a variety of physiochemical 
techniques, the details and values of which are listed below for each compound.  
 
2.2.1 Spectral data for the synthesized aromatic ring substituted 3,5-dibenzylidene-1-
methylpiperidin-4-ones and their hydrochloride salts (39a-39n and 40a-40n) 
 
3,5-Dibenzylidene-1-methylpiperidin-4-one (39a)  
Chemical Formula: C20H19NO. M.Wt : 289.15. Recrystallized from methanol. Yield: 41%. Rf : 
0.4 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 115-118°C (115-150°C, Mcelvain & Rorig, 1948).  
IR (golden gate/cm-1): 1679 (C=O),  1587 (C=C), 1621 (aromatic) 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 4.60 (s, 4H, aliph H), δ 7.49 -7.56 (m, 10H, 
arom H) and δ 7.87 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 54.41, 129.51, 130.69, 131.30, 134.11. LC-MS (m/z): 290.4 (M+H
+).    
3,5-Bis(2-chlorobenzylidene)-1-methylpiperidin-4-one (39b)  
Chemical Formula: C20H17Cl2NO. M.Wt : 358.26. Recrystallized from 95% ethanol. Yield: 74%. 
Rf : 0.56 (Silica TLC; DCM:EtAc, 2:1). M.Pt: 154-157°C (152-154°C, Mcelvain & Rorig, 1948). 
IR (golden gate/cm-1): 1679 (C=O), 1446 (C=C), 1547 (aromatic)    
1H-NMR (DMSO-d6): δ 2.26 (br s, 3H, aliph H), δ 3.60 (s, 4H, aliph H), δ 7.41 -7.44 (m, 8H, 
arom H) and δ 7.75 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 56.74, 127.90, 130.30, 131.42, 132.23, 135.46, 186.42 (C=O). LC-MS 
(m/z): 359.30 (M+H+).   
3,5-Bis(3-chlorobenzylidene)-1-methylpiperidin-4-one (39c)  
Chemical Formula: C20H17Cl2NO. M.Wt : 358.26. Recrystallized from 95% ethanol. Yield: 89%. 
Rf : 0.54 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 156-158°C.  
IR (golden gate/cm-1): 1679 (C=O), 1446 (C=C), 1547 (aromatic)    
1H-NMR (DMSO-d6): δ 2.37 (br s, 3H, aliph H), δ 3.72 (s, 4H, aliph H), δ 7.45 -7.49 (m, 8H, 
arom H) and δ 7.56 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 56.6, 129.4, 129.5, 130.4, 131.1, 133.8, 186.9 (C=O). LC-MS (m/z): 
359.30 (M+H+).   
   
3,5-Bis(4-chlorobenzylidene)-1-methylpiperidin-4-one (39d)  
Chemical Formula: C20H17Cl2NO. M.Wt : 358.26. Recrystallized from 95% ethanol. Yield: 82%. 
Rf : 0.57 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 156-159°C. 
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IR (golden gate/cm-1): 1679 (C=O), 1446 (C=C), 1547 (aromatic). 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 3.71 (s, 4H, aliph H), δ 7.48 -7.52 (m, 8H, 
arom H) and δ 7.57 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6) δ 56.78, 129.33, 132.74, 133.92, 134.77, 186.88 (C=O). LC-MS (m/z): 
359.30 (M+H+).    
3,5-Bis(2-bromobenzylidene)-1-methylpiperidin-4-one (39e)  
Chemical Formula: C20H17Br2NO. M.Wt : 447.16. Recrystallized from 95% ethanol. Yield: 
76%. Rf : 0.72 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 223-228°C. 
IR (golden gate/cm-1): 1672 (C=O), 1586 (C=C), 1618 (aromatic). 
1H-NMR (methanol-d4): δ 2.41 (br s, 3H, aliph H), δ 3.8 (s, 4H, aliph H), δ 7.36 -7.43 (m, 8H, 
arom H) and δ 7.89 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4): δ 57.84, 128.68, 130.21, 130.47, 131.93, 132.66, 134.91, 135.34. LC-
MS (m/z): 448.1 (M+H+).        
 
3,5-Bis(3-bromobenzylidene)-1-methylpiperidin-4-one (39f)  
Chemical Formula: C20H17Br2NO. M.Wt : 447.16. Recrystallized from 95% ethanol. Yield: 
84%. Rf : 0.74 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 225-230°C. 
IR (golden gate/cm-1): 1668 (C=O), 1586 (C=C), 1618 (aromatic). 
1H-NMR (methanol-d4): δ 2.47 (br s, 3H, aliph H), δ 3.81 (s, 4H, aliph H), δ 7.37 -7.43 (m, 8H, 
arom H) and δ 7.71 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4): δ 56.11, 122.32, 128.68, 130.21, 131.93, 132.66, 133.98, 134.90, 
137.12. LC-MS (m/z): 448.1 (M+H+).         
 
3,5-Bis(4-bromobenzylidene)-1-methylpiperidin-4-one (39g)  
Chemical Formula: C20H17Br2NO. M.Wt : 447.16. Recrystallized from 95% ethanol. Yield: 
75%. Rf : 0.61 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 229-232°C. 
IR (golden gate/cm-1): 1668 (C=O), 1587 (C=C), 1619 (aromatic). 
1H-NMR (methanol-d4): δ 2.47 (br s, 3H, aliph H), δ 3.81 (s, 4H, aliph H), δ 7.37 -7.43 (m, 8H, 
arom H) and δ 7.71 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4): δ 56.28, 128.67, 131.86, 132.66, 134.91. LC-MS (m/z): 448.1 
(M+H+).          
 
3,5-Bis(2-fluorobenzylidene)-1-methylpiperidin-4-one (39h)  
Chemical Formula: C20H17F2NO. M.Wt : 325.35. Recrystallized from 95% ethanol. Yield: 82%. 
Rf : 0.67 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 138-140°C. 
IR (golden gate/cm-1): 1677 (C=O), 1594 (C=C), 1622 (aromatic). 
1H-NMR (methanol-d4): δ 2.41 (br s, 3H, aliph H), δ 3.73 (s, 4H, aliph H), δ 7.42 -7.45 (m, 8H, 
arom H) and δ 7.88 (br s, 2H, benzyldiene H); 
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13C-NMR (methanol-d4): δ 124.14, 129.23, 130.66, 131.31, 131.37, 134.34, 161.88, 185.70 
(C=O). LC-MS (m/z): 326.4 (M+H+).           
3,5-Bis(3-fluorobenzylidene)-1-methylpiperidin-4-one (39i)  
Chemical Formula: C20H17F2NO. M.Wt : 325.35. Recrystallized from 95% ethanol. Yield: 71%. 
Rf : 0.58 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 135-138°C.  
IR (golden gate/cm-1): 1678 (C=O), 1590 (C=C), 1618 (aromatic). 
1H-NMR (CDCl3): δ 2.47 (br s, 3H, aliph H), δ 3.72 (s, 4H, aliph H), δ 7.37 -7.38 (m, 8H, arom 
H) and δ 7.72 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 46.03, 57.03, 116.03, 116.17, 116.76, 116.90, 126.36, 130.20, 130.26, 
134.02, 135.23, 161.91, 186.66 (C=O). LC-MS (m/z): 326.3 (M+H+).  
 
3,5-Bis(4-fluorobenzylidene)-1-methylpiperidin-4-one (39j)  
Chemical Formula: C20H17F2NO. M.Wt : 325.35. Recrystallized from 95% ethanol. Yield: 58%. 
Rf : 0.55 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 134-137°C.  
IR (golden gate/cm-1): 1674 (C=O), 1586 (C=C), 1608 (aromatic). 
1H-NMR (CDCl3): δ 2.47 (br s, 3H, aliph H), δ 3.72 (s, 4H, aliph H), δ 7.37 -7.38 (m, 8H, arom 
H) and δ 7.72 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 46.03, 57.04, 116.04, 116.17, 116.76, 116.86, 126.37, 130.21, 130.26, 
134.03, 135.23, 161.91, 186.67 (C=O). LC-MS (m/z): 326.3 (M+H+).  
 
3,5-Bis(2-methoxybenzylidene)-1-methylpiperidin-4-one (39k) 
Chemical Formula: C22H23NO3. M.Wt : 349.42. Recrystallized from 95% ethanol. Yield: 72%. 
Rf : 0.61 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 176-178°C.  
IR (golden gate/cm-1): 1670 (C=O), 1509 (C=C), 1596 (aromatic). 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 3.79 (s, 4H, aliph H), δ 7.44 -7.46 (m, 8H, 
arom H) and δ 7.54 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 55.85, 114.86, 127.79, 132.21, 132.94, 134.78, 160.59. LC-MS (m/z): 
350.4 (M+H+).   
3,5-Bis(4-methoxybenzylidene)-1-methylpiperidin-4-one (39l) 
Chemical Formula: C22H23NO3. M.Wt : 349.42. Recrystallized from 95% ethanol. Yield: 88%. 
Rf : 0.57 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 180-181°C.  
IR (golden gate/cm-1): 1670 (C=O), 1504 (C=C), 1596 (aromatic). 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 3.79 (s, 4H, aliph H), δ 7.44 -7.46 (m, 8H, 
arom H) and δ 7.54 (br s, 2H, benzyldiene H); 
1H-NMR (DMSO-d6): δ 55.85, 114.86, 127.79, 132.21, 132.94, 134.78, 160.59, 186.68 (C=O). 
LC-MS (m/z): 350.4 (M+H+).    
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3,5-Bis(2-iodobenzylidene)-1-methylpiperidin-4-one (39m) 
Chemical Formula: C20H17I2NO. M.Wt : 541.16. Recrystallized from 95% ethanol. Yield: 66%. 
Rf : 0.36 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 231-234°C.  
IR (golden gate/cm-1): 1660 (C=O), 1493 (C=C), 1577 (aromatic). 
1H-NMR (CDCl3): δ 2.33 (br s, 3H, aliph H), δ 3.53 (s, 4H, aliph H), δ 7.36 -7.38 (m, 8H, arom 
H) and δ 7.79 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 45.49, 56.44, 100.48, 127.85, 129.58, 130.02, 133.55, 139.59, 140.41. LC-
MS (m/z): 541.8 (M+H+).     
 
3,5-Bis(3-iodobenzylidene)-1-methylpiperidin-4-one (39n) 
Chemical Formula: C20H17I2NO. M.Wt : 541.16. Recrystallized from 95% ethanol. Yield: 45%. 
Rf : 0.36 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 232-234°C. 
IR (golden gate/cm-1): 1675 (C=O), 1505 (C=C), 1612 ( aromatic). 
1H-NMR (CDCl3): δ 2.46 (br s, 3H, aliph H), δ 3.75 (s, 4H, aliph H), δ 7.31 -7.34 (m, 8H, arom 
H) and δ 7.70 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 94.41, 129.24, 130.21, 137.98, 138.87. LC-MS (m/z): 541.8 (M+H
+).      
The molecular ion obtained for the hydrochloride salts of the 1-methylpiperidin-4-one 
dieneones (40a-40n) are consistent to that of their free base form (39a-39n).   
3,5-Dibenzylidene-1-methylpiperidin-4-one Hydrochloride (40a) 
Chemical Formula: C20H20ClNO. M.Wt : 325.12. Recrystallized from 5% hydrochloric acid. 
Yield: 53%. Rf : 0.37 (Silica TLC; DCM: EtAc, 19:1). M.Pt: 243-245°C (243.5-245.5°C, Mcelvain 
& Rorig, 1948). 
IR (golden gate/cm-1): 1679 (C=O),  1587 (C=C), 1621 (aromatic) 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 4.64 (s, 4H, aliph H), δ 7.5 -7.54 (m, 10H, 
arom H) and δ 7.87 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6) δ, 47.86, 129.39, 130.27, 131.01, 134.65, 137.94, 184.71 (C=O). LC-MS 
(m/z): 290.4 (M+H+).    
3,5-Bis(2-chlorobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40b) 
Chemical Formula: C20H18Cl3NO. M.Wt : 394.72. Recrystallized from 5% hydrochloric acid. 
Yield: 96%. Rf : 0.66 (Silica TLC;  DCM:EtAc, 2:1). M.Pt: 228-229°C (227-229°C, Mcelvain & 
Rorig, 1948).  
IR (golden gate/cm-1): 1684 (C=O), 1444 (C=C), 1583 (aromatic)    
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 3.32 (s, 4H, aliph H), δ 7.49 -7.53 (m, 8H, 
arom H) and δ 8.00 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6) δ 54.71, 128.13, 130.51, 131.46, 132.11. 132.21, 134.74. LC-MS (m/z): 
359.30 (M+H+).   
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3,5-Bis(3-chlorobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40c) 
Chemical Formula: C20H17Cl3NO. M.Wt : 394.72. Recrystallized from 5% hydrochloric acid. 
Yield: 93%. Rf : 0.66 (Silica TLC;  DCM:EtAc, 2:1). M.Pt: 228-231°C.  
IR (golden gate/cm-1): 1684 (C=O), 1444 (C=C). 
1H-NMR (DMSO-d6): δ 2.05 (br s, 3H, aliph H), δ 2.90 (s, 4H, aliph H), δ 7.53 -7.55 (m, 8H, 
arom H) and δ 7.63 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6) δ 56.84, 129.64, 130.60, 131.25, 134.17. LC-MS (m/z): 359.30 (M+H
+).    
3,5-Bis(4-chlorobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40d) 
Chemical Formula: C20H17Cl3NO. M.Wt : 394.72. Recrystallized from 5% hydrochloric acid. 
Yield: 96%. Rf : 0.46 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 227-228°C.  
IR (golden gate/cm-1): 1688 (C=O), 1446 (C=C), 1547 (aromatic)    
 1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 2.96 (s, 4H, aliph H), δ 7.56 -7.59 (m, 8H, 
arom H) and δ 7.87 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6) δ 56.61, 129.54, 133.04, 135.52, 138.96. LC-MS (m/z): 360.30 (M+H
+).     
3,5-Bis(2-bromobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40e) 
Chemical Formula: C20H18Br2ClNO. M.Wt : 483.62. Recrystallized from 5% hydrochloric acid. 
Yield: 82%. Rf : 0.81 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 275-280°C.  
IR (golden gate/cm-1): 1668 (C=O), 1591 (C=C), 1618 (aromatic). 
1H-NMR (methanol-d4): δ 3.29 (br s, 3H, aliph H), δ 3.31 (s, 4H, aliph H), δ 7.44 -7.45 (m, 8H, 
arom H) and δ 8.02 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4) δ 57.75, 122.65, 127.28, 128.78, 130.52, 132.79, 133.01, 135.76, 
140.04, 180.59 (C=O). LC-MS (m/z): 448.1 (M+H+).            
3,5-Bis(3-bromobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40f) 
Chemical Formula: C20H18Br2ClNO. M.Wt : 483.62. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 98%. Rf : 0.70 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 301-308°C. 
IR (golden gate/cm-1): 1672 (C=O), 1595 (C=C), 1622 (aromatic). 
1H-NMR (methanol-d4): δ 3.29 (br s, 3H, aliph H), δ 3.31 (s, 4H, aliph H), δ 7.44 -7.45 (m, 8H, 
arom H) and δ 8.02 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4) δ 57.24, 122.64, 128.78, 130.52, 132.79, 132.99, 135.79, 139.93. LC-
MS (m/z): 448.1 (M+H+).             
 
3,5-Bis(4-bromobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40g) 
 
Chemical Formula: C20H18Br2ClNO. M.Wt : 483.62. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 84%. Rf : 0.74 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 291-297°C. 
IR (golden gate/cm-1): 1666 (C=O), 1583 (C=C), 1615 (aromatic). 
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1H-NMR (methanol-d4): δ 3.07 (br s, 3H, aliph H), δ 4.67 (s, 4H, aliph H), δ 7.40 -7.42 (m, 8H, 
arom H) and δ 8.02 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4) δ 57.77, 124.61, 126.59, 132.00, 132.06, 132.60, 140.39, 180.69 
(C=O). LC-MS (m/z): 448.1 (M+H+). 
              
3,5-Bis(2-fluorobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40h) 
Chemical Formula: C20H18F2ClNO. M.Wt : 361.81. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 98%. Rf : 0.68 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 210-212°C. 
IR (golden gate/cm-1): 1677 (C=O), 1595 (C=C), 1623 (aromatic). 
1H-NMR (methanol-d4): δ 3.05 (br s, 3H, aliph H), δ 4.61 (s, 4H, aliph H), δ 7.53 -7.55 (m, 8H, 
arom H) and δ 8.14 (br s, 2H, benzyldiene H); 
13C-NMR (methanol-d4) δ 56.94, 124.61, 127.83, 130.92, 132.57, 132.63, 134.65, 160.07, 
161.73, 180.26 (C=O). LC-MS (m/z): 326.4 (M+H+).  
 
3,5-Bis(3-fluorobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40i) 
Chemical Formula: C20H18F2ClNO. M.Wt : 361.81. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 92%. Rf : 0.72 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 210-212°C. 
IR (golden gate/cm-1): 1687 (C=O), 1581 (C=C), 1608 (aromatic). 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 4.63 (s, 4H, aliph H), δ 7.54 -7.57 (m, 8H, 
arom H) and δ 7.86 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 57.22, 127.51, 131.52, 136.24, 161.87, 163.49. LC-MS (m/z): 326.2 
(M+H+).   
 
3,5-Bis(4-fluorobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40j) 
Chemical Formula: C20H18F2ClNO. M.Wt : 361.81. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 95%. Rf : 0.63 (Silica TLC;  DCM:EtAc, 19:1). M.Pt: 211-213°C. 
IR (golden gate/cm-1): 1678 (C=O), 1588 (C=C), 1613 (aromatic). 
1H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 4.14 (s, 4H, aliph H), δ 7.55 -7.57 (m, 8H, 
arom H) and δ 7.85 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 57.46, 127.49, 131.46, 131.52, 161.87, 163.49. LC-MS (m/z): 326.2 
(M+H+).    
 
3,5-Bis(2-methoxybenzylidene)-1-methylpiperidin-4-one Hydrochloride (40k) 
Chemical Formula: C22H24ClNO3. M.Wt : 385.88. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 76%. Rf : 0.69 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 216-218°C.  
IR (golden gate/cm-1): 1670 (C=O), 1508 (C=C), 1596 (aromatic). 
1H-NMR (DMSO-d6): δ 2.98 (br s, 3H, aliph H), δ 3.34 (s, 4H, aliph H), δ 7.51 -7.53 (m, 8H, 
arom H) and δ 7.84 (br s, 2H, benzyldiene H); 
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13C-NMR (DMSO-d6): δ 55.64, 115.09, 126.67, 133.56, 139.74, 161.45. LC-MS (m/z): 350.4 
(M+H+).    
3,5-Bis(4-methoxybenzylidene)-1-methylpiperidin-4-one Hydrochloride (40l) 
Chemical Formula: C22H24ClNO3. M.Wt : 385.88. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 87%. Rf : 0.62 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 235-237°C.  
IR (golden gate/cm-1): 1658 (C=O), 1501 (C=C), 1574 (aromatic). 
1H-NMR (DMSO-d6): δ 2.97 (br s, 3H, aliph H), δ 3.36 (s, 4H, aliph H), δ 7.51 -7.53 (m, 8H, 
arom H) and δ 7.83 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 56.12, 115.09, 125.33, 126.68, 133.56, 139.69, 161.42, 181.75 (C=O). 
LC-MS (m/z): 350.4 (M+H+).     
3,5-Bis(2-iodobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40m) 
Chemical Formula: C22H24ClI2NO3. M.Wt : 577.62. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 73%. Rf : 0.37 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 272-274°C.  
IR (golden gate/cm-1): 1675 (C=O), 1504 (C=C), 1612 (aromatic). 
1H-NMR (CDCl3): δ 2.69 (br s, 3H, aliph H), δ 4.08 (s, 4H, aliph H), δ 7.43 -7.46 (m, 8H, arom 
H) and δ 7.97 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 52.46, 128.74, 128.74, 129.28, 131.61, 139.89. LC-MS (m/z): 541.8 
(M+H+).      
3,5-Bis(3-iodobenzylidene)-1-methylpiperidin-4-one Hydrochloride (40n) 
Chemical Formula: C22H24ClI2NO3. M.Wt : 577.62. Recrystallized from 95% ethanol/1M 
hydrochloric acid. Yield: 62%. Rf : 0.44 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 271-273°C.  
IR (golden gate/cm-1): 1662 (C=O), 1550 (C=C), 1600 (aromatic). 
1H-NMR (CDCl3): δ 2.49 (br s, 3H, aliph H), δ 4.08 (s, 4H, aliph H), δ 7.28 -7.46 (m, 8H, arom 
H) and δ 7.69 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 53.41, 128.74, 129.28, 131.61, 139.89. LC-MS (m/z): 541.8 (M+H
+).   
 
The spectroscopic and spectrometric data for all synthesized methyl piperidone 
dibenzylidene derivatives was consistent to their assigned structures.   
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2.2.2 Spectral data for the synthesized aromatic ring substituted 3,5-dibenzylidene-1-
piperidin-4-ones and their hydrochloride salts (41a-41n and 42a-42n) 
 
3,5-Dibenzylidenepiperidin-4-one (41a)  
Chemical Formula: C19H17O. M.Wt : 275.34. 95% ethanol. Yield: 68%. Rf : 0.38 (Silica TLC; 
DCM:EtAc, 10:1). M.Pt: 112-115°C.  
IR (golden gate/cm-1): 1674 (C=O), 1447 (C=C), 1590 (aromatic), 3249 (N-H). 
1H-NMR (CDCl3): δ 1.61 (br s, H, aliph H), δ 4.15 (s, 4H, aliph H), δ 7.37 -7.40 (m, 10H, arom 
H) and δ 7.79 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.23, 128.65, 129.16, 130.58, 135.09, 136.08, 188.12 (C=O). LC-MS 
(m/z): 276.3 (M+H+).   
3,5-Bis(2-chlorobenzylidene)piperidin-4-one (41b) 
Chemical Formula: C19H15Cl2NO. M.Wt : 344.23. Recrystallized from 95% ethanol. Yield: 58%. 
Rf : 0.40 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 148-150°C.  
IR (golden gate/cm-1): 1669 (C=O), 1396 (C=C), 1590 (aromatic), 3235 (N-H). 
1H-NMR (CDCl3): δ 1.57 (br s, H, aliph H), δ 3.98 (s, 4H, aliph H), δ 7.43 -7.44 (m, 8H, arom H) 
and δ 7.94 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.07, 126.50, 130.03, 130.18, 130.73, 133.78, 187.69 (C=O). LC-MS 
(m/z): 345.2 (M+H+).    
3,5-Bis(3-chlorobenzylidene)piperidin-4-one (41c) 
Chemical Formula: C19H15Cl2NO. M.Wt : 344.23. Recrystallized from 95% ethanol. Yield: 33%. 
Rf : 0.28 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 153-156°C. 
IR (golden gate/cm-1): 1669 (C=O), 1400 (C=C), 1590 (aromatic), 3235 (N-H). 
1H-NMR (CDCl3): δ 1.65 (br s, H, aliph H), δ 4.12 (s, 4H, aliph H), δ 7.32 -7.35 (m, 8H, arom H) 
and δ 7.70 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.09, 128.62, 129.17, 129.91, 130.15, 134.65, 187.56 (C=O). LC-MS 
(m/z): 345.2 (M+H+).     
3,5-Bis(4-chlorobenzylidene)piperidin-4-one (41d) 
Chemical Formula: C19H15Cl2NO. M.Wt : 344.23. Recrystallized from 95% ethanol. Yield: 63%. 
Rf : 0.51 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 151-153°C. 
IR (golden gate/cm-1): 1674 (C=O), 1447 (C=C), 1590 (aromatic), 3245 (N-H). 
1H-NMR (CDCl3): δ 1.59 (br s, H, aliph H), δ 3.95 (s, 4H, aliph H), δ 7.16 -7.19 (m, 8H, arom H) 
and δ 7.84 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 47.98, 127.12, 130.29, 130.72, 133.24, 135.41, 135.47, 187.62 (C=O). LC-
MS (m/z): 345.2 (M+H+).      
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3,5-Bis(2-bromobenzylidene)piperidin-4-one (41e) 
Chemical Formula: C19H15Br2NO. M.Wt : 433.14. Recrystallized from 95% ethanol. Yield: 
58%. Rf : 0.57 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 178-180°C. 
IR (golden gate/cm-1): 1669 (C=O), 1396 (C=C), 1586 (aromatic), 3240 (N-H). 
1H-NMR (CDCl3): δ 1.59 (br s, H, aliph H), δ 4.10 (s, 4H, aliph H), δ 7.36 -7.38 (m, 8H, arom H) 
and δ 7.71 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.13, 128.96, 131.76, 134.83, 135.30, 187.64 (C=O). LC-MS (m/z): 434.0 
(M+H+).       
3,5-Bis(3-bromobenzylidene)piperidin-4-one (41f) 
Chemical Formula: C19H15Br2NO. M.Wt : 433.14. Recrystallized from 95% ethanol. Yield: 
55%. Rf : 0.46 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 179-182°C. 
IR (golden gate/cm-1): 1674 (C=O), 1396 (C=C), 1586 (aromatic), 3245 (N-H). 
1H-NMR (CDCl3): δ 1.67 (br s, H, aliph H), δ 4.12 (s, 4H, aliph H), δ 7.23 -7.25 (m, 8H, arom H) 
and δ 7.55 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.13, 123.64, 131.96, 131.97, 134.06, 134.89, 135.39, 187.63 (C=O). LC-
MS (m/z): 434.0 (M+H+).   
3,5-Bis(4-bromobenzylidene)piperidin-4-one (41g) 
Chemical Formula: C19H15Br2NO. M.Wt : 433.14. Recrystallized from 95% ethanol. Yield: 
41%. Rf : 0.53 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 185-187°C. 
IR (golden gate/cm-1): 1674 (C=O), 1401 (C=C), 1586 (aromatic), 3245 (N-H). 
1H-NMR (CDCl3): δ 1.57 (br s, H, aliph H), δ 4.12 (s, 4H, aliph H), δ 7.48 -7.50 (m, 8H, arom H) 
and δ 7.70 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.07, 129.03, 130.16, 131.94, 132.08, 133.05, 134.56, 135.94, 187.50 
(C=O). LC-MS (m/z): 434.1 (M+H+).    
3,5-Bis(2-fluorobenzylidene)piperidin-4-one (41h) 
Chemical Formula: C19H15F2NO. M.Wt : 311.33. Recrystallized from 95% ethanol. Yield: 47%. 
Rf : 0.53 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 126-128°C. 
IR (golden gate/cm-1): 1674 (C=O), 1401 (C=C), 1590 (aromatic), 3245 (N-H). 
1H-NMR (CDCl3): δ 1.59 (br s, H, aliph H), δ 4.08 (s, 4H, aliph H), δ 7.33 -7.35 (m, 8H, arom H) 
and δ 7.84 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.27, 115.92, 116.07, 123.19, 123.28, 124.00, 128.80, 131.00, 136.85, 
160.14, 161.81, 187.48 (C=O). LC-MS (m/z): 312.3 (M+H+).     
3,5-Bis(3-fluorobenzylidene)piperidin-4-one (41i) 
Chemical Formula: C19H15F2NO. M.Wt : 311.33. Recrystallized from 95% ethanol. Yield: 46%. 
Rf : 0.38 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 127-128°C. 
IR (golden gate/cm-1): 1666 (C=O), 1400 (C=C), 1587 (aromatic), 3233 (N-H). 
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1H-NMR (CDCl3): δ 1.57 (br s, H, aliph H), δ 4.12 (s, 4H, aliph H), δ 7.36 -7.38 (m, 8H, arom H) 
and δ 7.72 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.02, 115.98, 116.11, 116.79, 116.94, 126.27, 130.14, 134.74, 135.74, 
137.22, 161.82, 163.46, 187.59 (C=O). LC-MS (m/z): 312.1 (M+H+).      
3,5-Bis(4-fluorobenzylidene)piperidin-4-one (41j) 
Chemical Formula: C19H15F2NO. M.Wt : 311.33. Recrystallized from 95% ethanol. Yield: 52%. 
Rf : 0.64 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 126-130°C (127-130°C, Leonova et al, 2010).  
IR (golden gate/cm-1): 1664 (C=O), 1425 (C=C), 1577 (aromatic), 3312 (N-H). 
1H-NMR (CDCl3): δ 1.58 (br s, H, aliph H), δ 4.12 (s, 4H, aliph H), δ 7.36 -7.38 (m, 8H, arom H) 
and δ 7.72 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.01, 115.98, 116.11, 116.79, 116.94, 126.27, 130.14, 134.74, 135.74, 
161.82, 163.46, 187.59 (C=O). LC-MS (m/z): 312.1 (M+H+).       
3,5-Bis(2-methoxybenzylidene)piperidin-4-one (41k) 
Chemical Formula: C21H21NO3. M.Wt : 335.40. Recrystallized from 95% ethanol. Yield: 46%. 
Rf : 0.57 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 175-177°C. 
IR (golden gate/cm-1): 1670 (C=O), 1508 (C=C), 1587 (aromatic), 3247 (N-H). 
1H-NMR (DMSO-d6): δ 2.49 (br s, H, aliph H), δ 3.79 (s, 4H, aliph H), δ 7.42 -7.44 (m, 8H, 
arom H) and δ 7.52 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 46.92, 114.75, 128.10, 132.88, 133.91, 134.56, 160.43. LC-MS (m/z): 
336.2 (M+H+).        
3,5-Bis(4-methoxybenzylidene)piperidin-4-one (41l) 
Chemical Formula: C21H21NO3. M.Wt : 335.40. Recrystallized from 95% ethanol. Yield: 45%. 
Rf : 0.51 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 179-180°C. 
IR (golden gate/cm-1): 1666 (C=O), 1508 (C=C), 1591 (aromatic), 3242 (N-H). 
1H-NMR (DMSO-d6): δ 2.48 (br s, H, aliph H), δ 3.79 (s, 4H, aliph H), δ 7.42 -7.44 (m, 8H, 
arom H) and δ 7.52 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 46.67, 114.75, 132.88, 133.92, 160.43. LC-MS (m/z): 336.2 (M+H
+).        
3,5-Bis(2-iodobenzylidene)piperidin-4-one (41m) 
Chemical Formula: C19H15I2NO. M.Wt : 527.14. Recrystallized from 95% ethanol. Yield: 35%. 
Rf : 0.29 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 222-225°C. 
IR (golden gate/cm-1): 1670 (C=O), 1454 (C=C), 1612 (aromatic), 3308 (N-H). 
1H-NMR (CDCl3): δ 1.56 (br s, H, aliph H), δ 3.93 (s, 4H, aliph H), δ 7.36 -7.38 (m, 8H, arom H) 
and δ 7.76 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 47.86, 100.78, 127.95, 129.98, 130.21, 135.69, 138.89, 139.67. LC-MS 
(m/z): 528.8 (M+H+).         
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3,5-Bis(3-iodobenzylidene)piperidin-4-one (41n) 
Chemical Formula: C19H15I2NO. M.Wt : 527.14. Recrystallized from 95% ethanol. Yield: 31%. 
Rf : 0.40 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 223-225°C. 
IR (golden gate/cm-1): 1658 (C=O), 1550 (C=C), 1604 (aromatic), 3308 (N-H). 
1H-NMR (CDCl3): δ 1.53 (br s, H, aliph H), δ 4.09 (s, 4H, aliph H), δ 7.65-7.68 (m, 8H, arom H) 
and δ 7.71 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 47.95, 94.33, 129.49, 130.17, 134.38, 137.89, 138.92. LC-MS (m/z): 528.9 
(M+H+).     
The molecular ion obtained for the hydrochloride salts of the piperidin-4-one dieneones 
(42a-42n) are consistent to that of their free base form (41a-41n).   
3,5-Dibenzylidenepiperidin-4-one Hydrochloride (42a)  
Chemical Formula: C19H18ClNO. M.Wt : 311.81. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 90%. Rf : 0.51 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 241-243°C.  
IR (golden gate/cm-1): 1678 (C=O), 1442 (C=C), 1613 (aromatic), 3245 (N-H). 
1H-NMR (DMSO-d6): δ 2.48 (br s, H, aliph H), δ 4.46 (s, 4H, aliph H), δ 7.50 -7.53 (m, 10H, 
arom H) and δ 7.87 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 48.34, 128.57, 129.49, 130.62, 131.08, 134.26, 139.65, 183.04 (C=O). 
LC-MS (m/z): 276.3 (M+H+).    
    
3,5-Bis(2-chlorobenzylidene)piperidin-4-one Hydrochloride (42b) 
Chemical Formula: C19H16Cl3NO. M.Wt : 380.70. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 92%. Rf : 0.51 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 221-223°C.  
IR (golden gate/cm-1): 1667 (C=O), 1590 (C=C), 1609 (aromatic), 3245 (N-H). 
1H-NMR (DMSO-d6): δ 2.07 (br s, H, aliph H), δ 4.49 (s, 4H, aliph H), δ 7.55 -7.58 (m, 8H, 
arom H) and δ 7.84 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 47.58, 129.49, 130.41, 132.81. LC-MS (m/z): 345.2 (M+H
+).     
3,5-Bis(3-chlorobenzylidene)piperidin-4-one Hydrochloride (42c) 
Chemical Formula: C19H16Cl3NO. M.Wt : 380.70. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 85%. Rf : 0.45 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 220-223°C.  
IR (golden gate/cm-1): 1669 (C=O), 1396 (C=C), 1590 (aromatic), 3245 (N-H). 
1H-NMR (DMSO-d6): δ 2.07 (br s, H, aliph H), δ 4.49 (s, 4H, aliph H), δ 7.54 -7.58 (m, 8H, 
arom H) and δ 7.85 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 48.41, 128.92, 129.55, 130.45, 132.85, 138.38, 138.54. LC-MS (m/z): 
345.2 (M+H+).  
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3,5-Bis(4-chlorobenzylidene)piperidin-4-one Hydrochloride (42d) 
Chemical Formula: C19H16Cl3NO. M.Wt : 380.70. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 95%. Rf : 0.54 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 222-223°C.  
IR (golden gate/cm-1): 1674 (C=O), 1447 (C=C), 1609 (aromatic), 3240 (N-H). 
1H-NMR (DMSO-d6): δ 2.48 (br s, H, aliph H), δ 4.45 (s, 4H, aliph H), δ 7.58 -7.59 (m, 8H, 
arom H) and δ 7.85 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 46.87, 129.09, 129.54, 132.83, 133.11, 138.40, 182.86 (C=O). LC-MS 
(m/z): 345.2 (M+H+).   
3,5-Bis(2-bromobenzylidene)piperidin-4-one Hydrochloride (42e) 
Chemical Formula: C19H16Br2ClNO. M.Wt : 469.60. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 88%. Rf : 0.63 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 252-255°C. 
IR (golden gate/cm-1): 1669 (C=O), 1401 (C=C), 1590 (aromatic), 3235 (N-H). 
1H-NMR (DMSO-d6): δ 2.08 (br s, H, aliph H), δ 4.31 (s, 4H, aliph H), δ 7.42 -7.44 (m, 8H, 
arom H) and δ 7.92 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 48.34, 125.21, 128.57, 131.39, 132.22, 133.71, 134.03. LC-MS (m/z): 
434.0 (M+H+).       
3,5-Bis(3-bromobenzylidene)piperidin-4-one Hydrochloride (42f) 
 
Chemical Formula: C19H16Br2ClNO. M.Wt : 469.60. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 97%. Rf : 0.57 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 260-262°C. 
IR (golden gate/cm-1): 1678 (C=O), 1442 (C=C), 1608 (aromatic), 3249 (N-H). 
1H-NMR (DMSO-d6): δ 2.07 (br s, H, aliph H), δ 4.41 (s, 4H, aliph H), δ 7.44 -7.48 (m, 8H, 
arom H) and δ 7.80 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 44.68, 124.18, 129.61, 132.45, 132.99, 133.49, 138.19. LC-MS (m/z): 
434.0 (M+H+).        
 
3,5-Bis(4-bromobenzylidene)piperidin-4-one Hydrochloride (42g) 
 
Chemical Formula: C19H16Br2ClNO. M.Wt : 469.60. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 90%. Rf : 0.63 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 264-269°C. 
IR (golden gate/cm-1): 1674 (C=O), 1396 (C=C), 1586 (aromatic), 3249 (N-H). 
1H-NMR (DMSO-d6): δ 2.07 (br s, H, aliph H), δ 4.47 (s, 4H, aliph H), δ 7.46 -7.49 (m, 8H, 
arom H) and δ 7.83 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 44.36, 129.86, 131.52, 133.21, 133.27, 138.32. LC-MS (m/z): 434.0 
(M+H+).     
3,5-Bis(2-fluorobenzylidene)piperidin-4-one Hydrochloride (42h) 
Chemical Formula: C19H16F2ClNO. M.Wt : 347.79. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 76%. Rf : 0.70 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 198-201°C. 
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IR (golden gate/cm-1): 1664 (C=O), 1401 (C=C), 1590 (aromatic), 3318 (N-H). 
1H-NMR (DMSO-d6): δ 2.49 (br s, H, aliph H), δ 4.36 (s, 4H, aliph H), δ 7.55 -7.57 (m, 8H, 
arom H) and δ 7.89 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 44.39, 116.52, 116.66, 125.45, 131.53, 132.31, 133.02, 133.08. LC-MS 
(m/z): 312.3 (M+H+).      
3,5-Bis(3-fluorobenzylidene)piperidin-4-one Hydrochloride (42i) 
Chemical Formula: C19H16F2ClNO. M.Wt : 347.79. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 55%. Rf : 0.53 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 201-204°C. 
IR (golden gate/cm-1): 1672 (C=O), 1487 (C=C), 1606 (aromatic), 3377 (N-H). 
1H-NMR (DMSO-d6): δ 3.32 (br s, H, aliph H), δ 4.49 (s, 4H, aliph H), δ 7.55 -7.58 (m, 8H, 
arom H) and δ 7.86 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 45.35, 117.35, 117.45, 117.59, 127.20, 129.54, 131.47, 136.46, 
138.43, 161.85, 163.47, 182.89 (C=O). LC-MS (m/z): 312.1 (M+H+).       
3,5-Bis(4-fluorobenzylidene)piperidin-4-one Hydrochloride (42j) 
Chemical Formula: C19H16F2ClNO. M.Wt : 347.79. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 56%. Rf : 0.69 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 202-204°C. 
IR (golden gate/cm-1): 1662 (C=O), 1425 (C=C), 1575 (aromatic), 3316 (N-H). 
1H-NMR (CDCl3): δ 1.23 (br s, H, aliph H), δ 1.53 (s, 4H, aliph H), δ 7.24 -7.25 (m, 8H, arom H) 
and δ 7.51 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 45.58, 127.94, 129.67, 130.11, 139.68, 140.52. LC-MS (m/z): 312.1 
(M+H+).        
3,5-Bis(2-methoxybenzylidene)piperidin-4-one Hydrochloride (42k) 
Chemical Formula: C21H22ClNO3. M.Wt : 371.86. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 85%. Rf : 0.70 (Silica TLC; DCM:EtAc, 19:1). M.Pt: 215-218°C. 
IR (golden gate/cm-1): 1668 (C=O), 1511 (C=C), 1590 (aromatic), 3246 (N-H). 
1H-NMR (DMSO-d6): δ 2.49 (br s, H, aliph H), δ 4.45 (s, 4H, aliph H), δ 7.48 -7.51 (m, 8H, 
arom H) and δ 7.82 (br s, 2H, benzyldiene H); 
13C-NMR (DMSO-d6): δ 45.48, 115.09, 126.35, 126.85, 133.30, 139.27, 161.32, 182.76 (C=O). 
LC-MS (m/z): 336.2 (M+H+).         
3,5-Bis(4-methoxybenzylidene)piperidin-4-one Hydrochloride (42l) 
Chemical Formula: C21H22ClNO3. M.Wt : 371.86. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 92%. Rf : 0.70 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 234-237°C. 
IR (golden gate/cm-1): 1666 (C=O), 1508 (C=C), 1596 (aromatic), 3250 (N-H). 
1H-NMR (DMSO-d6): δ 2.49 (br s, H, aliph H), δ 4.45 (s, 4H, aliph H), δ 7.48 -7.50 (m, 8H, 
arom H) and δ 7.81 (br s, 2H, benzyldiene H); 
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13C-NMR (DMSO-d6): δ 45.41, 115.09, 126.85, 133.29, 139.26, 161.32. LC-MS (m/z): 336.2 
(M+H+).          
3,5-Bis(2-iodobenzylidene)piperidin-4-one Hydrochloride (42m) 
Chemical Formula: C19H16ClI2NO. M.Wt : 563.60. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 71%. Rf : 0.38 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 248-251°C. 
IR (golden gate/cm-1): 1675 (C=O), 1454 (C=C), 1612 (aromatic), 3312 (N-H). 
1H-NMR (CDCl3): δ 1.54 (br s, H, aliph H), δ 3.93 (s, 4H, aliph H), δ 7.34 -7.36 (m, 8H, arom H) 
and δ 7.76 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 48.04, 129.59, 130.26, 134.49, 137.98, 139.01. LC-MS (m/z): 528.8 
(M+H+).  
3,5-Bis(3-iodobenzylidene)piperidin-4-one Hydrochloride (42n) 
Chemical Formula: C19H16ClI2NO. M.Wt : 563.60. Recrystallized from 95% ethanol/37% 
hydrochloric acid. Yield: 79%. Rf : 0.48 (Silica TLC; DCM:EtAc, 10:1). M.Pt: 251-253°C. 
IR (golden gate/cm-1): 1666 (C=O), 1421 (C=C), 1616 (aromatic). 
1H-NMR (CDCl3): δ 1.23 (br s, H, aliph H), δ 4.13 (s, 4H, aliph H), δ 7.30 -7.32 (m, 8H, arom H) 
and δ 7.70 (br s, 2H, benzyldiene H); 
13C-NMR (CDCl3): δ 49.98, 93.67, 123.98, 133.06. LC-MS (m/z): 528.8 (M+H
+).         
 
The spectroscopic and spectrometric data for all synthesized piperidone dieneone 
derivatives was consistent to their assigned structures.   
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2.2.3 Spectral data for the synthesized tropan-3-one (47a, 47d) 
 
4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoic acid (47a) 
Chemical Formula: C14H15NO3. M.Wt : 245.27. Recrystallized from methanol. Yield: 18%. Rf : 
0.46 (Silica TLC; DCM). M.Pt: 236-240°C. 
IR (KBr disk /cm-1): 1710 (C=O on C-3 of tropanone ring), 1673 (C=0 on C-15 (benzoic acid), 
1603 (aromatic). 
1H-NMR (CDCl3): δ 1.54 (q, 4H aliphatic H, C6 and C7, predicted: 1.66), δ 2.07 (d, 4H aliphatic 
H, C2 and C4, predicted: 2.5-2.75), δ 2.37 (m, 4H aliphatic H, C1 and C5, predicted: 3.32), 
δ 6.6 (m, 4H arom H, C10 and C14, predicted: 7.03), δ 7.69 (m, 4H arom H, C11 and C13, 
predicted: 7.76). 1H-NMR predictions generated using ChemBioDraw Ultra13 (Perkin Elmer).    
13C-NMR (CDCl3): δ 28.62, 39.35, 39.55, 39.76, 39.97, 40.18, 40.39, 40.59, 45.85, 54.07, 
113.63, 120.10, 131.87, 148.50, 168.29 (C=O on C-15), 207.14 (C=O on C-3). LC-MS (m/z): 
244.1 (M-H+). 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 26- The chemical structure of 4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid (47a) with its 
relevant carbon and nitrogen numbering.  
 
Benzocaine (43d) 
Chemical Formula: C9H11NO2. M.Wt : 165.19. Recrystallized from 95% Ethanol/water. Yield: 
42%. Rf : 0.48 (Silica TLC; DCM:EtAc, 10:1).  M.Pt: 89-91°C (Sigma-Aldrich, 2013).  
IR (golden gate/cm-1): 1638 (C=O), 1592 (aromatic), 2984 (C-H), 3343 (N-H).  
1H-NMR (DMSO-d6): δ 1.26 (m, 3H, methyl, C9, predicted: 1.30), δ 4.18 (m, 2H, methylene, 
C8, predicted: 4.30), δ 5.92 (s, 2H, amine, predicted: 5.48), δ 6.54 (d, 4H, arom, C3 and C5, 
predicted: 6.47), δ 7.62 (s, 4H, arom, C2 and C6, predicted: 7.63). 1H-NMR predictions 
generated using ChemBioDraw Ultra13 (Perkin Elmer).          
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13C-NMR (DMSO-d6): δ 14.89, 59.99, 113.16, 116.56, 131.55, 153.95, 166.40. LC-MS (m/z): 
166.21 (M+H+). 
 
 
 
 
 
  
Figure 27- The chemical structure of benzocaine (43d) with its relevant carbon numbering. 
ethyl-4-((1R,5S)-3-oxo-8 azabicyclo [3.2.1]octan-8-yl) benzoate (47d)    
Chemical Formula: C16H19NO3. M.Wt : 273.33. Recrystallized from methanol. Yield: 45%. Rf : 
0.25 (Silica TLC; Cyclohexane:EtAc, 2:1).  M.Pt: 252-255°C. 
IR (golden gate/cm-1): 1711 (C=O on C-3 of tropanone ring), 1673 (C=0 on C 15 (benzoate), 
1603 (aromatic), 2988 (C-H).  
1H-NMR (DMSO-d6): δ 1.67 (q, 4H aliphatic H, C6 and C7, predicted: 1.66), δ 2.22 (d, 4H 
aliphatic H, C2 and C4, predicted: 2.5-2.75), δ 3.30 (m, 4H aliphatic H, C1 and C5, predicted: 
3.32), δ 6.99 (d, 4H, arom, C10 and C14, predicted: 6.93), δ 7.81 (s, 4H, arom, C11 and C13, 
predicted: 7.84). 1H-NMR predictions generated using ChemBioDraw Ultra13 (Perkin Elmer).          
 13C-NMR (DMSO-d6): δ 60.38, 113.15, 113.90, 117.34, 131.08, 131.64, 148.17, 151.31 (C=O 
on C-15), 166.37 (C=O on C-3). LC-MS (m/z): 244.1 (M-H+).     
    
 
 
 
 
 
  
  
 
Figure 28- The chemical structure of ethyl-4-((1R,5S)-3-oxo-8 azabicyclo [3.2.1]octan-8-yl) benzoate (47d) 
with its relevant carbon and nitrogen numbering.  
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Chapter 3.1: Materials and Methods 
 
3.1.1 Materials and Assays: 
3.1.1.1 Fungal Strains and Cancer Cell Line  
The fungal strains of Saccharomyces cerevisiae ATCC 46182, Candida albicans NCYC 854 and 
Aspergillus niger ATCC 16888 were obtained from the University of Hertfordshire Fungal 
Culture collection. The adherent cell line of the adenocarcinoma human alveolar basal 
epithelial A549 cells ATCC CCL-185 was obtained from the University of Nottingham. Before 
use the cell line had been re-seeded with media 23 times.  
Table 3- Culture strain numbers of University of Hertfordshire collection: 
Fungal strain/ Cell line ATCC/ NCYC number University’s record 
number 
Saccharomyces cerevisiae ATCC 46182, a wild type strain Y13a 
Candida albicans NCYC 854 Y100 
Aspergillus niger ATCC 16888, a wild type strain F8 
A549 human carcinoma  ATCC CCL-185 A549 
    
3.1.1.2 Media 
 Mueller-Hinton Broth: (Oxoid) was used for seeding the yeasting fungi. It was 
prepared by dissolving 21g of powder in 1L of distilled water.  
 Mueller-Hinton Agar: (Oxoid) was used for seeding and testing against filamentous 
fungi. It was prepared by dissolving 20g of the powder in 400ml distilled water.  
All media were sterilized by autoclaving at 121°C and 15psi pressure for 15-20 minutes. 
 The media used to seed the A549 human carcinoma cells was purchased from Sigma-
Aldrich and was composed of Dulbecco's Modified Eagle Medium (DMEM, high 
glucose) supplemented with 10% fetal bovine serum (FBS), 0.1 mM MEM Non- 
Essential Amino Acids (NEAA), 2 mM L-glutamine, and 1% Pen-Strep.   
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 The proteolytic enzyme trypsin was used in solution to hydrolyse proteins in the 
A549 cells so they become detached from the surface of the flask.   
3.1.1.3 Stock Solutions of Controls 
Miconazole (purchased from Sigma-Aldrich as miconazole nitrate salt) is an azole antifungal 
which was used as a reference agent. In studies of the inhibition of fungal growth 
miconazole was used as a positive control. The salt was weighed (2mg) and dissolved in 
2.5ml of DMSO (99.98%; Fischer Chemical) giving a concentration of 0.8mg/ml. A 1:10 
dilution of this gave a final stock concentration of 0.4µg/ml.  
Triton X-100 is a non-ionic surfactant used as a positive (kill) control in cytotoxicity studies. 
Triton X-100 (50µl) was added to 5ml of DMEM to give final concentration of 5% Triton X-
100.    
3.1.1.4 Stock Solutions of Compounds (from chapter 2) 
Based on the Relative Molecular Mass (RMM) of each of the synthesized dibenzylidenes and 
the tropan-3-one, a certain amount of material (56.3-200mg) was dissolved in 2ml of DMSO 
giving a final stock concentration of 2 x 10-1 M. This stock solution was diluted to make 
further stock solutions ranging from 2 x 10-2 M- 2 x 10-5 M. When treating the fungal cells 
with test compounds the final concentration of DMSO added was equal or less than 1.5%.    
When working with the human carcinoma A549 cell line stock solutions were made fresh 
and further diluted using the DMEM media to give final concentrations of 2 x 10-3 M- 2 x 10-7 
M. Thus ensuring that when treating the cells with test compounds, the final concentration 
of DMSO was less than or equal to 1%.  
All stock solutions were preserved at 4°C and fresh stock solutions were made for each 
experiment on the day of treatment with the different cell cultures.   
3.1.1.5 Stock Solutions of 1,2- Benzothiazine Compounds 
The various 1,2-benzothiazine derivatives tested for their antifungal properties against 
Saccharomyces cerevisiae were synthesized by a former research student at the University 
of Hertfordshire (Patel, 2012).   
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Figure 29- Parent 1,2-benzothiazine molecule with varying R substituents (48a-48as)  
Table 4- Various substituent groups present on the 1,2-benzothiazine derivatives.  
Compound R1 R
2
 R
3
 R
4
 R
5 Molecular Formula 
48a H H H H Br C17H16BrNO5S 
48b H H H CH3 Br C18H18BrNO5S 
48c H H H CH2CH3 Br C19H20BrNO5S 
48d H H H Ph Br C23H20BrNO5S 
48e H H H PhCH2 Br C24H22BrNO5S 
48f CH3 H H H Br C18H18BrNO5S 
48g CH3 H H CH3 Br C19H20BrNO5S 
48h CH3 H H CH2CH3 Br C20H22BrNO5S 
48i CH3 H H Ph Br C24H22BrNO5S 
48j CH3 H H PhCH2 Br C25H24BrNO5S 
48k Cl H H H Br C17H15BrClNO5S 
48l Cl H H CH3 Br C18H17BrClNO5S 
48m Cl H H CH2CH3 Br C19H19BrClNO5S 
48n Cl H H Ph Br C23H19BrClNO5S 
48o Cl H H PhCH2 Br C24H21BrClNO5S 
48p Br H H H Br C17H15Br2NO5S 
48q Br H H CH3 Br C18H17Br2NO5S 
48r Br H H CH2CH3 Br C19H19Br2NO5S 
48s Br H H Ph Br C23H19Br2NO5S 
48t Br H H PhCH2 Br C24H21Br2NO5S 
48u F H H H Br C17H15BrFNO5S 
48v F H H CH3 Br C18H17BrFNO5S 
48x F H H CH2CH3 Br C19H19BrFNO5S 
48y F H H Ph Br C23H19BrFNO5S 
48z F H H PhCH2 Br C24H21BrFNO5S 
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Table 4 (continued) various substituent groups present on the 1,2-benzothiazine 
derivatives.  
 
As described in section 3.1.1.4 for the piperidone compounds, stock solutions of final 
concentration 2 x 10-1 M were prepared by dissolving an amount of each 1,2-benzothiazine 
based on their RMM (161-239mg) in 2ml DMSO. This was followed by relevant dilutions to 
make stock solutions ranging between; 2 x 10-2- 2 x 10-5 M, ensuring that the yeast were 
treated with test compounds in DMSO at DMSO concentration less than or equal to 1.5%. 
All stock solutions were made on the day of treating the cells and maintained at 4°C.   
 
 
Compound R1 R
2
 R
3
 R
4
 R
5 Molecular Formula 
48aa H Cl H H Br C17H15BrClNO5S 
48ab H Cl H CH3 Br C18H17BrClNO5S 
48ac H Cl H CH2CH3 Br C19H19BrClNO5S 
48ad H Cl H Ph Br C23H19BrClNO5S 
48ae H Cl H PhCH2 Br C24H21BrClNO5S 
48af H Br H H Br C17H15Br2NO5S 
48ag H Br H CH3 Br C18H17Br2NO5S 
48ah H Br H CH2CH3 Br C19H19Br2NO5S 
48ai H Br H Ph Br C23H19Br2NO5S 
48aj H Br H PhCH2 Br C24H21Br2NO5S 
48ak H H Cl H Br C17H15BrClNO5S 
48al H H Cl CH3 Br C18H17BrClNO5S 
48al H H Cl CH2CH3 Br C19H19BrClNO5S 
48am H H Cl Ph Br C23H19BrClNO5S 
48an H H Cl PhCH2 Br C24H21BrClNO5S 
48ao H H Br H Br C17H15Br2NO5S 
48ap H H Br CH3 Br C18H17Br2NO5S 
48aq H H Br CH2CH3 Br C19H19Br2NO5S 
48ar H H Br Ph Br C23H19Br2NO5S 
48as H H Br PhCH2 Br C24H21Br2NO5S 
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3.1.1.6 Antimicrobial Disks  
Blank disks (Oxoid) made from paper with a diameter of 6mm were used for antifungal 
diffusion susceptibility testing against A.niger. All disks used were sterilized by autoclaving 
at 121°C and 15psi pressure for 5 hours. After inoculation with the various compounds the 
disks were stored at -20°C prior to placing on agar plates.   
3.1.1.7 MTS Assay 
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) assay kit was purchased from Promega.  A one solution reagent 
containing the MTS (317µg/ml) and an electron coupling reagent (phenazine ethosulfate; 
PES) was stored in the dark at -20°C. Before use it was thawed in a water bath at 37°C.  
3.1.1.8 LDH Assay  
The lactate dehydrogenase (LDH) assay kit (Promega) included; a substrate mix, assay buffer 
and stop solution, all of which were stored at -20°C. The CytoTox-ONE solution was 
prepared by thawing the substrate mix and assay buffer in an incubator (22°C), followed by 
the addition of 11ml of the assay buffer to the substrate mix. The stop solution was thawed 
by incubating at 22°C before use.   
3.1.1.9 Absorbance and Fluorescent Measurement  
A UV spectrophotometer (UNICAM; helios α) was used to measure the absorbance (600nm) 
in inhibition of yeast cell growth. The absorbance values from the MTS assay were measured 
using an ELISA plate reader (Labsystems; Multiskan Ascent). Fluorescent measurements 
were obtained from the LDH assay using a fluorescence spectrometer (PerkinElmer LS55 
with a 96-well plate reader attachment).     
 
 
 
 
 
69 | P a g e  
 
3.1.2 Methods   
3.1.2.1 Inhibition of growth of S. cerevisiae and C. albicans  
3-((1R,5S)-3-oxo-8azabicyclo[3.2.1]octan-8-yl) benzoic acid along with benzylidene 
derivatives of piperidone and 4-piperidone and a library of 1,2-benzothiazines were used for 
susceptibility testing against actively growing yeast species; S. cerevisiae ATCC 46182 and  
C. albicans NCYC 854. Initially the cell growth of both fungi was analysed for each 
experiment to determine the mid-exponential (log) phase, defined as the point at which the 
cells are proliferating at their maximum rate. 
Using standard aseptic techniques a few colonies of the yeast were inoculated in a 250ml 
conical flask containing Mueller-Hinton broth (80ml). The flasks were incubated at 32°C and 
shaken at 100 revs/min overnight. The flasks were mixed well and cell counts (Neubauer 
haemocytometer) and an absorbance reading at 600nm (UNICAM; helios α) were obtained 
from 1ml of the cell suspension, thus giving an approximation of the number of cells present 
in the flasks after 24 hours incubation. After mixing the flasks thoroughly 1ml (9.13 x 108 
cells/ml) of cell suspension was re-suspended in a fresh 250ml conical flask containing 80ml 
Mueller-Hinton broth. The flasks were incubated at 32°C and shaken at 100 revs/min. Cell 
counts and absorbance readings at 600nm were noted hourly between 1-8 hours and then 
after 24 hours incubation. Cell growth curves were constructed plotting the absorbance at 
600nm against time. From the growth curves it was concluded that the mid-exponential 
phase for both the yeasting fungi was between 5-7 hours of incubation (refer to Figure 30, 
Page 75).  
The susceptibility test was performed using a liquid broth dilution method (Fothergill, 2012, 
CLSI, 2013). A set of 5ml glass bijous were acid washed and dried before adding 2ml of 
Mueller-Hinton broth followed by autoclaving (121°C, 15psi, 5 hours). Relevant stock 
solutions of miconazole nitrate, synthesized benzylidene piperidones, methyl-piperidones, 
3-((1R,5S)-3-oxo-8 azabicyclo[3.2.1]octan-8-yl) benzoic acid and 1,2-benzothiazines were 
made using DMSO. Various concentrations of the compounds and controls were added to 
the 2ml media in each bijou. DMSO (1.5%) was also used as a control to verify that DMSO 
had no effect on the growth of the cell line as all compounds including the control were 
dissolved in DMSO.      
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S. cerevisiae cell suspension (1ml) taken from an overnight growth was re-suspended in a 
250ml conical flask containing 80ml Mueller-Hinton broth. The flask was incubated for 5 
hours (32°C, 100 revs/min) to get the cells in the mid-exponential phase, after which 1ml of 
cell suspension was removed and absorbance at 600nm recorded to estimate the number of 
cells present per ml. A broth dilution method was performed and after a 1:300 dilution, 
100µl of the diluted cell suspension was added to each bijou (final number of cells per bijou: 
4.76 x 104 cells/ml). All tests were conducted in duplicate. Bijous were incubated at 32°C 
and shaken at 100 revs/min with absorbance readings (600nm) being recorded after 24 and 
48 hours incubation. The most potent compounds from the first screen were re-tested using 
a fresh growth of S. cerevisiae.  
The most potent compounds were also used for susceptibility testing against C. albicans. 
The method was as described previously for the susceptibility testing on S. cerevisiae. The 
experiment was repeated twice in duplicate using a fresh growth of cell culture. The final 
number of cells per bijou was between 5.3 x 104- 5.4 x 104 cells/ml.    
Results were expressed as percent inhibition of cell growth as compared to the 1.5% DMSO 
treated control using the following formula:  
100 - (AbsD / AbsC x 100)        Equation (3) 
Where AbsD = absorbance (600nm) of cells + drug and AbsC = absorbance (600nm) of cells + 
control (1.5% DMSO).  
3.1.2.2 Studies on the inhibition of growth of A. niger  
The inhibitory effects of the compounds on the growth of A. niger ATCC 16888 was analysed 
using a disk diffusion assay (Fothergill, 2012, CLSI, 2013). A few mycelial fragments of A. 
niger were aseptically inoculated onto two sterile Potato Dextrose Agar (PDA) plates and 
grown for 7 days at 35°C. Stock inoculum suspensions of conidia were prepared from the 7-
day old cultures grown by adding sterile distilled water (2.5ml) to each plate. The plates 
were shaken on a plate shaker (Heidolph, Titramax 100) at 150rpm/min for 20 minutes. The 
conidial suspension from each plate (1ml) was added to two separate sterile 20ml 
universals. Absorbance at 530nm for each sample was read before the samples were 
simultaneously mixed and then split again.   
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The samples were adjusted spectrophotometrically on the day of treatment with 
compounds to optical densities ranged between 0.09-0.11 using a 1:10 dilution with sterile 
distilled water. (Espinel-Ingroff et al, 2007). The final concentrations of the stock inoculum 
suspensions ranged from 8.6 x 105 to 2.4 x 106 CFU/ml, as demonstrated by quantitative 
colony counts on Sabouraud dextrose agar. The entire surface of each agar plate was 
inoculated simultaneously in three directions with 100µl of the stock inoculum using a 
sterile glass spreader. The inoculated agar was allowed to dry for 20 minutes. Sterile paper 
disks were loaded with various quantities of the most potent compounds (as defined by the 
inhibition studies on yeasts), miconazole nitrate (0.6µg) or DMSO (1.5%). The disks were 
allowed to dry for 60 minutes before being applied to the inoculated agar using sterile 
forceps. The plates were covered with lids and incubated in ambient air at 35°C within 10 
minutes of disk application to the inoculated agar. Each experiment was conducted in 
duplicate and the experiment repeated using a fresh growth of A. niger ATCC 16888.  
In the disk diffusion assay zone of inhibition diameters were measured to the nearest whole 
millimetre at the point where there was a measurable reduction of growth after 16, 24 and 
72 hours of incubation. Corrected diameters were acquired by subtracting the diameter of 
the paper disks (6mm) from the inhibition zone.   
3.1.2.3 Cytotoxic Evaluation of Compounds Against Human Carcinoma A549 Cell Line  
3.1.2.3.1 A549 Cell Harvest and Growth Analysis 
The A549 (ATCC CCL-185) human lung carcinoma cell line obtained from the University of 
Nottingham was used to analyse the cytotoxicity of the most potent compounds as defined 
by inhibition studies on yeasts. Selected compounds were tested against A549 cells for their 
effect on mitochondrial activity (MTS) and membrane integrity (LDH). Due to time 
limitations only four compounds were analysed for their cytotoxic properties. Cells were 
harvested in sterile T75 flasks consisting of Dulbecco's Modified Eagle Medium (DMEM, high 
glucose) supplemented with 10% fetal bovine serum (FBS), 0.1 mM MEM Non- essential 
amino acids (NEAA), 2 mM L-glutamine, and 1% Pen-Strep and kept in conditions of 37°C, 
5% CO2. Cells were passaged into fresh sterile T75 flasks every fortnight containing fresh 
media warmed to 37°C. PBS was used to remove any excess media and/or dead cells. 
Trypsin (0.5%), a serine protease was used to cleave proteins bonding the cultured cells to 
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the flask. Trypsin was removed by centrifuging the cell suspension at 250g, 18-25°C, 5 mins 
(Thermo scientific; Heraeus Labofuge 400R). 
The growth of A549 cells was studied to determine the mid-exponential phase. A549 cells 
were seeded into a 96-well plate at a concentration of 1 x 104 cells/100µl/well. The plate 
was incubated at 37°C, 5% CO2 and cell counts were obtained in triplicate from six wells 
daily for a total of 9 days. Cells were counted using a Neubauer haemocytometer with 
dilution and scaling factors applied to determine the number of cells per ml.  A dye 
exclusion assay (Trypan blue) was used when performing cell counts to discount any dead 
cells. Trypan Blue actively stains the cytoplasm of deceased cells so they can be easily 
viewed using a light microscope (Baust & Baust, 2007). The mid exponential phase of the 
cell line was found to be after 3 days of cultivation (see Figure 52, Page 143).  
For testing purposes; 96-well plates were seeded with the cells at a concentration of 1 x 104 
cells/100µl/well. Plates were incubated for three days at 37°C, 5% CO2. The compounds 
tested were initially dissolved in DMSO and then diluted using DMEM such that the final 
concentration of DMSO was 1%. The cells were then treated with a positive (kill) control (5% 
Triton X-100), negative control (1% DMSO) and varying concentrations of each compound 
tested (2 x 10-3- 2 x 10-7 M). Each control and concentration of compound tested was 
examined in sextuplicate. The experiment was repeated using a fresh growth of A549 cells. 
3.1.2.3.2 Cytotoxicity Studies of Test Compounds Using The MTS Assay  
The MTS assay was used to determine if the compounds have an effect on reducing 
mitochondrial activity thus possessing cytotoxic properties. The MTS assay is often defined 
as a ‘one-step’ MTT assay as the reagent can be added directly to the cell culture without 
the need of intermediate steps. (Burger & Fiebig, 2004). The test is centred on the ability of 
viable cells to convert the MTS reagent into a soluble blue/purple formazan dye. Thus viable 
cells appear blue/purple whereas dead cells are unaffected and remain pale yellow. (Burger 
& Fiebig, 2004). The exact cellular mechanism of MTS reduction into formazan involves 
reactions with intracellular NADH-oxidoreductases (Berridge et al, 2005). It is believed to 
occur mainly through the action of mitochondrial succinate dehydrogenase (Lobner, 2000).   
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After the cells were treated with the test compounds for 48 hours 20µl of the MTS reagent 
(317µg/ml) was added to each well of the 96-well plates. Plates were covered in aluminium 
foil to avoid interaction with light and were briefly shaken on a plate shaker (Heidolph, 
Titramax 100) for 30 seconds. All plates were incubated for 3 hours at 37°C, 5% CO2. The 
absorbance was determined using a multi-well plate reader (Labsystems; Multiskan Ascent) 
at 490nm. Results were expressed as percent cytotoxicity as compared to the controls (1% 
DMSO, 5% Triton X-100). The following formula was utilised to determine percent 
cytotoxicity: 
100 – (100 x (AbsD - AbsPC) / (AbsNC - AbsPC) )  Equation (4) 
Where AbsD= absorbance (600nm) of cells + drug, AbsPC= absorbance (600nm) of cells + 
positive control (5% Triton X-100) and AbsNC= absorbance (600nm) of cells + negative 
control (1.5% DMSO).   
 3.1.2.3.3 Cytotoxicity Studies of Test Compounds Using The LDH assay  
The effect on cell membrane integrity by potentially toxic compounds was measured using 
the lactate dehydrogenase (LDH) assay. LDH is an oxidoreductase which exists in most 
organisms and it catalyses the inter-conversion of pyruvate and lactate with an associated 
inter-conversion of NADH and NAD+, LDH is used as a catalyst. Pyruvate is used by the cell as 
a ‘dump’ of excess reducing power i.e. NADH in the absence of oxygen. This is facilitated by 
the action of the enzyme LDH (Fotakis & Timbrell, 2006). When a tissue suffers membrane 
damage, cells release LDH into the bloodstream. Since LDH is a stable enzyme it is widely 
used for detection of damaged cells (Fotakis & Timbrell, 2006). The enzymatic activity of 
LDH is temperature sensitive, thus it is recommended to equilibrate the temperature of the 
assay plates with the CytoTox-ONE reagent at 22 °C. The reagent consists of resazurin which 
is converted to resorufin when LDH is released into the culture medium. Production of the 
fluorescent reosurfin product is proportional to the quantity of LDH (Promega, 2012). An 
increase in LDH release is shown by an increase in fluorescence which indicates increasing 
cytotoxicity. Both the resazurin and the resorufin product formed during the assay are light-
sensitive. Therefore this experiment was carried out under minimum light conditions and 
black 96-well plates were used which were stored in dark conditions until the fluorescence 
was read to avoid discrepancies. 
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Plates containing cells incubated with test compounds for 48 hours were initially incubated 
in ambient air at 22°C for 30 minutes. The CytoTox-ONE reagent was made by mixing the 
assay buffer (11ml) with the lyophilised substrate mix post incubation (22 °C). The CytoTox-
ONE reagent (100µl) was added to each well of the plates. The plates were covered in 
aluminium foil and shaken briefly on the plate reader (Heidolph, Titramax 100) for 20 
seconds before incubation at 22°C for 10 minutes. Post incubation 50µl of ‘stop’ solution 
was added to each well. The ‘stop’ solution is used to rapidly stop the continued generation 
of fluorescent product thus allowing the plate to be read without variability in the time of 
incubation. All plates were shaken for 10 seconds and the fluorescence was measured using 
an excitation wavelength of 560nm and an emission wavelength of 590nm (PerkinElmer 
LS55 Fluorescence spectrophotometer). Results were expressed as percent cytotoxicity as 
compared to the controls (1% DMSO, 5% Triton X-100). The following formula was applied 
to determine percent cytotoxicity:  
 100 x (FD-FNC) / (FPC-FNC)  Equation (5) 
Where FD= fluorescence (Ex 560nm, Em 590nm) of cells + drug, FPC= fluorescence (Ex 560nm, 
Em 590nm) of cells + positive control (5% Triton X-100), FNC= fluorescence (Ex 560nm, Em 
590nm) of cells + negative control (1.5% DMSO), Ex= excitation wavelength and Em= 
emission wavelength.  
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Chapter 3.2: Results- Screening 
 
3.2.1 Inhibition of Growth of Saccharomyces cerevisiae and Candida albicans by Novel 
Compounds 
3.2.1.1 Growth Curves for S. cerevisiae and C. albicans  
The growth of the yeasts S. cerevisiae and C. albicans was analysed in order to determine the 
mid exponential phase. The exponential phase is defined as the point at which the cells are 
proliferating at their maximum rate. Absorbance readings at 600nm and cell counts were 
determined hourly between 1-8 hours and after 24 hours incubation (37°C, 100 revs/min). 
Cell growth curves were constructed of absorbance at 600nm against time.       
 
 
 
 
 
 
 
 
 
  
  
Figure 30- Growth curve showing the absorbance at 600 nm for S. cerevisiae and C. albicans taken at hourly 
intervals during growth (37°C).   
As shown in figure 30, both the fungal species were in lag phase until 4-5 hours of growth. 
The exponential (or log) phase is seen between 5-7 hours. After 7 hours the cells enter the 
stationary phase followed by the deceleration phase after 24 hours incubation. When 
determining the inhibitory potencies of the novel compounds against the growth of these 
fungi, the cells were initially incubated at 37°C for 5 hours (to obtain an absorbance reading 
between 0.3-0.4) to ensure they were in exponential phase and actively metabolizing.      
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3.2.1.2 Inhibition of Growth of S. cerevisiae After 24 hours Treatment With Ring 
Substituted 3,5-dibenzylidene-1-methyl Piperidin-4-ones (39a-39n) and Their 
Hydrochloride Salts (40a-40n)  
The ability of the novel compounds to inhibit cell growth in S. cerevisiae ATCC 46182 was 
analysed using a liquid broth dilution method. Bijous initially containing 4.76 x 104 cells/ml 
in 2ml Mueller-Hinton broth media were treated with various concentrations of the 
compounds, along with controls and the antifungal drug miconazole as a reference. Bijous 
were incubated for 24 hours (37°C, 100 revs/min). Post incubation absorbance (600nm) was 
obtained from a 1ml sample from each bijou. All tests were conducted in duplicate. As the 
compounds and controls were dissolved in DMSO (1.5%), an initial test to determine the 
effect of DMSO at a final concentration of 1.5% on cell growth was conducted. DMSO at a 
concentration of 1.5% had no effect on cell growth with results being expressed as percent 
inhibition (see Equation 3, Page 70) as compared to the untreated controls. Ring substituted 
dieneones were compared against dieneones without any ring substituents.      
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Figure 31- Dose response curves of the free base and hydrochloride salts of ortho-substituted (A, B), meta-
substituted (C, D) and para-substituted (E, F) 3,5-dibenzylidene-1-methyl piperidin-4-ones; showing the effect 
of increasing concentration on the % inhibition of cell growth of S. cerevisiae after a 24 hour treatment. The 
data is presented as percentages of the control (1.5% DMSO). The reference drug miconazole at a 
concentration of 0.835 x 10
-6
 M gave an average absorbance (600nm) of 0.609 (39% inhibition) and 0.107 
(89% inhibition) at 1.67 x 10
-6
 M. The concentrations of compound resulting in 10% inhibition (IC10) were 
determined from the dose-response curve. IC50 values were determined using the graphical software 
package GraphPad, Prism 5.   
Figure 31 shows that increasing the concentration of each of the compounds causes 
inhibition of growth of the yeast. However there is a point where increasing concentration 
has no increased effect on inhibition (as seen by plateau in the dose-response curves) which 
varies from compound to compound. The highest concentration used (3 x 10-3 M) of each 
compound gave a significantly higher percentage inhibition. However it can be seen that the 
Iodo-substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones (39m and 39n) and their 
hydrochloride salts (40m and 40n) gave the highest level of inhibition, whereas compounds 
without ring substituents gave the lowest level of inhibition (39a, 40a). There was very little 
variability between the free base compounds and their hydrochloride salts, with the free 
base compounds generally giving higher levels of inhibition. However, the major factor was 
the ‘R’ substituent where iodo substituted compounds were the most potent growth 
inhibitors and un-substituted compounds produced the lowest level of inhibition. Another 
factor affecting the level of inhibition was the position of the substituent where para 
substituted compounds were the most potent and ortho substituted compounds were the 
least potent. Compound 39n was the most potent giving 83% inhibition at a concentration 
of 3 x 10-3 M, whereas miconazole gave 89% inhibition at 1.67 x 10-6 M.     
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3.2.1.3 Inhibition of Growth of S. cerevisiae After 24 hours Treatment with Ring 
Substituted 3,5-dibenzylidene-1-piperidin-4-ones (41a-41n) and Their Hydrochloride Salts 
(42a-42n) 
Ring substituted 3,5-dibenzylidene-1-piperidin-4-ones (41a-41n) and their hydrochloride 
salts (42a-42n) were examined for their inhibitory effect on the cell growth of S. cerevisiae 
ATCC 46182 as described in 3.2.1.2.  
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Figure 32- Dose response curves of the free base and hydrochloride salts of ortho-substituted (A, B), meta-
substituted (C, D) and para-substituted (E, F) 3,5-dibenzylidene-1- piperidin-4-ones; showing the effect of 
increasing concentration on the % inhibition of cell growth of S. cerevisiae after a 24 hour treatment. The 
data is presented as percentages of the control (1.5% DMSO). The reference drug miconazole at a 
concentration of 0.835 x 10
-6
 M gave an average absorbance (600nm) of 0.618 (38% inhibition) and 0.108 
(89% inhibition) at 1.67 x 10
-6
 M. The concentrations of compound resulting in 10% inhibition (IC10) were 
determined from the dose-response curve. IC50 values were determined using the graphical software 
package GraphPad, Prism 5.    
The results obtained resemble the data obtained in 3.2.1.3; increasing concentrations of 
each compound increased the inhibition of cell growth with DMSO (1.5%) having no effect 
on growth. These compounds however show higher degrees of growth inhibition in 
comparison to the ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones and their 
respective hydrochloride salts. There is not a significant difference between the results 
obtained for the free base and the hydrochloride salts of the ring substituted 3,5-
dibenzylidene-1-piperidin-4-ones. In both cases the iodo-substituted compounds produced 
the highest level of inhibition and un-substituted compounds were the least potent growth 
inhibitors. The position of the substituent conveyed an effect on inhibition, where para-
substituted substituents gave rise to the most potent inhibitors and ortho-substituted 
substituents produced the least potent compounds. Compound 41n was the most potent 
giving 89% inhibition at a concentration of 3 x 10-3 M, whereas miconazole gave the same 
level of inhibition at 1.67 x 10-6 M.       
3.2.1.4 Inhibition of Growth of S. cerevisiae After 48 hours Treatment with Ring 
Substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones (39a-39n) and Their 
Hydrochloride Salts (40a-40n)  
The experiment as described in 3.2.1.2 was repeated except that cells were treated with the 
compounds for 48 rather than 24 hours. Results of inhibition studies were repeated using 
the most potent compounds. The data was combined and percent inhibition calculated.  
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Figure 33- Dose response curves of the free base and hydrochloride salts of ortho-substituted (A, B), meta-
substituted (C, D) and para-substituted (E, F) 3,5-dibenzylidene-1-methyl piperidin-4-one; showing the effect 
of increasing concentration on the % inhibition of cell growth of S. cerevisiae after a 48 hour treatment. The 
data is presented as percentages of the control (1.5% DMSO). The reference drug miconazole at a 
concentration of 0.835 x 10
-6
 M gave an average absorbance (600nm) of 0.603 (39% inhibition) and 0.104 
(90% inhibition) at 1.67 x 10
-6
 M. The concentrations of compound resulting in 10% inhibition (IC10) were 
determined from the dose-response curve. IC50 values were determined using the graphical software 
package GraphPad, Prism 5.    
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Incubating the cells with the compounds for a longer period resulted in an increase in 
growth inhibition, whereby increasing the incubation period by a further 24 hours has 
resulted in further increase in inhibition of growth. This is the case for both the free base 
and hydrochloride salts of the ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones. 
Compound 39n was the most potent giving 86% inhibition at a concentration of 3 x 10-3 M, 
whereas miconazole gave 90% inhibition at 1.67 x 10-6 M.       
3.2.1.5 Inhibition of Growth of S. cerevisiae After 48 hours Treatment With Ring 
Substituted 3,5-dibenzylidene-1-piperidin-4-ones (41a-41n) and Their Hydrochloride Salts 
(42a-42n)  
3,5-dibenzylidene-1-piperidin-4-ones and their hydrochloride salts were re-tested for their 
inhibitory potencies against S. cerevisiae as described in 3.2.1.2, however the cells were 
treated with the compounds for 48 hours rather than 24.  
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Figure 34- Dose response curves of the free base and hydrochloride salts of ortho-substituted (A, B), meta-
substituted (C, D) and para-substituted (E, F) 3,5-dibenzylidene-1- piperidin-4-ones; showing the effect of 
increasing concentration on the % inhibition of cell growth of S. cerevisiae after a 48 hour treatment. The 
data is presented as percentages of the control (1.5% DMSO). The reference drug miconazole at a 
concentration of 0.835 x 10
-6
 M gave an average absorbance (600nm) of 0.606 (40% inhibition) and 0.103 
(90% inhibition) at 1.67 x 10
-6
 M. The concentrations of compound resulting in 10% and 90% inhibition (IC10, 
IC90) were determined from the dose-response curve. IC50 values were determined using the graphical 
software package GraphPad, Prism 5.    
In comparison to the 24 hour treatment (3.2.1.3), 48 hours incubation with compounds 
resulted in a higher degree of cell growth inhibition. Both the free base and the 
hydrochloride salts of the ring substituted 3,5-dibenzylidene-1- piperidin-4-ones showed an 
increase in cell growth inhibition when incubated for a further 24 hours. Compound 41n was 
the most potent giving 91% inhibition at a concentration of 3 x 10-3 M, whereas miconazole 
gave 90% inhibition at 1.67 x 10-6 M.        
3.2.1.6 Inhibition of Growth of S. cerevisiae After 24 and 48 hours Treatment With 
Substituted 1,2-Benzothiazines (48a-48as)  
The 1,2-benzothiazine derivatives (see section 3.1.1.5) which have previously shown activity 
against various bacterial species (Patel, 2012)  were tested in an identical manner as 
described in 3.2.1.2. Cells were treated with the compounds for 24 and 48 hours to 
determine if incubation time had an effect on cell growth inhibition. Of the 45 compounds 
tested; only 4 compounds displayed significant inhibition (10% or above inhibition) after 24 
or 48 hours incubation with the S. cerevisiae cells.       
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Figure 35- Dose response curves of the various substituted 1,2-benzothiazines; showing the effect of 
increasing concentration on the % inhibition of cell growth of S. cerevisiae after a 24 (A) and 48 (B) hour 
treatment. The data is presented as percentages of the control (1.5% DMSO).The reference drug miconazole 
at a concentration of 0.835 x 10
-6
 M gave an average absorbance (600nm) of 0.614 (38% inhibition) and 
0.107 (89% inhibition) at 1.67 x 10
-6
 M. The concentrations of compound resulting in 10% inhibition (IC10) 
were determined from the dose-response curve. Dose response curves were generated using a graphical 
software package GraphPad, Prism 5.    
The benzothiazine derivatives were not as effective as the piperidone derivatives at 
inhibiting the growth of S. cerevisiae. Only 4 out of the 45 compounds tested exhibited 
inhibition of 10% and above. Although increasing the concentration increased the level of 
inhibition, only the compounds (4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-
benzo[e][1,2]thiazin-3-yl)(p-tolyl) methanone (48f) and (4-bromo-6,7-dimethoxy-1,1-
dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4 chlorophenyl) methanone (48k) gave 
significant levels of inhibition (approximately 20%). Increasing the incubation time had little 
effect on the degree of inhibition, with little variability between the data obtained for 24 
and 48 hours treatment. Miconazole was a far more potent inhibitor providing 89% 
inhibition at a concentration of 1.67 x 10-6 M.      
3.2.1.7 Inhibition of Growth of S. cerevisiae After 24 and 48 hours Treatment With 4-
((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) Benzoic acid (47a) 
Tropanones belong to the same family of compounds as piperidones, with the difference 
being the presence of an ethylene bridge. They are also known to possess antifungal 
properties (Humphery & O’Hagan, 2001). The synthesized 4-((1R,5S)-3-oxo-8-
azabicyclo[3.2.1]octan-8-yl) benzoic acid was tested against S. cerevisiae for its potency to 
inhibit cell growth as described in section 3.2.1.2 over 24 and 48 hours incubation. Results 
indicated that the compound had a minute effect on growth inhibition as it produced less 
than 10% inhibition. Thus a dose response curve could not be constructed.  
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3.2.1.8 Inhibition of Growth of C. albicans After 48 hours Treatment With A Subset of Ring 
Substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones  
The most potent ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones indicated by 
the results obtained from the screening against S. cerevisiae were tested as described in 
section 3.2.1.2 except that S. cerevisiae was replaced with C. albicans NCYC 854. Candida 
cells were treated with the compounds for 48 hours as testing against S. cerevisiae had 
revealed that 48 hour incubations resulted in higher levels of inhibition compared to the 24 
hour treatment. All tests were conducted in duplicate and the experiment repeated using a 
fresh cell growth. The hydrochloride salts were not tested because although the differences 
were small, the free base compounds generally gave higher levels of inhibition when testing 
against S. cerevisiae. Initial tests confirmed DMSO (1.5%) had no effect on C. albicans cell 
growth.  
 
  
 
 
 
 
 
   
 
Figure 36- Dose response curves of the free base ortho-substituted (A), meta-substituted (B) and para-
substituted (C) 3,5-dibenzylidene-1-methyl piperidin-4-ones; showing the effect of increasing concentration 
on the % inhibition of cell growth of C. albicans after a 48 hour treatment. The data is presented as 
percentages of the control (1.5% DMSO). The reference drug miconazole at a concentration of 0.835 x 10
-6
 M 
gave an average absorbance (600nm) of 0.603 (40% inhibition) and 0.105 (90% inhibition) at 1.67 x 10
-6
 M.  
The concentrations of compound resulting in 10% inhibition (IC10) were determined from the dose-response 
curve. IC50 values were determined using the graphical software package GraphPad, Prism 5.    
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The data obtained correlated with that of testing against the S. cerevisiae species (3.2.1.4). 
Increasing concentration of each compound resulted in an increase in inhibition of 
C. albicans cell growth. The iodo-substituted compounds gave rise to the most potent 
inhibitors and para-substituted substituents produced the most potent inhibitors.   
3.2.1.9 Inhibition of Growth of C. albicans After 48 hours Treatment with Selected Ring 
Substituted 3,5-dibenzylidene-1-piperidin-4-ones  
A selection of ring substituted 3,5-dibenzylidene-1-piperidin-4-ones which gave the highest 
levels of inhibition as exhibited by screening against S. cerevisiae (3.2.1.5) after 48 hours 
incubation were screened against the C. albicans species in the same manner. The 
hydrochloride salts were not tested as the free base compounds produced higher levels of S. 
cerevisiae growth inhibition.    
  
  
 
 
 
 
 
 
 
  
Figure 37- Dose response curves of the free base ortho-substituted (A), meta-substituted (B) and para-
substituted (C) 3,5-dibenzylidene-1-piperidin-4-ones; showing the effect of increasing concentration on the % 
inhibition of cell growth of C. albicans after a 48 hour treatment. The data is presented as percentages of the 
control (1.5% DMSO). The reference drug miconazole at a concentration of 0.835 x 10
-6
 M gave an average 
absorbance (600nm) of 0.603 (40% inhibition) and 0.105 (90% inhibition) at 1.67 x 10
-6
 M.  The 
concentrations of compound resulting in 10% and 90% inhibition (IC10, IC90) were determined from the dose-
response curve. IC50 values were determined using the graphical software package GraphPad, Prism 5.    
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The compounds had a similar inhibitory effect on the growth of C. albicans as compared to 
S. cerevisiae (section 3.2.1.5, Figure 34). In both cases increasing the concentration of the 
compound gave an increase in inhibition. Para substituted compounds were more potent 
than ortho or meta substituted compounds. The iodo-substituted compounds gave rise to 
the most effective inhibitor, with the 3’-iodo substituted 3,5-dibenzylidene-1-piperidin-4-
one giving the highest level of inhibition (91%) at a concentration of 3 x 10-3 M. Whereas 
miconazole nitrate at a concentration of 1.67 x 10-6 inhibited 90% of cell growth.    
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Table 5- The relevant IC10, IC50 and IC90 values of each compound tested for growth 
inhibition against various fungal species over 24 and 48 hours.  
Compound 
type 
Compound 
no. 
Fungal 
species S. cerevisiae ATCC 46182 C. albicans NCYC 854  
% inhibition 
IC10                    
(x 10-6 M) 
IC50  
(x 10-6 M) 
IC90  
(x 10-3 M) 
IC10 (x 
10-6 M) 
IC50 (x 
10-6 M) 
IC90 (x 
10-3 M) 
Time of 
incubation 
(hours)  24 48 24 48 24 48 48 48 48 
R
in
g 
su
b
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it
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te
d
 3
,5
-d
ib
en
zy
lid
en
e
-1
-m
e
th
yl
 
p
ip
e
ri
d
in
-4
-o
n
es
  
39a 
  
129 59 N/R N/R N/R N/R N/R N/R N/R 
39b 9.12 6.3 N/R N/R N/R N/R N/R N/R N/R 
39c 8.71 5.9 N/R N/R N/R N/R N/R N/R N/R 
39d 7.24 4.8 N/R N/R N/R N/R N/R N/R N/R 
39e 0.87 0.59 23.12 19.7 N/R N/R 0.63 21.5 N/R 
39f 0.79 0.56 17.97 16.85 N/R N/R 0.59 17.3 N/R 
39g 0.58 0.46 14.57 10.93 N/R N/R 0.51 13.1 N/R 
39h 32.4 23.9 N/R N/R N/R N/R N/R N/R N/R 
39i 32.3 19.5 N/R N/R N/R N/R N/R N/R N/R 
39j 28.2 14.1 N/R N/R N/R N/R N/R N/R N/R 
39k 16.2 1.35 22.89 22.5 N/R N/R 1.15 28.8 N/R 
39l 14.5 0.91 22.46 11.7 N/R N/R 1.02 19.3 N/R 
39m 0.33 0.28 6.52 4.44 N/R N/R 0.26 3.18 N/R 
39n 0.32 0.26 6.19 4.27 N/R N/R 0.26 2.67 N/R 
H
C
l s
al
ts
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n
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d
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3
,5
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n
zy
lid
e
n
e
-1
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 p
ip
er
id
in
-4
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n
es
  
40a 
  
603 316 N/R N/R N/R N/R N/R N/R N/R 
40b 25.1 12.6 N/R N/R N/R N/R N/R N/R N/R 
40c 22.4 10.5 N/R N/R N/R N/R N/R N/R N/R 
40d 12.3 7.6 N/R N/R N/R N/R N/R N/R N/R 
40e 1.15 0.68 29.9 22.9 N/R N/R N/R N/R N/R 
40f 0.96 0.62 20.6 20.14 N/R N/R N/R N/R N/R 
40g 0.72 0.5 18.4 13.7 N/R N/R N/R N/R N/R 
40h 64.6 30.2 N/R N/R N/R N/R N/R N/R N/R 
40i 52.5 25.1 N/R N/R N/R N/R N/R N/R N/R 
40j 38 22.9 N/R N/R N/R N/R N/R N/R N/R 
40k 1.74 1.29 35.4 27.7 N/R N/R N/R N/R N/R 
40l 1.55 0.98 33.2 29.2 N/R N/R N/R N/R N/R 
40m 0.42 0.32 9.5 7.38 N/R N/R N/R N/R N/R 
40n 0.38 0.29 8.03 6.87 N/R N/R N/R N/R N/R 
 
N/R: not reached, particular level of inhibition not reached by tested compound.  
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Table 5 (continued) - The relevant IC10, IC50 and IC90 values of each compound tested for 
growth inhibition against various fungal species over 24 and 48 hours. 
Compound 
type 
Compound 
no. 
Fungal 
species S. cerevisiae ATCC 46182 C. albicans NCYC 854  
% inhibition 
IC10                             
(x 10-6 M) 
IC50  
(x 10-6 M) 
IC90  
(x 10-3 M) 
IC10 (x 
10-6 M) 
IC50 (x 
10-6 M) 
IC90 (x 
10-3 M) 
Time of 
incubation 
(hours) 24 48 24 48 24 48 48 48 48 
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41a 
  
123 56.2 N/R N/R N/R N/R N/R N/R N/R 
41b 5.62 3.89 N/R N/R N/R N/R N/R N/R N/R 
41c 4.17 3.47 N/R N/R N/R N/R N/R N/R N/R 
41d 3.63 2.45 N/R N/R N/R N/R N/R N/R N/R 
41e 0.5 0.44 17.03 7.96 N/R N/R 0.44 8.54 N/R 
41f 0.45 0.42 15.89 7.89 N/R N/R 0.38 7.98 N/R 
41g 0.39 0.33 13.2 7.62 N/R N/R 0.35 7.53 N/R 
41h 67.6 30.2 N/R N/R N/R N/R N/R N/R N/R 
41i 23.9 11.2 N/R N/R N/R N/R N/R N/R N/R 
41j 20.9 6.61 N/R N/R N/R N/R N/R N/R N/R 
41k 1.02 0.91 20.37 11.8 N/R N/R 0.79 15.49 N/R 
41l 0.93 0.76 19.77 10.9 N/R N/R 0.69 12.88 N/R 
41m 0.26 0.19 4.71 4.15 N/R N/R 0.2 2.9 N/R 
41n 0.17 0.11 3.22 3.39 N/R 1.35 0.083 2.34 1.55 
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42a 
  
126 74.1 N/R N/R N/R N/R N/R N/R N/R 
42b 7.24 5.37 N/R N/R N/R N/R N/R N/R N/R 
42c 5.37 3.8 N/R N/R N/R N/R N/R N/R N/R 
42d 4.57 3.4 N/R N/R N/R N/R N/R N/R N/R 
42e 0.63 0.49 22.72 8.49 N/R N/R N/R N/R N/R 
42f 0.51 0.46 21.7 11.9 N/R N/R N/R N/R N/R 
42g 0.47 0.37 16.8 7.79 N/R N/R N/R N/R N/R 
42h 38 33.1 N/R N/R N/R N/R N/R N/R N/R 
42i 30.2 13.5 N/R N/R N/R N/R N/R N/R N/R 
42j 21.4 9.77 N/R N/R N/R N/R N/R N/R N/R 
42k 1.35 0.96 22.3 15.25 N/R N/R N/R N/R N/R 
42l 1.15 0.81 22.1 10.3 N/R N/R N/R N/R N/R 
42m 0.26 0.22 4.83 4.35 N/R N/R N/R N/R N/R 
42n 0.21 0.18 4.62 3.93 N/R N/R N/R N/R N/R 
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 48f 
  
7.94 6.03 N/R N/R N/R N/R N/R N/R N/R 
48k 8.71 6.92 N/R N/R N/R N/R N/R N/R N/R 
48p 18.62 9.55 N/R N/R N/R N/R N/R N/R N/R 
48ao 26.3 12.3 N/R N/R N/R N/R N/R N/R N/R 
48ar 31.6 16.59 N/R N/R N/R N/R N/R N/R N/R 
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The dose response curves and IC50 values were generated using the software package 
GraphPad, Prism 5. The concentrations required to inhibit 10% or 90% cell growth (IC10 and 
IC90) were obtained manually from the dose response curves. The free base compounds 
produced slightly lower IC10 and IC50 values when compared to their respective 
hydrochloride salts. Results indicated that 48 hours treatment with the compounds gave 
lower IC10 and IC50 values rather than 24 hours. The most potent compound was 41n (3’-
iodo 3,5-dibenzylidene-1-piperidin-4-one) with the lowest  IC10 and IC50 values against both 
species of yeast respectively. It is also the only compound to give greater than 90% 
inhibition of cell growth for both species giving IC90 values of 1.35 x 10
-3 M against S. 
cerevisiae and 1.55 x 10-3 M against C. albicans after 48 hours incubation, whereas 
miconazole nitrate, the reference antifungal, at a concentration of 1.67 x 10-6 M gave 89.5% 
inhibition of cell growth against both species with the same incubation period. Compounds 
with no ring substituents (39a, 40a, 41a and 42a) produced the highest IC10 and IC50 values 
thus the lowest level of growth inhibition. Para substitution gave lower IC10 and IC50 values 
when compared to meta or ortho substituted compounds. The free base 3,5-dibenzylidene- 
1-piperidin-4-ones (41a-41n) produced the lowest corresponding IC10 and IC50 values against 
both S. cerevisiae and C. albicans. A selected subset of compounds as defined by their 
potencies against S. cerevisiae were tested against C. albicans producing similar results 
suggesting that the compounds had an equal effect on both types of species.    
The benzene ring substituted piperidones gave lower IC10 and IC50 values when compared to 
the 1,2-benzothiazine derivatives or the tropan-3-one. Of the 45 1,2-benzothiazine  
compounds tested; only four compounds displayed inhibition of greater than 10% after 24 
or 48 hours incubation with S. cerevisiae. Compound 47a (4-((1R,5S)-3-oxo-8-
azabicyclo[3.2.1]octan-8-yl) benzoic acid) was an ineffective inhibitor of cell growth as it 
produced inhibition of below 10%.   
3.2.2 Inhibition of Growth of Aspergillus niger  
3.2.2.1 Inhibition of growth of A. niger After 48 and 72 hours Treatment With A Subset of 
Ring Substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones  
A subset of compounds selected by their ability to inhibit growth of yeasts to levels greater 
than 50% were examined for their effect on the inhibition of growth of the filamentous 
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fungus A. niger ATCC 16888 using the disk diffusion assay (Fothergill, 2012, CLSI, 2013). PDA 
plates were inoculated with 8.6 x 105 to 2.4 x 106 cfu/ml which were obtained from 7-day 
old cultures and adjusted to optical densities (530nm) between 0.09-0.11 by dilution with 
sterile deionised water. Plates were loaded with pre-soaked paper disks containing various 
amounts of the test compounds, miconazole (0.6µg) and DMSO (1.5%). The plates were 
incubated in ambient air at 35°C within 10 minutes of disk application and zone of inhibition 
diameters were measured after 16, 24 and 72 hours of incubation. All tests were carried out 
in duplicates and the experiment repeated using a fresh growth of A. niger. Preliminary tests 
revealed that DMSO had no effect on the cell growth of A. niger. Of the seven selected 3,5-
dibenzylidene-1-methyl piperidin-4-ones tested only three showed meaningful growth 
inhibition after 72 hours. None of the compounds tested inhibited cell growth after 16 or 24 
hours incubation. Zone of inhibition diameters were determined by measuring the radius of 
the zone of inhibition (r) and the width/diameter (D). The following equation was then 
applied to determine an average diameter: 2r+D /2.   
 
 
 
 
 
 
 
 
Figure 38- Disk diffusion assay showing the zone of inhibition diameters against A. niger ATCC 16888 for 
1.5% DMSO (1), 10µl of 1.253µM (12.53 nmoles) miconazole (2) and various amounts (10µl of 1 x10
-6
 M to 3 
x10
-3
 M)
 
 of  3,5-Bis(3-bromobenzylidene)-1-methylpiperidin-4-one (4f) (3) to (10) following 72 h incubation. 
Zone of inhibition diameters were determined by measuring ‘D’ and ‘r’ of each relevant inhibition zone. 
Corrected diameters were determined by subtracting the diameter of the paper disks (6mm) from the 
diameter of the zone of inhibition.    
Assays of microbial susceptibility to drugs by the agar diffusion method are analysed using 
linear fitting of the diameter or squared diameter of the inhibition zones against the natural 
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logarithm (ln) of drug concentration at the source. (Bonev, Hooper, & Parisot, 2008).This 
reflects a solution of the differential equation describing free diffusion in one-dimension 
(refer to Equation 2, Page 13). In order to find the most suitable linear fitting various graphs 
were plotted of D, D2, Ď (corrected by subtracting from the diameter of the paper disks) and 
Ď2 against ln of the drug concentrations. The R2 values were deduced from each graph and 
then compared (Microsoft Excel). R2 values indicate how well data points fit in a linear 
regression as it represents the variation of the data explained by the fitted line. The closer 
the R2 value is to 1 the better the linear regression fit.        
Table 6- R2 values for ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones from 
linear regression analysis using quadratic or linear dependence of zone size (mm) against 
ln (c)     
 
From the data in table 6 it was evident that plots of D and D2 against ln (concentration) gave 
better fitted linear regressions as their corresponding R2 values were closer to 1. Therefore 
plots of D and D2 against ln (concentration) were generated using the software package 
GraphPad, Prism 5 following which the minimum concentration required to induce cell 
growth inhibition (MIC) was deduced for each of the compound tested. MIC values were 
deduced from the x-intercept of each graph.  
 
  
R2 value  
Compound 
no.  
Compound type Ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones  
Incubation time 
(hours) 48 72 
Parameter D D2 D - Ď (D - Ď)2 D D2 D - Ď (D - Ď)2 
39g   0.990 0.997 0.990 1.000 0.986 0.980 0.986 0.966 
39m   0.998 0.988 0.998 0.965 0.989 0.961 0.989 0.913 
39n   0.999 0.990 0.999 0.974 0.980 0.954 0.980 0.918 
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Figure 39- Linear regression fits of selected 3,5-dibenzylidene-1-methyl piperidin-4-ones against A. niger 
showing the effect on the zone of inhibition diameter (D) as amount of compound loaded is increased. 
Inhibition zone diameters D (mm) and their squared values (D
2
) were plotted against ln (conc) in linear fits. 
The effects on D and D
2
 after 48 hours treatment with the test compounds is shown by graphs A and B, 
whereas graphs C and D show the effect of 72 hours treatment. The reference drug miconazole nitrate (10µl 
of 1.253µM (12.53 nmoles) gave an average zone of inhibition diameter of 17mm after 48 hours incubation 
and 18mm after 72 hours incubation. All graphs were constructed using the graphical software package 
GraphPad, Prism 5 and MIC values were determined by each respective intercept from the linear fits.     
None of the test compounds produced zone of inhibition at 16 and 24 hours of incubation. 
From the 7 selected compounds only 3 compounds produced measurable zone of inhibition 
diameters after 48 and 72 hours incubation. Increasing the concentration of these 
compounds increased the zone of inhibition diameters. Increasing the incubation period 
from 48 to 72 hours also showed an improvement in cell growth inhibition. Compound 39g 
(3,5-bis(4-bromobenzylidene)-1-methylpiperidin-4-one) was the least potent giving lower 
diameters at each given concentration, whereas compound 39n (3,5-bis(3-iodobenzy- 
lidene)-1-methylpiperidin-4-one) was the most potent growth inhibitor. Graph D shows that 
the iodo-substituted compounds (39m and 39n) do not give linear regression of best fit 
when plotting D2 against ln (concentration) after a 72 hour treatment suggesting that 
hydrophobicity is a key factor affecting their potency to inhibit cell growth. (Bonev et al, 
2008).   
3.2.2.2 Inhibition of Growth of A. niger After 48 and 72 hours Treatment With A Subset of 
Ring Substituted 3,5-dibenzylidene-1-piperidin-4-ones  
On the basis of the highest potency as distinguished by susceptibility testing against yeast a 
selection of ring substituted 3,5-dibenzylidene-1-piperidin-4-ones were examined for their 
potency to inhibit growth of A. niger ATCC 16888 in the same manner described in 3.2.2.1. 
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Of the seven compounds selected for screening only three compounds produced zone of 
inhibition diameters after 48 hours incubation and four compounds showed activity after 72 
hours.     
Table 7- R2 values for ring substituted 3,5-dibenzylidene-1-piperidin-4-ones from linear 
regression analysis using quadratic or linear dependence of zone size (mm) against ln (c)  
   
The R2 values for plots of D and D2 against ln (concentration) were closer to 1 thus giving 
better linear fits. Plots of D and D2 against ln (concentration) were constructed and MIC 
values deduced from the x-intercepts respectively.    
 
 
 
 
 
 
 
 
 
 
 
 
  
R2 value  
Compound 
no.  
Compound type Ring substituted 3,5-dibenzylidene-1-piperidin-4-ones  
Incubation time 
(hours) 48 72 
Parameter D D2 D - Ď (D - Ď)2 D D2 D - Ď (D - Ď)2 
41g   0.996 0.997 0.996 0.992 0.995 0.992 0.995 0.977 
41l   N/A N/A N/A N/A 0.989 0.978 0.989 0.956 
41m   0.993 0.988 0.993 0.976 0.978 0.949 0.978 0.913 
41n  0.995 0.986 0.995 0.971 0.983 0.962 0.983 0.936 
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Figure 40- Linear regression fits of selected 3,5-dibenzylidene-1-piperidin-4-ones against A. niger showing 
the effect on the zone of inhibition diameter (D) as amount of compound loaded is increased. Inhibition zone 
diameters D (mm) and their squared values (D
2
) were plotted against ln (conc) in linear fits. The effects on D 
and D
2
 after 48 hours treatment with the test compounds is shown by graphs A and B, whereas graphs C and 
D show the effect of 72 hours treatment. The reference drug miconazole nitrate (10µl of 1.253µM (12.53 
nmoles) gave an average zone of inhibition diameter of 17mm after 48 hours incubation and 18mm after 72 
hours incubation. All graphs were constructed using the graphical software package GraphPad, Prism 5 and 
MIC values were determined by each respective intercept from the linear fits.     
Equally to the ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones (figure 39), the 
3,5-dibenzylidene-1- piperidin-4-ones (figure 40) showed no zone of inhibition after 16 and 
24 hours incubation. From the 7 test compounds screened only 4 compounds showed 
activity after 48 and 72 hours incubation. Increasing the concentration of the compounds 
resulted in an increase in inhibition of cell growth as shown by an increase in zone of 
inhibition diameters. The screened compounds were more effective after 72 hours 
incubation with A. niger than 48 hours. Of the compounds tested the 4’-methoxy 
substituted derivative (41l) was the least potent inhibitor whereas the 3’-iodo substituted 
compound (41n) was the most potent. As shown in graph D (D2 against ln (concentration) 
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the iodo substituted compounds (41m and 41n) do not give linear regression of best fit after 
72 hours of treatment proposing that hydrophobicity of these compounds affects the 
potency to inhibit cell growth (Bonev et al, 2008).  
Table 8- Susceptibility of A. niger to a subset of 3,5-dibenzylidene-1-methyl piperidin-4-
ones and 3,5-dibenzylidene-1-piperidin-4-ones. MIC (M) and R2 values from linear 
regression analysis using quadratic ((D - Ď)2) or linear dependence of zone diameter (mm) 
on ln (concentration) 
Compound  Compound Nº 
Incubation 
time (hours) 48 72 
Parameter D/ln (C) D2/ln (C) D/ln (C) D2/ln (C) 
Ring substituted 
3,5-
dibenzylidene-
1-methyl 
piperidin-4-
ones  
39g 
MIC (x 10-8 M) 1.51 247 0.91 147 
R2 0.9897 0.9971 0.9857 0.9803 
39m 
MIC (x 10-8 M) 0.35 67.4 0.036 11.6 
R2 0.9976 0.9881 0.9894 0.961 
39n 
MIC (x 10-8 M) 0.29 61.6 0.035 11.9 
R2 0.9989 0.99 0.9802 0.9543 
Ring substituted 
3,5-
dibenzylidene-
1-piperidin-4-
ones  
41g 
MIC (x 10-8 M) 1.62 263 1.55 183 
R2 0.9956 0.9973 0.995 0.9915 
41l 
MIC (x 10-8 M) N/A N/A 28.2 1490 
R2 N/A N/A 0.9889 0.9779 
41m 
MIC (x 10-8 M) 0.58 82.3 0.079 17.8 
R2 0.9932 0.988 0.9776 0.9494 
41n 
MIC (x 10-8 M) 0.52 80.7 0.05 13.5 
R2 0.9949 0.9855 0.9831 0.9624 
 
The MIC for each of the test compounds decreased significantly as the time of incubation 
was increased from 48 to 72 hours. In general the iodo- substituted 3,5-dibenzylidene-1-
methyl piperidin-4-ones and 3,5-dibenzylidene-1-piperidin-4-ones were the most potent as 
displayed by their lower MIC values compared to the other compounds. However meta 
substitution provided a more potent inhibitor. Compound 39n was the most potent 
compound giving the lowest MIC values after 72 hours incubation from both plots  
(3.6 x 10-10 M (D/ln (c)) and 11.6 x 10-8 M (D2/ln (C)). Compound 41l was the least potent 
compound with the highest MIC values after 72 hours incubation as determined from each 
plot (2.82 x 10-7 M (D/ln (C)) and 1.49 x 10-5 M (D2/ln (C)). The quadratic model was accurate 
for compounds 39g and 41g whereas linear fits are more accurate in all other cases.    
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3.2.3 Cytotoxic Evaluation of Selected Compounds Against human carcinoma A549 cell line 
3.2.3.1 Cytotoxic Studies of Selected 3,5-dibenzylidene-1-piperidin-4-ones using The MTS 
Assay 
The cytotoxic properties of four selected 3,5-dibenzylidene-1-piperidin-4-ones (as 
exemplified by their higher potencies against yeasts or filamentous fungi) against 
mammalian A549 ATCC CCL-185 cells were analysed using the MTS assay. The MTS assay 
was utilised to determine the effect on the mitochondrial activity of the cells by the test 
compounds. Sterile polystyrene 96-well plates were seeded with cells (1 x 104 
cells/100µl/well) and incubated for three days at 37°C, at an atmosphere of 5% CO2 to 
ensure the cells were in mid exponential phase for testing purposes. Post incubation the 
cells (3.7 x 104 cells/100µl/well) were treated with various concentrations of the test 
compounds as well as a positive (kill) control (5% Triton X-100) and a negative control (1% 
DMSO) and re-incubated for a further 48 hours. To each well of the 96-well plates 20µl of 
the MTS reagent (317µg/ml) was added, following which the plates were incubated for 3 
hours. Absorbance readings at 490nm were obtained (Labsystems; Multiskan Ascent) and 
results were expressed as percent cytotoxicity as compared to the controls (1% DMSO, 5% 
Triton X-100) (see Equation 4, Page 73). Preliminary results showed DMSO (1%) had no 
cytotoxic effect on the cells.    
 
 
 
 
  
  
  
Figure 41- Dose response curves of the free base ring substituted 3,5-dibenzylidene-1-piperidin-4-ones; 
showing the effect of increasing concentration on the % cytotoxicity of A549 ATCC CCL-185 after 48 hours of 
treatment. The data is presented as percentages of the controls (1% DMSO and 5% Triton X-100). The 
positive control (5% Triton X-100) gave an average absorbance (490nm) of 0.2 after 48 hours incubation.  
The concentrations of compound giving 10% cytotoxicity (IC10) were determined manually from the dose-
response curve. IC50 values were determined using the graphical software package GraphPad, Prism 5.    
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Increasing the concentration of the test compounds consequently increased the percent 
cytotoxicity against the A549 cells suggesting that each compound is reducing the 
mitochondrial activity of these cells. However it was evident that the iodo substituted 3,5-
dibenzylidene-1-piperidin-4-ones were the most effective compounds as shown by their 
increased cytotoxicity. 3,5-bis(3-iodobenzylidene) piperidin-4-one (41n) was the most 
effective compound as it had the highest percent cytotoxicity compared to the other 
screened compounds whereas compound 41l (3,5-bis(4-methoxybenzylidene) piperidin-4-
one was the least potent.  
3.2.3.2 Cytotoxic studies of Selected 3,5-dibenzylidene-1-piperidin-4-ones  using The LDH 
Assay 
The cytotoxic properties of the selected compounds in respect to their effect on the 
membrane integrity of A549 ATCC CCL-185 cells was analysed using the Lactate 
Dehydrogenase (LDH) assay. The assay measures changes in fluorescence where an increase 
indicates higher levels of LDH thus indicating a greater loss of membrane integrity. The cells 
were seeded and treated with the same test compounds in a similar fashion as described in 
3.2.3.2. Post 48 hour treatment CytoTox-ONE reagent (100µl) was added to each well of the 
plates and the plates were incubated at 22°C for 10 minutes, after which 50µl of ‘stop’ 
solution was added to each well. Plates were shaken for 10 seconds and the fluorescence 
was measured using an excitation (Ex) wavelength of 560nm and an emission (Em) 
wavelength of 590nm (PerkinElmer LS55 Fluorescence spectrophotometer fitted with a 96-
well plate reader attachment). Results were expressed as percent cytotoxicity as compared 
to the controls (1% DMSO, 5% Triton X-100) (see Equation 5, Page 74).    
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Figure 42- Dose response curves of the free base ring substituted 3,5-dibenzylidene-1-piperidin-4-ones; 
showing the effect of increasing concentration on the % cytotoxicity of A549 ATCC CCL-185 cells after a 48 
hour treatment. The data is presented as percentages of the controls (1% DMSO and 5% Triton X-100). The 
positive control (5% Triton X-100) gave an average Fluorescence (Ex: 560nm, Em: 590nm) of 869 after 48 
hours incubation.  The concentrations of compound resulting in 10% cytotoxicity (IC10) were determined 
manually from the dose-response curve. IC50 values were determined using the graphical software package 
GraphPad, Prism 5.    
Increasing the concentration of test compounds resulted in an increase in damage to the 
membrane integrity thus an increase in cytotoxicity. The data obtained bears a resemblance 
to the results in figure 41 (section 3.2.3.1) with compound 41n being the most potent 
cytotoxic compound thus having the most effective damaging effect on membrane integrity 
and compound 41l the least cytotoxic compound.      
Table 9- The relevant IC10, IC50 and IC90  values of selected 3,5-dibenzylidene-1-piperidin-4-
ones  compounds tested for cytotoxicity studies against A549 ATCC CCL-185 cells after 48 
hours treatment using the MTS and LDH assays.    
Compound Number  
Assay type  MTS LDH 
% 
cytotoxicity  
IC10         
 (x 10-7 M ) 
IC50            
(x 10-4 M ) 
IC90 IC10         
(x 10-7 M ) 
IC50            
(x 10-4 M ) 
IC90 
41g   2.60 1.05 N/R 2.19 1.8 N/R 
41l   12.3 54 N/R 5.62 50.6 N/R 
41m   1.95 0.30 N/R 1.95 0.26 N/R 
41n   1.41 0.17 N/R 1.62 0.21 N/R 
 
N/R: not reached, particular level of inhibition not reached by tested compound. 
The IC50 values obtained for each of the tested compounds between the two assays were 
fairly similar. In both cases compound 41n (3,5-bis(3-iodobenzylidene) piperidin-4-one) 
provided the lowest IC50 values (MTS: 0.17 x10
-4 M, LDH: 0.21 x10-4 M) implying it is the 
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most cytotoxic compound thus having the most potent effect on membrane integrity and 
mitochondrial activity. With IC50 values of 5.4 x 10
-3 M (MTS) and 5.06 x 10-3 M (LDH) 3,5-
bis(4-methoxybenzylidene) piperidin-4-one (41l) is the least cytotoxic compound of those 
tested. Of the two iodo-substituted compounds tested meta substitution gave rise to a 
more cytotoxic compound.   
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Chapter 4 
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Chapter 4.1: Synthetic Procedures 
 
The need for novel antifungal and anticancer agents has significantly increased over recent 
years due to an rise in cancer cases and increased resistance of pathogenic fungi to clinically 
used antifungal agents, with only a few novel antifungal and anticancer agents being 
introduced in the last decade (Norby et al, 2005). The European Society of Chemical 
Microbiology and Infectious Diseases (ESCMID) has noted that production of novel 
compounds has decreased considerably over recent years (Norby et al, 2005). Resistance 
occurs predominantly as a result of altered genetics (Projan & Youngman, 2002). The 
number of cases of multidrug resistant fungal infections is increasing (Gulshan & Moye-
Rowley, 2007) suggesting an urgent need for new classes of antifungal agents (Oren, Yalcin, 
Sener & Ucarturk, 2004). The emergence of drug-resistant strains of fungi is a significant 
threat to human and animal health as immunocompromised patients such as those 
suffering from HIV/AIDS, undergoing chemotherapy or organ transplantation are more 
susceptible to fungal infections (Norby et al, 2005). The antifungal and anticancer properties 
of some novel tropan-3-ones (Dimmock et al, 2002), piperidones (Pati et al, 2009) and 
libraries of 1,2-benzothiazines (Park et al, 2002, Ahmad et al, 2011) have encouraged 
research on the synthesis of novel tropan-3-ones, piperidones and 1,2-benzothiazines, with 
subsequent analysis of their antifungal and anticancer properties.  
4.1.1 Synthesis of Ring Substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones, 3,5-
dibenzylidene-1- piperidin-4-ones and Their Hydrochloride Salts.  
In the present study an aldol condensation of N-methyl-4-piperidone (32) or 4-piperidone 
hydrochloride monohydrate (33) with various aromatic aldehydes (refer to Table 1, Page 37) 
was performed. The aldol condensation involves a nucleophilic addition between an enolate 
and the carbonyl group of an aldehyde or ketone to produce β-hydroxyketone (aldols) 
(Noyce & Pryor, 1955). The reaction requires the use of a strong base such as NaOH in the 
presence of a solvent system usually comprised of ethanol and water or alternatively the 
reaction can occur using a strong acid such as a Lewis acid (Leonova et al, 2010). 
Dehydration of the aldols by the E1 mechanism then gives rise to a conjugated α,β-
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unsaturated enone with the loss of a water molecule. Again this step is often base catalysed 
however an acid may be used instead (Climent et al, 2002) 
Several synthetic approaches have been deployed for this reaction, which vary in the nature 
of the solvent and catalyst used. In most cases the methods used are variations on the 
condensation of ketones with aldehydes in a basic aqueous alcoholic medium (McElvain & 
Rorig, 1948). 
   
 
  
 
 
 
 
 
 
 
Figure 43- General protocol for the coupling of substituted benzaldehydes with N-methyl-4-piperidone (A) or 
4-piperidone hydrochloride monohydrate (B) 
An effective method for the coupling of various substituted aromatic aldehydes at the C-3 
and C-5 position of either the N-methyl-4-piperidone or the 4-piperidone hydrochloride 
monohydrate was used (McElvain & Rorig, 1948). The groups alpha (α) to the carbonyl 
group in each parent compound are enolisable meaning they can undergo keto-enol 
tautomerism (Otera, 2001), thus an aldol condensation at these points results in formation 
of C=C double bond from the coupling of R-substituted benzaldehydes. Compounds were 
purified by recrystallization using various solvents. All compounds synthesized showed only 
one spot on silica TLC and where characterized by 1H and 13C NMR, IR and mass 
spectrometry. Generally the condensation occurred in good yield with yields ranging from 
41-89% achieved for the ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones (39a-
39n) and 53-98% for their respective hydrochloride salts (5a-5n). Yields of 31-68% were 
A 
B 
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obtained for the ring substituted 3,5-dibenzylidene-1-piperidin-4-ones (39a-39n) and 55-
97% for their corresponding hydrochloride salts. For all compounds synthesized the range of 
the melting points was within 3°C.  
The structures of the resultant condensation products were established using 1H and 13C 
NMR, IR spectroscopy and mass spectrometry. The IR spectra of all compounds show a peak 
between 1658-1688 cm-1 corresponding to an unsaturated carbonyl (C=O) group. The 
ketonic C=O peak of N-methylpiperidin-4-one is observed at about 1721.2 cm-1 however due 
to the conjugation with the α,β-unsaturated bond the peaks are shifted to a lower 
wavenumber. The presence of the carbonyl peak is further confirmed by chemical shifts 
(between δ 180-188 ppm) in the 13C NMR spectra for compounds ( 39b, 39c, 39d, 39h, 39i, 
39j, 39k, 40a, 40e, 40g, 40h, 40l, 41a, 41b, 41c, 41d, 41e, 41f, 41g, 41h, 41i, 41j, 42a, 42d, 
42i and 42k). The carbonyl peak is not observed for the other compounds in their 13C NMR 
spectra which suggests low levels of keto-enol tautomerism. This can also be explained by 
shifts in the 13C NMR caused by the fusion of the benzaldehydes on respective α carbons 
which shifts the carbonyl peak to a lower ppm as addressed by a previous study which 
studied the chemical shift correlations for changes in structure for progestrones, androst-4-
enedione and testosterones  (Reich, Jautelat, Messe, Weigert, & Roberts, 1966). However it 
is not fully understood why the carbonyl peaks are seen in some compounds and not all.  
IR peaks between 1396-1595 cm-1 for all compounds are indicative of presence of a (C=C) 
double bond whereas peaks between 1547-1623 cm-1 suggest presence of the aromatic C-C 
single bond. The ring substituted 3,5-dibenzylidene-1-piperidin-4-ones (41a-41n) and their 
hydrochloride salts (42a-42n) display peaks between 3233-3377 cm-1 which indicates the 
existence of the N-H group.   
Analysis by UV spectroscopy on various free bases of 3,5-dibenzylidene-1-methyl piperidin-
4-ones produced UV doublets on the spectra in regions between 220-241nm and 316-
357nm indicating the presence of an unsaturated carbonyl (Obili, 2014).         
For all synthesized compounds the theoretical molecular mass was predicted using the 
software package ChemBioDraw Ultra13 (Perkin Elmer). The molecular ion for each 
compound obtained from mass spectrometry was equivalent to the predicted molecular 
mass (+/- Hydrogen atom).    
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The 1H NMR of the 3,5-dibenzylidene-1-methyl piperidin-4-ones (39a-39n) and their 
hydrochloride salts (40a-40n) showed the presence of aliphatic protons on the CH3 group 
with broad singlet peaks appearing at δ 2.05-3.29. A peak between δ 1.57-2.49 confirms the 
presence of an amino proton on the N-H group associated with the 3,5-dibenzylidene-1- 
piperidin-4-ones (41a-41n) and their hydrochloride salts (42a-42n).  
In the 1H NMR spectra of all compounds, the signals for protons of the substituted aromatic 
rings appear as multiplets at δ 7.16-7.68, which is characteristic of E isomers (Das et al, 
2008). Singlet peaks are observed at δ 2.96-4.67 for the aliphatic protons on the piperidone 
ring and benzyldiene protons are distinguished by singlet peaks between δ 7.54-8.14.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44- The 
1
H NMR spectra of un-substituted 3,5-dibenzylidene-1-methyl piperidin-4-one (39a) where the 
relevant peaks on the spectra have been assigned to the different proton environments found on the 
compound. 
1
H-NMR (DMSO-d6): δ 2.49 (br s, 3H, aliph H), δ 4.60 (s, 4H, aliph H),  
δ 7.49 -7.56 (m, 10H, arom H) and δ 7.87 (br s, 2H, benzyldiene H) 
 
High-performance liquid chromatography analysis on various free base 3,5-dibenzylidene-1-
methyl piperidin-4-ones (39a-39n) has shown that these compounds degrade in aqueous 
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methanol to about five unidentified molecules following incubation at 4°C for 5-7 days 
(Obili, 2014).           
4.1.2 Attempted Synthesis of (2, 3 and 4)-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) 
benzoic acid (47a, 47b, 47c) and ethyl-4-((1R,5S)-3-oxo-8 azabicyclo [3.2.1]octan-8-yl) 
benzoate (47d)    
A variety of synthetic approaches have been identified for synthesizing tropane derivatives 
including Michael addition of an amine to substituted cycloheptadieone, oxalyl addition to 
pyrroles or nitrile oxide cycloaddition (Tufariello, 1979). However the modified Robinson 
reaction (Stoll et al, 1954) is the most suitable and commonly used route for the synthesis of 
various tropane derivatives (Thuo, 2008).   
 
Figure 45- Synthesis of tropanone using Robinson’s one-pot synthesis where x= H, CO2H or CO2Et (Thuo, 
2008) 
A two-step procedure was used to synthesize various tropane-3-one derivatives. Step one 
involved the synthesis of succindialdehyde from 2,5-dimethoxytetrahydrofuran (H2O, HCl, 
55°C) (Stoll et al, 1954). The second step involved reacting the succindialdehyde with 
various substituted aminobenzoic acids or their ethyl ester and acetone 1,3-dicarboxylic acid 
(3-oxopentanedioic acid) in the presence of aqueous NaOAc to yield the corresponding 
products. Step two of the reaction is the Robinson one pot synthesis (1917) which is widely 
used for the synthesis of tropane and its various derivatives (Thuo, 2008).    
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Figure 46- Generalised reaction scheme for the synthesis of (2, 3 or 4)-((1R,5S)-3-oxo-8 azabicyclo [3.2.1] 
octan-8-yl) benzoic acids and ethyl-4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoate, where 43a: 4-
NH2/R=H, 43b: 2-NH2/R=H, 43c: 3-NH2/R=H, 43d: 4-NH2/R=Et and 47a: 4-CO2/R=H, 47b: 2-CO2/R=H, 47c: 3-
CO2/R=H, 47d: 4-CO2/R=Et.  
 
Compound 47a produced a yield of only 18% with the range of the melting point within 4°C. 
The compound was purified by recrystallizing from methanol and only one spot was 
observed on silica TLC. 1H and 13C NMR, IR spectroscopy and mass spectrometry were 
employed to characterize the compound and determine its structure. The molecular weight 
of the compound was confirmed using mass spectrometry with the molecular ion being 
244.1 (M-H+) and the theoretical molecular mass of the compound 245. IR spectra showed 
the presence of the C=O group on C-3 of the tropanone ring at 1710 cm-1 and the C=O (as 
part of the benzoic acid) group on C-15 at 1673 cm-1. The presence of these carbonyl peaks 
was further confirmed by the 13C NMR spectra. The carbonyl group at C-3 is predicted to be 
at δ 207.3 by ChemBioDraw Ultra13 (Perkin Elmer) and at approximately 200.4 using 
literature tables (Silverstein & Webster, 2005) and the peak was observed at δ 207.14. The 
C=O group at C-15 is predicted at δ 169.3 by ChemBioDraw Ultra13  and at approximately δ 
168 using literature tables and it was observed at δ 168.29. The difference in the peaks is 
possibly due to a long range inductive effect caused by the oxygen molecules in the benzoic 
acid which may cause the peaks to shift up/downfield (Silverstein & Webster, 2005). A sharp 
peak at 1603 cm-1 in the IR spectrum confirms presence of the aromatic C-C single bond. 
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The 1H NMR analysis of the compound shows the presence of aliphatic protons on; C-6 and 
C-7 at δ 1.54 (predicted δ 1.66), C-2 and C-4 at δ 2.07 (predicted between δ 2.5-2.75) and  C-
1 and C-5 at δ 2.37 (predicted 3.32). The aromatic protons on C-10 and C-14 are observed at 
δ 6.6 (predicted δ 7.03) and at δ 7.69 for C-11 and C-13 (predicted δ 7.76).  
Succindialdehyde is a very reactive aldehyde which can oxidise with ease (Mondal & 
Mukherjee, 2003) forming succinic acid or undergo disproportionation to produce 4-
hydroxybutyric acid. If one or both of these occurred before the completion of the reaction 
it would explain the low yield obtained.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 47- Chemical structure of 4-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl) benzoic acid (47a) with its 
relevant carbon and nitrogen numbering. 
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The synthesis of ethyl-4-((1R,5S)-3-oxo-8 azabicyclo [3.2.1]octan-8-yl) benzoate (47d) 
initially required the synthesis of benzocaine (43d). 4-Aminobenzoic acid in the presence of 
absolute ethanol was stirred under reflux (100°C, 4 hours) yielding the product. The reaction 
scheme is shown below.   
 
 
 
 
 
 
 
Figure 48- reaction scheme for the synthesis of benzocaine (43d) 
 
Compound 43d was purified by recrystallization from ethanol/water with only one spot 
being observed on silica TLC. The yield of the product was 42% and a melting point range of 
89-91°C (literature range: 88-90°C (Sigma-Aldrich, 2013) was obtained. The carbonyl group 
on C-7 was detected at 1638 cm-1 on the IR spectrum and further confirmed at δ 166.40 on 
the 13C NMR spectra (predicted: δ 164.6). IR spectroscopy suggests the existence of the 
aromatic C-C bond at 1592 cm-1, a peak at 2984 cm-1 provides evidence of C-H bonds and 
indication of the N-H group at 3343 cm-1. The 1H NMR analysis of the compound 
distinguished the presence of the methyl protons on C-9 at δ 1.26 (predicted: δ 1.30), the 
methylene protons on C-8 at δ 4.18 (predicted δ 4.30) and the protons associated with the 
amino group at δ 5.92 (predicted: 5.48). The aromatic protons on C-3 and C-5 where evident 
at δ 6.54 (predicted: 6.47), whereas those on C-2 and C-6 were shown at δ 7.62 (predicted: 
δ 7.63). Analysis by mass spectrometry revealed the molecular ion to be 166.21 (M-H+) with 
the theoretical molecular mass of the compound being 165.19.  
          
 
 
(43a) (43d) 
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Figure 49- Chemical structure of benzocaine (43d) with its relevant carbon numbering. 
The resultant benzocaine (43d) was used for the attempted synthesis of ethyl-4-((1R,5S)-3-
oxo-8 azabicyclo [3.2.1]octan-8-yl)benzoate (47d) (refer to Figure 50). The product had a 
yield of 45% with a melting point range within 3°C.  The product was recrystallized from 
methanol and analysis using silica TLC gave one spot for the product. The IR spectrum 
exhibited the presence of the C=O group on C-3 of the tropanone ring at 1711 cm-1 and the 
C=O group on C-15 at 1673 cm-1. Further peaks at 1603 cm-1 and 2988 cm-1 were consistent 
with aromatic C-C bonds and C-H bonding respectively. The C=O peak for C-15 (predicted at 
δ 165.9 by ChemBioDraw Ultra13 and at δ 170.5 using literature tables was observed at δ 
166.37 on the 13C NMR. However the carbonyl peak for C-3 (predicted at δ 207.3 by 
ChemBioDraw Ultra13 and at 200.4 using literature tables) had been shifted to a lower ppm 
and was shown at δ 151.63. The shift is possibly due to a long range inductive effect caused 
by the oxygen molecules in the ester (Reich et al, 1966). 
Analysis by 1H NMR analysis indicate the presence of the aliphatic protons on; C-6 and C-7 at 
δ 1.67 (predicted δ 1.66), C-2 and C-4 at δ 2.22 (predicted between δ 2.5-2.75) and  C-1 and 
C-5 at δ 3.30 (predicted 3.32). The aromatic protons on C10 and C14 are detected at δ 6.99 
(predicted δ 6.93) and at δ 7.81 for C-11 and C-13 (predicted δ 7.84). The methyl protons on 
C-17 and the methylene protons on C-16 are not observed. As these are very distinctive 
peaks it suggests that there is no ester group present on C-15. Furthermore the 1H NMR 
resembles that of compound 47a and the molecular ion of the compound was also the same 
(244.1 (M-H+) with the theoretical molecular mass predicted to be 273.33. Therefore it 
seems that the compound is structurally identical to 47a suggesting that during or before 
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the reaction the ester group on the benzocaine reactant has been hydrolysed to form its 
benzoic acid derivative (PABA).   
    
 
 
 
 
 
  
  
  
Figure 50- The chemical structure of ethyl-4-((1R,5S)-3-oxo-8 azabicyclo [3.2.1]octan-8-yl) benzoate (47d) 
with its relevant carbon and nitrogen numbering.  
The attempted synthesis of 2-((1R,5S)-3-oxo-8-azabicyclo[3.2.1]octan-8-yl)benzoic acid 
(47b) was unsuccessful as analysis by TLC on the obtained material revealed the solid was 
predominantly 2-aminobenzoic acid and no product had been formed. Although the 
reaction was repeated under a nitrogen atmosphere to remove any oxygen which could 
have possibly oxidised the succindialdehyde to succinic acid the same outcome occurred. 
Addition of methanol resulted in the formation of an emulsion. Brine was added in an 
attempt to break down the emulsion but this proved ineffective.    
Several problems were encountered in the attempted synthesis of 3-((1R,5S)-3-oxo-8-
azabicyclo[3.2.1]octan-8-yl) benzoic acid (47c). Initially the brown solid formed did not 
recrystallize when dissolved in methanol. Analysis by silica TLC showed the material 
consisted of starting material with no new products being formed. The experiment was 
repeated under minimum light conditions to reduce photosensitivity and an excess of 
succindialdehyde and acetone 1,3-dicarboxylic acid was used. However no product was 
formed as defined by silica TLC. The synthesis of both (2 and 3)-((1R,5S)-3-oxo-8 azabicyclo 
[3.2.1]octan-8-yl) benzoic acids  were unsuccessful and the reasons for no products being 
formed are not understood.   
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Chapter 4.2: Antifungal Testing   
 
Fungi belong to a large group of eukaryotic organisms including microorganism such as 
yeasts, filamentous fungi and moulds of various types. Fungi play important roles in nutrient 
cycling and exchange, as well as decomposition of organic matter (Kavanagh, 2011).    
Although fungi have various industrial and medical benefits they are also the cause of many 
infectious diseases in both plants and animals. Additionally there is an increase in resistance 
of pathogenic fungi to clinical and agricultural antifungals. Fungi that cause disease in 
humans or other organisms are termed pathogenic fungi. Candida species are the largest 
group of human pathogens which often cause nasal, subcutaneous or GI infections 
particularly in immunocompromised patients such as AIDS sufferers or transplant patients. 
Saccharomyces cerevisiae is usually not considered a pathogen as diseases caused by this 
type of yeast are rare however there have been reported incidents (Mermel et al, 2009). 
Most yeast infections are associated with C. albicans. Exposure to S. cerevisiae particularly 
for immunosuppressed individuals can be fatal. Aspergillus niger, a filamentous fungus can 
cause serious lung disease (aspergillosis) and is the most common cause of otomycosis 
(fungal ear infection). As genomes of the yeast species S. cerevisiae and C. albicans have 
been sequenced and are easily cultured, and A.niger is the most abundant of the pathogenic 
filamentous species, it makes them good models for aiding diagnostic and novel antifungal 
drug development strategies (Kavanagh, 2011). The Clinical Laboratory and Standards 
Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
have approved methods for antifungal susceptibility testing of both yeast and moulds 
(filamentous fungi). According to the CLSI and EUCAST the liquid broth dilution method is 
most appropriate for yeasts whereas the disk diffusion assay is more suited to filamentous 
fungi (Fothergill, 2012, CLSI, 2013 & Kahlmeter et al, 2006). 
Azoles are a class of antifungals which work by blocking ergosterol synthesis. N-decyl 
imidazole was the first azole found to inhibit ergosterol production, and it was the lead 
compound from which various azoles have been developed. Azole type drugs therefore 
contain an imidazole structure. Ergosterol is an essential steroid found in fungi and is 
required for plasma membrane stability (Lewis, 2011). Miconazole is a commonly used 
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example of azole drugs used to treat various fungal infections (Sawyer et al, 1975). In the 
present study miconazole was used as a reference drug against which all the synthesized 
compounds were compared.  
When analysing the effects of the various piperidone dieneones, tropan-3-ones and 1,2 
benzothiazines on the inhibition of growth of yeast species; IC10, IC50 and IC90 
(concentrations required to inhibit 10%, 50% or 90% of cell growth) values were determined 
rather than the minimum inhibitory concentration (MIC). An earlier study revealed that 
when three yeast species were treated with miconazole the MIC values vary significantly 
with inoculum size whereas IC50 values remain constant (Galgiani & Stevens, 1976). Thus 
inter-laboratory comparisons are easier.  
Because the disk diffusion assay was used for examining the potential growth inhibitory 
potencies of the compounds against A. niger IC50 values could not be determined hence MIC 
values were obtained instead.  
Compounds with similar chemical and physical properties to those used in this study i.e. 
containing an α,β-unsaturated ketone, have previously shown activity against various fungal 
species (Dimmock et al, 1974, Natesh et al, 2003, Pati et al, 2009, Senthil et al, 2011 & 
Mittal et al, 2011). 
Various substituted compounds consisting of a piperidone or tropanone ring have shown to 
possess antifungal properties (Das et al, 2007). It has been suggested that the presence of 
an α,β-unsaturated ketone particularly in dieneone structures is linked with reducing the 
level of reduced glutathione in the cells by reaction with glutathione thiolate anions 
(Michael addition) leading to inhibition of cell growth or death (Pati et al, 2009). Other 
reports propose that structures having α,β–unsaturated carbonyls are responsible for 
blocking proton export by having an effect on the plasma membrane ATPase (Manavathu et 
al, 1999) or by blocking the mitochondrial phosphate transporter (Griffiths et al, 1981), both 
of which are essential for cell growth (Graham & Stevens, 1999).   
Various compounds consisting of a parent benzothiazine structure have shown antifungal 
activity (Niewiadomy et al,  2011). It is believed that presence of sulphur, nitrogen or oxygen 
in the heterocyclic structure results in antifungal properties (Projan & Youngman, 2002). 
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4.2.1 Antifungal Analysis of Some 3,5-dibenzylidene-1-methyl piperidin-4-ones, 3,5-
dibenzylidene-1-piperidin-4-ones, Their Hydrochloride Salts, Tropan-3-ones and 1,2-
Benzothiazines Against The yeasts S. cerevisiae and C. albicans 
Growth of the yeast species S. cerevisiae and C. albicans was studied to determine the mid 
exponential phase of growth. The exponential (or log) phase for both species was seen after 
5-7 hours. 
All test compounds as well as the reference drug (miconazole) were dissolved in DMSO thus 
initial tests were carried out to determine the effect of DMSO on cell growth. DMSO had no 
effect on the growth of either S. cerevisiae or C. albicans at a final concentration of 1.5%.     
Although 1,2-benzothiazines have shown antibacterial properties (Patel & Bassin, 2012), 
their ability to inhibit the growth of  S. cerevisiae was poor. All 45 derivatives (48a-48as) 
were tested, of which only four compounds exhibited inhibition at or above 10% after either 
24 or 48 hours incubation (refer to Figure 35, Page 83). Increasing the incubation time from 
24 to 48 hours had little effect on the degree of inhibition, with little variability in the data 
obtained.  
Tropanones contain the same carbon skeleton as piperidones, with the addition of an 1,5 
ethylene bridge. They are also known to possess antifungal properties (Humphery & 
O’Hagan, 2001). However the data obtained with 47a suggested that the compound had 
little effect on the cell growth as it gave less than 10% inhibition. The compound consists of 
a parent tropan-3-one structure with no additional groups (i.e. ring substituted dieneones) 
attached on the carbons α to the carbonyl group therefore it does not contain a highly 
conjugated system unlike the piperidone dieneones. Also there is no α,β-unsaturated or 
styryl ketone like structure embedded into the compound. The lack of the α,β-unsaturated 
carbonyl could lead to their low potencies. Previous studies suggest that the presence of 
α,β-unsaturated carbonyls contributes to their antifungal potencies (Dimmock and Taylor, 
1974).   
Data obtained showed that incubating the S. cerevisiae cells with various piperidone 
derivatives for 48 hours produced greater levels of growth inhibition compared to 24 hours 
incubation. The free bases of 3,5-dibenzylidene-1-methyl piperidin-4-ones (39a-39n) and 
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3,5-dibenzylidene-1-piperidin-4-ones (41a-41n) were slightly more effective cell growth 
inhibitors when compared to their respective hydrochloride salts. In general the presence of 
the methyl group on the heterocyclic nitrogen (compounds 39a-40n) results in lower 
potencies whereas presence of a hydrogen atom results in more potent compounds (41a-
42n). The un-substituted compounds were the least effective, whereas the iodo-substituted 
compounds gave the greatest level of inhibition with the 3’-iodo substituted 3,5-
dibenzylidene-1-piperidin-4-one producing the highest degree of inhibition (91%) at a 
concentration of 3 x 10-3 M. Para substitution produced the most effective compound with 
higher levels of inhibition obtained when compared to ortho or meta substituted 
compounds. However none of the compounds were found to be as potent as the reference 
drug (miconazole nitrate) which produced 89% inhibition at concentration of 1.67 x 10-6 M.             
Further antifungal testing was carried out using only the free bases of the piperidone 
derivatives due to time constraints and their increased potencies in comparison to the 
tropan-3-ones and 1,2-benzothiazines. Based on their potency against S. cerevisiae a subset 
of compounds were screened against C. albicans. The selected compounds were incubated 
with the cells for 48 hours and their ability to inhibit cell growth determined. Results 
showed these compounds had similar potencies against C. albicans when compared to S. 
cerevisiae. This was further confirmed by the determination of the respective IC10, IC50 and 
IC90 values for each compound tested against both fungal species (refer to Table 5, Page 87). 
Both species of yeast gave lower IC10 and IC50 values for para substituted compounds when 
compared to meta or ortho substituted analogues (para>meta>ortho). Compounds with no 
aromatic substituents had the highest IC10 and IC50 values (refer to Table 5, Page 87) hence 
they were the least potent. It appears that increasing the volume of the substituent group 
results in an increase in their potency with the iodo-substituted compounds being the most 
potent growth inhibitors. This can be further explained by the difference in electronic 
properties of the substituents on the benzene rings where the antifungal potency of the 
piperidone dieneones decreased with an increase of electron withdrawing properties of the 
R substituent. This is the opposite to that found in recent anticancer studies using novel N-
phosphorylalkyl substituted E,E-3,5-bis (arylidene) piperid-4-ones and N-phosphorylated 
E,E-3,5-bis (thienylidene) piperid-4-ones which suggest that increasing the electron 
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withdrawing properties of the R substituents increases potency. (Makarov et al, 2009, 
Makarov et al, 2010).    
The most potent compound was 41n (3’-iodo 3,5-dibenzylidene-1-methyl piperidin-4-one) 
having the lowest  IC10 and IC50 values against both species of yeast respectively. It is also 
the only compound to give greater than 90% inhibition of cell growth for both species giving 
IC90 values of 1.35 x 10
-3 M against S. cerevisiae and 1.55 x 10-3 M against C. albicans after 48 
hours incubation. However the reference drug (miconazole nitrate) under the same 
conditions, was more potent against both species producing 89-90% inhibition at a lower 
concentration (1.67 x 10-6 M). 
The synthesized piperidones all contain a double α,β-unsaturated ketone structure 
(dieneone) and it has been proposed by various studies that interactions with thiolate 
anions are believed to occur at the olefinic carbon atoms (as shown by CA and CB in Figure 
51) (Das et al, 2008, Mutus et al, 1989). The nucleophilic attack would be expected to occur 
at these points due to the electron-withdrawing influences of the carbonyl group 
(Manavathu et al, 1999). α,β-Unsaturated compounds can undergo Michael reactions with 
cellular nucleophiles such as thiolate anions found in proteins and cofactors such as 
glutathione with little or no affinity for hydroxyl and amino groups in nucleic acids (Pati et 
al, 2009). Thiols are distinctive as unlike amino and hydroxyl groups they are not found in 
nucleic acids. For the mitochondrial permeability transition pore complex to open it requires 
alkylation or cross-linking of a critical thiol on the protein permeability transition pore 
complex (Das et al, 2007). Since some of the compounds used in this investigation contain 
an α,β-unsaturated ketone they should react easily with thiolate anions via the Michael 
addition. Thus the mitochondrial permeability transition pore complex cannot open 
efficiently which activates the caspase system resulting in the destruction of the 
mitochondria, consequently leading to the initiation of cell death by apoptosis (Das et al, 
2007). 
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Figure 51- The structure of synthesized ring substituted 3,5-dibenzylidene-1-methyl piperidin-4-ones (where 
x= CH3) or 3,5-dibenzylidene-1-piperidin-4-ones (where x= H). The various substituents on the benzene rings 
are represented by R (see Table 1, Page 37). Olefinic carbon atoms are shown by C
A
 and C
B    
Glutathione is a cellular antioxidant which prevents damage to important cellular 
components (Kaplowitz, 1981). Glutathione and the side chain of the essential amino acid 
cysteine contain thiolate anions which act as nucleophiles and attack the electrophilic 
olefinic carbons on the α,β-unsaturated structure (Das et al, 2008, Mutus et al, 1989).  
Alternatively compounds containing a dieneone structure can have an adverse effect on 
fungal cell growth by interference with certain mitochondrial functions such as ROS 
generation or oxygen consumption by the electron transport chain (Helal et al, 2013). An 
increase in the level of reactive oxygen species (ROS) can lead to an overload of antioxidant 
defences culminating in cell death (Apel & Hirt, 2004). Oxidative phosphorylation is essential 
for cell growth and inhibition of this process may lead to an increase in the concentrations 
of ROS. This could affect the rate of oxygen consumption in the cell and also have a marked 
effect on the mitochondrial membrane potential (MMP) (Helal et al, 2013).          
Other reports suggest that compounds containing the α,β-unsaturated structure block the 
P-type proton-translocating ATPase (H+-ATPase) of various fungal species (Manavathu et al, 
1999) or they block the mitochondrial phosphate transporter (Griffiths et al, 1981), both of 
which are essential for cell growth (Graham & Stevens, 1999). The H+-ATPase is a plasma-
membrane located ATP-driven proton pump belonging to the P-type ATPase superfamily 
(Manavathu et al, 1999).    
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4.2.2 Analysis of Antifungal Activity By a Subset of Ring Substituted 3,5-dibenzylidene-1-
methylpiperidin-4-ones and 3,5-dibenzylidene-1-piperidin-4-ones Against the Filamentous 
Fungus A. niger 
The piperidone dieneones which produced inhibition of yeast growth at levels greater than 
50% were screened for their capacity to inhibit the growth of the filamentous fungus A. 
niger. The standard method for susceptibility testing using filamentous (mould) fungi was 
applied (Fothergill, 2012, CLSI, 2013). Initial tests revealed that DMSO up to a concentration 
of 1.5% had no effect on the cell growth of A.niger. None of the compounds tested showed 
inhibition of cell growth after either 16 or 24 hours incubation. Results showed that the 
compounds were not as effective at inhibiting growth of A.niger as only 7 of the 14 tested 
compounds showed activity. Filamentous fungi are multicellular organisms containing long 
branched filaments called hyphae which aggregate to form a mycelial mass thus making it 
more difficult for compounds to cross both the chitin based cell wall and the plasma 
membrane (Bärlocher, 2008). Therefore adverse effects by the piperidone dieneones on 
filamentous fungi would be expected to be lower in contrast to yeast which would be more 
vulnerable to these compounds.  
Increasing the incubation period from 48 to 72 hours enhanced inhibition of fungal growth. 
Compound 39g (3,5-bis(4-bromobenzylidene)-1-methylpiperidin-4-one) was the least potent 
giving smaller zone of inhibition diameters at each given concentration when compared to 
the other dieneones. As with the yeasts tested, compound 39n (3,5-bis(3-iodobenzylidene)-
1-methylpiperidin-4-one) was the most potent inhibitor of growth. Again as also 
demonstrated by the yeast studies the data obtained showed that para-substitution 
produced the most effective compound. Increasing the volume of the aromatic substituent 
and decreasing its electronegativity (electron withdrawing properties) also improved 
potency.       
Assays of microbial susceptibility to drugs via the agar diffusion method were analysed using 
linear fitting of either the diameter or squared diameter of the inhibition zones against the 
natural logarithm (ln) of drug concentration at the source;  
ln (MIC) = ln (c) – D2 /4dt  Equation (2)  
118 | P a g e  
 
Where D= zone of inhibition diameter, d= diffusion coefficient presumed to be independent 
of concentration and t= time of drug diffusion) (Kronvall, 1982). This reflects a solution of 
the differential equation describing free diffusion in one dimension which takes into account 
the dependence of the drug concentration on distance from the source and on time. 
(Bonev, Hooper & Parisot, 2008). In order to find the most suitable linear fitting, various 
graphs were plotted of D, D2, Ď (corrected by subtracting the diameter of the paper disks 
from D) and Ď2 against ln (drug concentration). The R2 values were deduced from each graph 
and then compared (Microsoft Excel). R2 values indicate how well data points fit in a linear 
regression as it represents the variation of the data explained by the fitted line. The closer 
the R2 value is to 1 the better the linear regression fit (Colin & Windmeijer, 1997).        
As seen in Tables 6 and 7 (Pages 91 & 93 respectively) plots of D or D2 against ln 
(concentration) gave better fitted linear regressions as their corresponding R2 values were 
closer to 1 as compared to plots for (D - Ď) and (D - Ď)2 against log (concentration). MIC 
values were attained from the x intercept of each graph. MIC values from Table 8 (Page 95) 
suggest that increasing the incubation time from 48 hours to 72 hours increased the level of 
inhibition. Due to the multicellular nature of A. niger it is likely that the piperidone 
dieneones took longer to have an effect on these cells. Generally the iodo substituted 
dieneones were the most potent as shown by their lower MIC values compared to the other 
compounds, though meta substitution provided a more potent inhibitor. Compound 39n 
was the most potent with MIC values after 72 hours incubation from both plots (3.6 x 10-10 
M (D/ln (c)) and 11.6 x 10-8 M (D2/ln (C)). Compound 41l was the least potent compound 
with the highest MIC values after 72 hours incubation from each plot (2.82 x 10-7 M (D/ln 
(C)) and 1.49 x 10-5 M (D2/ln (C)). The quadratic model was accurate for compounds 39g and 
41g whereas linear fits are more accurate in all other cases. The reference drug miconazole 
nitrate was a far more effective inhibitor of A. niger as it produced average zone of 
inhibition diameters of 17mm after 48 hours incubation and 18mm after 72 hours 
incubation at a concentration of 1.253µM (10µl applied, 12.53 nmoles).   
When using the disk diffusion assay the concentration of compound loaded is not a true 
concentration, it is an apparent concentration based on the amount of drug loaded on the 
disks which diffuses into the agar (Bonev et al, 2008).   
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The hydrophobicity of the piperidone dieneones also has a part in level of inhibition as well 
as other factors including thickness of the medium gel (Bonev et al, 2008). 
There is approximately a 150-300 fold difference between the MIC values obtained from 
plots of D/ln (C) and D2/ln (C); however it can be assumed that because D/ln (C) give R2 
values closer to 1, the MIC values obtained from these plots are more accurate (Bonev et al, 
2008).  
It is evident from the data obtained that the compounds possess antifungal properties as 
they have an inhibitory effect on the growth of both yeast and filamentous fungi. In general 
it appears that the presence of hydrogen on the heterocyclic nitrogen of the piperidone ring 
gives compounds with lower potencies than compounds having a methyl group in the same 
position. The compounds however are not as effective against filamentous fungi as they are 
against yeasts. This is probably due to the multicellular structure of filamentous fungi. 
Further experiments are needed to confirm this theory as there is substantial difference 
between IC10, IC50 and IC90 values obtained with yeasts and the MIC values acquired from the 
filamentous fungus. Using the disk diffusion assay for yeasts as well as filamentous fungi 
could be useful for making accurate comparisons.   
As mentioned previously there are many means by which the piperidone dieneones may 
affect the growth of these fungi. This requires further exploration. The present study has 
revealed that the position of the substituent on the benzene rings, its volume as well as its 
electron withdrawing properties play a vital role in the overall potency. Although not as 
potent as the marketed antifungal drug miconazole; there is indication that further study on 
the structures of the dieneones can give predictions of a more potent agent.  
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Chapter 4.3: Anticancer Testing    
 
Cancer is a disease in which abnormal cells divide in an uncontrolled manner ultimately 
invading surrounding tissues. (Macdonald et al, 2004). Although many treatments are 
available for suppressing or eliminating cancers and tumours, the prognosis in many types 
of cancer is limited. Research to develop novel anti-neoplastic agents is therefore required 
(Macdonald et al, 2004). Cancer research has advanced over the years due to the availability 
of many cancer cell lines derived from various cancer patients (Ferreira, 2013). The adherent 
culture strain of the human adenocarcinoma alveolar basal epithelial A549 ATCC CCL-185 
was used in this study. Several cytotoxicity assays have been approved by the National 
Cancer Institute (NCI) of which the most commonly used are the lactate dehydrogenase 
(LDH) and the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxy- phenyl)-2-(4-sulfophenyl)-
2H tetrazolium, inner salt (MTS) assays (Baharith et al, 2006). 
Due to time restrictions four selected 3,5-dibenzylidene-1-piperidin-4-ones (as exemplified 
by their potencies against both yeasts and filamentous fungi when compared to other 
dieneones) were chosen for the testing of their cytotoxic properties using the MTS and LDH 
assays.     
The MTS assay was utilised to determine if the compounds had an effect on reducing 
mitochondrial dehydrogenase activity thus indicating they possessed cytotoxic properties 
(Burger & Fiebig, 2004). The effect on cell membrane integrity of the compounds was 
analysed using the LDH assay (Fotakis & Timbrell, 2006).    
Although both assays are approved by the NCI they are not very accurate indicators of 
cytotoxicity as results can be affected in various ways (Berridge et al, 2005). As the MTS 
assay measures optical density and the LDH assay measures fluorescence there is always an 
issue of light interference which can have an effect on the accuracy of the collected data 
(Lobner, 2000). Also, due to the small volumes of reagents used, precautions are required to 
reduce errors which in many cases can be difficult.      
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4.3.1 Cytotoxic Evaluation of Test Compounds using The MTS and LDH assays 
Initial tests were carried out to study the effect of DMSO on the cells. Results showed that 
DMSO up to a concentration of 1% was not cytotoxic to A549 cells. The cytotoxicity analysis 
revealed that the iodo-substituted compounds were the most cytotoxic with the methoxy-
substituted compound being the least potent (see Figure 41 (Page 96) and Figure 42 (Page 
98). Compound 41n (3,5-bis(3-iodobenzylidene) piperidin-4-one) had the greatest effect on 
membrane integrity and mitochondrial activity as indicated by having the lowest IC50 values; 
1.7 x10-5 M (MTT) and  LDH: 2.1 x10-5 M (LDH) in comparison to the other compounds (Table 
9, Page 98). Compound (41l) (3,5-bis(4-methoxybenzylidene) piperidin-4-one) was the least 
cytotoxic with IC50 values of 5.4 x 10
-3 M (MTS) and 5.06 x 10-3 M (LDH) (Table 9, Page 98). Of 
the two iodo-substituted compounds tested meta substitution gave the most cytotoxic 
compound.   
The cytotoxic analysis of the piperidone dieneones on the mammalian cancer cell line A549 
reveals that these compounds are having an adverse effect on both mitochondrial activity 
and membrane integrity. It provides further evidence that the position of the R substituent 
on the benzene ring is important in determining the compounds potency. Additionally 
increasing the volume of the molecular group and decreasing its electron withdrawing 
properties increased potency.   
As a result of time restrictions a subset of piperidone dieneones were tested against A549 
cells based on their increased potencies against fungal cells when compared to other 
dieneones. However a recent study using N-phosphorylalkyl substituted E,E-3,5-bis 
(arylidene) piperid-4-ones, which also contain an α,β-unsaturated ketone structure revealed 
that increasing the electron withdrawing properties of the R substituents increases potency. 
Using a nitro group in the para-position of the benzene ring produced the most cytotoxic 
compound out of an analogue of fourteen ring substituted piperidones against various 
cancer cell lines including A549 cells (Makarov et al, 2009). Evidence from this study 
suggests that the piperidone dieneones containing substituents of high electronegativity 
(i.e. F, Cl) should be examined for their cytotoxic properties.               
It is expected that these compounds have similar effects on both fungal and mammalian 
cells. Both cell types are eukaryotic with similar structures and contain many of the same 
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enzymes (Brown, 2010). As previously mentioned for the antifungal analysis there are many 
ways at which these compounds may have their cytotoxic effects on cell membrane and 
mitochondrial activity. Most commonly these compounds are said to be involved in 
alkylation of thiols present on important cellular components such as glutathione. 
(Dimmock et al, 2002). However as reported by Manavathu et al, (1999) compounds of 
similar nature i.e containing an α,β-unsaturated ketone are responsible for blocking the 
plasma membrane proton-translocating ATPase (H+-ATPase) of various cells which is 
essential for cell growth. Alternatively other reports suggest that compounds of this kind 
interfere with mitochondrial functions such as ROS generation, oxygen consumption by the 
electron transport chain and phosphate transport (Helal et al, 2013 & Griffiths, et al, 1981).  
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Chapter 5.1: Further Work   
 
Due to limited time available it was not possible to synthesize various dibenzylidene 
derivatives of the synthesized tropan-3-one. Tropan-3-ones are from the same family of 
compounds as piperidones and they have also shown antifungal and cytotoxic properties 
(Pati et al, 2009). By synthesizing various dibenzylidene derivatives of tropan-3-one using 
the aldol condensation it could be determined whether the presence of an ethylene bridge 
has an effect on the potency.   
With all synthesized compounds the definitive structures could have been further confirmed 
using X-ray crystallography. This is a fairly accurate tool used to determine the atomic and 
molecular structure of a solid compound. It uses a beam of x-ray which atoms diffract at 
different angles and intensities. Measurement of these properties can enable construction 
of a three-dimensional image from which the position of atoms, electron densities and 
chemical bonds can be distinguished (Sayre, 2002).     
Although the piperidone derivatives were not as effective as the reference drug miconazole, 
they show potential for further improvement which can lead to increased potencies. The 
introduction of hydrophobic or bioactive groups on the heterocyclic nitrogen in the 
piperidone derivatives can increase both the potency and also the bioavailability by assisting 
approach of the cytotoxin to a specific binding site (Makarov et al, 2010).  
The current study revealed that para substitution produced the most effective compound 
and increasing the volume and decreasing the electron withdrawing properties of the R 
substituent increased potency. Whereas this is contradicted by recent anticancer studies 
using novel N-phophorylalkyl substituted E,E-3,5-bis (arylidene)piperid-4-ones and N-
phosphorylated E,E-3,5-bis (thienylidene) piperid-4-ones which suggest that increasing the 
electron withdrawing properties of the R substituents increases potency (Makarov et al, 
2009, Makarov et al, 2010). Based on these findings further novel structures can be 
synthesized with stronger electron withdrawing R substituents such as acids or nitro groups 
or effectively addition of more than one group on the relevant benzene rings. The data 
collected in this study in conjunction with the theoretical logP values which distinguish the 
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hydrophobic properties of the compounds can be used to study structure-activity 
relationships. From this a QSAR analysis can be generated and the structure of a 
theoretically more potent compound. The same can be applied to the benzothiazine 
compounds.       
Additional hydrophobic groups can also be added to the carbonyl group on the piperidone 
ring to increase potency and bioavailability. The use of substituted pyridine rings rather than 
benzene can be beneficial as it would increase solubility thus bioavailability as suggested by  
Leonova and co-workers (2010). Alternatively thienyl rings can be added to the parent 
piperidone compounds which may also increase potency (Makarov et al, 2010).    
All compounds were tested for their antifungal properties against S. cerevisiae, from which 
the most potent were selected for screening against C. albicans and A.niger. Four 
compounds were analysed against the A549 cancer cells due to restriction of time. In order 
to further validate the findings all compounds could be screened against additional cell lines 
as well as those used in this study.   
Though it was found that certain compounds inhibit fungal cell growth and reduce cell 
viability of a particular cancer cell line, the manner in which they do so is not fully 
understood. Various biological techniques can be used to further study this field which 
would be of great interest as it can give ideas on how these compounds function as 
potential antifungal or anticancer agents. Most compounds of similar nature are believed to 
play a role in alkylation of critical cellular thiols such as glutathione. Therefore the effect of 
these compounds on glutathione and cysteine levels can be analysed using a inactivation 
assay as proposed by Manavathu and co-workers (1999). The assay is a good tool to 
determine the inactivation of the antifungal activity of the piperidone dieneones by various 
thiol reagents such as cysteine or glutathione. Manavathu and co-workers (1999) showed 
that incubation of various Mannich bases of a series of cyclic conjugated stryl ketones with 
various concentrations of glutathione and cysteine eliminated their antifungal activity in a 
concentration-dependant fashion.    
Alternatively the proton pumping activities of the cells after incubation with the compounds 
can be analysed by monitoring glucose-induced acidification of the external medium by 
measuring differences in pH (Manavathu et al, 1999). This would provide evidence whether 
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the compounds play a part in blocking the plasma membrane proton-translocating ATPase 
(H+-ATPase). This can be verified by isolating the plasma membrane and to assay the ATPase 
activity with and without presence of the compounds.   
The effect of the compounds on mitochondrial function such as ROS generation can be 
analysed using a sulforhodamine B assay which measures fluorescent intensities that are 
proportional to the level of ROS generated (Helal et al, 2013).  
Alternative assays which could have been applied to cytotoxicity studies include various NCI 
approved assays such as the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide (XTT) assay which is proposed to give an improved dynamic range and higher 
sensitivity (Berridge et al, 2005).    
An improved approach to quantify the number of viable and non-viable cells is the use of a 
flow cytometer. Flow cytometry uses a computer software programme to quantify small 
particles such as cells (Ormerod, 2000). It can simultaneously examine chemical and physical 
characteristics of many thousands of particles. The technique can also determine if cell 
death is occurring by means of apoptosis or necrosis and it can also study cell viability and 
the cell cycle of the cell line being examined. Although this technique is more time 
consuming it reduces human error and can produce more precise data.    
Further work exploring other pharmacological properties of these compounds can be 
conducted such as anti-inflammatory and analgesic action. Several piperid-4-one containing 
analogues of curcumin exhibited inhibition on lipopolysaccharide (LPS) induced IL-6 release 
in RAW2647 macrophage cell showing cytokine-inhibitory activity (Wu et al, 2013). This 
study suggests that compounds containing an α,β unsaturated carbonyl possess anti-
inflammatory properties thus the anti-inflammatory potencies of the piperidone dieneones 
should be investigated.   
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Chapter 5.2: Conclusion   
 
In summary a library of 3,5-dibenzylidene-1-methyl piperidin-4-ones, 3,5-dibenzylidene-1-
piperidin-4-ones, and their respective hydrochloride salts was synthesized. A parent tropan-
3-one structure was also synthesized which will be used as a precursor to develop a library 
of tropanone dieneones. The synthesized compounds, along with a previously synthesized 
library of 1,2-benzothiazines were examined for their antifungal properties against various 
fungal cell lines and anticancer properties against a cancer cell line. Results obtained suggest 
that the tropan-3-one and benzothiazines are ineffective as antifungal agents, whereas the 
synthesized piperidone dieneones show a wide spectrum of activity. The free base 
piperidone dieneones are slightly more potent than their corresponding hydrochloride salts. 
In general the presence of a hydrogen atom on the heterocyclic nitrogen rather than a 
methyl group increases activity against yeast while the opposite is true in filamentous fungi. 
Antifungal testing against yeast cells showed that 48 hours incubation leads to a higher 
percentage of growth inhibition rather than 24 hours, with 72 hours of incubation proving 
most effective when tested against the filamentous fungi. The compounds are not as 
effective at inhibiting cell growth against filamentous fungi when compared to yeast. This is 
probably due to the multicellular structure of filamentous fungi.  
The aromatic ‘R’ substituent on the benzene rings of piperidone dieneones plays a role in 
potency whereby para substitution produces the most potent compound followed by meta 
and ortho substitution. The volume and electron withdrawing properties of the R 
substituent is also vital, where R substituents of larger volume and lower electron 
withdrawing properties produce more potent compounds. The 3’-iodo substituted 
piperidones (39n and 41n) emerged as the most promising agents from the group of 
compounds in respect to their antifungal and cytotoxic potencies, though the compounds 
were not as effective as the reference drug miconazole. This study has revealed the 
potential of these substituted piperidones in particular the iodo substituted to be used as 
the starting point for further development to improve potency.            
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Figure 52- Growth curve showing cell counts of A549 cells taken at daily intervals. Initially A549 cells were 
seeded into a 96-well plate at a concentration of 1 x 10
4
 cells/100µl/well at day 0. The plate was incubated 
at 37°C, 5% CO2 and cell counts were obtained in triplicate from six wells daily for a total of 9 days.     
 
 
 
 
 
 
 
 
 
 
 
 
 
142 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53- Disk diffusion assay showing the zone of inhibition diameters against Aspergillus niger ATCC 
16888 for 1.5% DMSO (1), 10µl of 1.253µM (12.53 nmoles) miconazole (2) and various amounts (10µl of 1 
x10
-6
 M to 3 x10
-3
 M)
 
 of  selected ring substituted 1-methylpiperidin-4-one dieneones  (3) to (10) following 72 
h incubation. Zone of inhibition diameters were determined by measuring ‘D’ and ‘r’ of each relevant 
inhibition zone. Corrected diameters were determined by subtracting the diameter of the paper disks (6mm) 
from the diameter of the zone of inhibition. 
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Figure 54- Disk diffusion assay showing the zone of inhibition diameters against Aspergillus niger ATCC 
16888 for 1.5% DMSO (1), 10µl of 1.253µM (12.53 nmoles) miconazole (2) and various amounts (10µl of 1 
x10
-6
 M to 3 x10
-3
 M)
 
 of  selected ring substituted piperidin-4-one dieneones  (3) to (10) following 72 h 
incubation. Zone of inhibition diameters were determined by measuring ‘D’ and ‘r’ of each relevant 
inhibition zone. Corrected diameters were determined by subtracting the diameter of the paper disks (6mm) 
from the diameter of the zone of inhibition. 
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Table 10- The relevant compound numbers and codes for ring substituted 1-
methylpiperidin-4-one dieneones as displayed in the thesis, logbook and spectral data  
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39n Pip 29a 
H
C
l s
al
ts
 o
f 
ri
n
g 
su
b
st
it
u
te
d
 o
f 
3
,5
-d
ib
e
n
zy
lid
e
n
e
-
1
-m
e
th
yl
 p
ip
er
id
in
-4
-o
n
e
s 
40a Pip 1b 
40b Pip 3b 
40c Pip 4b 
40d Pip 5b 
40e Pip 6b 
40f Pip 7b 
40g Pip 8b 
40h Pip 9b 
40i Pip 20b 
40j Pip 21b 
40k Pip 26b 
40l Pip 27b 
40m Pip 28b 
40n Pip 29b 
 
 
 
 
145 | P a g e  
 
Table 11- The relevant compound numbers and codes for ring substituted piperidin-4-one 
dieneones as displayed in the thesis, logbook and spectral data  
 
Compound 
type 
Compound no. 
(thesis) 
Compound code 
(logbook and spectral 
data) 
R
in
g 
su
b
st
it
u
te
d
 3
,5
-d
ib
e
n
zy
lid
en
e
-1
-p
ip
er
id
in
 -
4
-
o
n
es
 
41a Pip 10a 
41b Pip 11a 
41c Pip 12a 
41d Pip 13a 
41e Pip 14a 
41f Pip 15a 
41g Pip 16a 
41h Pip 17a 
41i Pip 18a 
41j Pip 19a 
41k Pip 24a 
41l Pip 25a 
41m Pip 30a 
41n Pip 31a 
H
C
l s
al
ts
 o
f 
ri
n
g 
su
b
st
it
u
te
d
 3
,5
-d
ib
e
n
zy
lid
e
n
e
- 
1
-
p
ip
er
id
in
-4
-o
n
es
 
42a Pip 10b 
42b Pip 11b 
42c Pip 12b 
42d Pip 13b 
42e Pip 14b 
42f Pip 15b 
42g Pip 16b 
42h Pip 17b 
42i Pip 18b 
42j Pip 19b 
42k Pip 24b 
42l Pip 25b 
42m Pip 30b 
42n Pip 31b 
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Table 12- The relevant compound numbers and codes for ring substituted 1,2-
benzothiazine derivatives  as displayed in the thesis and logbook  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound no. 
(thesis) 
Compound code 
(logbook and 
spectral data) 
48a BT1 
48b BT2 
48c BT3 
48d BT4 
48e BT5 
48f BT6 
48g BT7 
48h BT8 
48i BT9 
48j BT10 
48k BT11 
48l BT12 
48m BT13 
48n BT14 
48o BT15 
48p BT16 
48q BT17 
48r BT18 
48s BT19 
48t BT20 
48u BT21 
48v BT22 
48x BT23 
48y BT24 
48z BT25 
48aa BT26 
48ab BT27 
48ac BT28 
48ad BT29 
48ae BT30 
48af BT31 
48ag BT32 
48ah BT33 
48ai BT34 
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Table 12 (continued) - The relevant compound numbers and codes for ring substituted 1,2-
benzothiazine derivatives  as displayed in the thesis and logbook  
 
Compound no. 
(thesis) 
Compound code 
(logbook and 
spectral data) 
48aj BT35 
48ak BT36 
48al BT37 
48al BT38 
48am BT39 
48an BT40 
48ao BT41 
48ap BT42 
48aq BT43 
48ar BT44 
48as BT45 
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